data_2lt4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lt4 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 121.093 0.473 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 . . . . . 0 CA--C 1.538 0.517 0 CA-C-O 121.319 0.581 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 121.198 0.523 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 . . . . . 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 C--O 1.237 0.424 0 CA-C-O 121.072 0.463 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.8 m80 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 121.133 0.492 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 . . . . . 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 . . . . . 0 CA--C 1.539 0.521 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 . . . . . 0 C--O 1.237 0.399 0 CA-C-O 121.16 0.505 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 . . . . . 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 CA--C 1.538 0.518 0 CA-C-O 121.054 0.454 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 . . . . . 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.639 0 CA-C-O 121.088 0.471 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 . . . . . 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 . . . . . 0 CA--C 1.538 0.49 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 . . . . . 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 . . . . . 0 CA--C 1.545 0.761 0 CA-C-O 121.002 0.429 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 . . . . . 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 . . . . . 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 120.978 0.418 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 . . . . . 0 CA--C 1.546 0.801 0 CA-C-O 121.15 0.5 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 . . . . . 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 121.061 0.458 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 . . . . . 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 . . . . . 0 CA--C 1.537 0.458 0 CA-C-O 121.531 0.681 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 . . . . . 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.654 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 CA--C 1.541 0.609 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.068 0.461 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 . . . . . 0 CA--C 1.545 0.765 0 CA-C-O 121.325 0.583 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 . . . . . 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.257 0 CA-C-O 120.559 0.219 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.61 173.32 39.7 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.121 1.343 . . . . 0.0 112.973 175.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.6 p80 -150.76 152.38 33.76 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.171 1.788 . . . . 0.0 111.157 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.51 178.18 9.84 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.845 1.258 . . . . 0.0 111.99 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -125.68 106.66 9.89 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.31 1.444 . . . . 0.0 111.791 176.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 p -106.69 173.0 6.51 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.981 2.113 . . . . 0.0 110.945 175.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.76 158.76 20.92 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.677 1.191 . . . . 0.0 111.625 175.058 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -124.03 159.87 28.91 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.173 1.389 . . . . 0.0 110.499 175.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -83.48 136.44 34.29 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 36.1 pt -109.75 -6.82 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.904 1.682 . . . . 0.0 114.164 174.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.25 93.6 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 122.648 1.213 . . . . 0.0 109.335 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.0 t -83.36 33.22 0.45 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.219 2.208 . . . . 0.0 112.246 176.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -80.14 118.99 22.33 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.153 1.381 . . . . 0.0 110.975 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -128.47 -171.21 2.41 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.404 1.882 . . . . 0.0 110.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.8 t70 . . . . . 0 CA--C 1.557 1.218 0 C-N-CA 125.42 1.488 . . . . 0.0 113.58 175.334 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.316 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.53 -33.32 1.89 Allowed Glycine 0 N--CA 1.475 1.288 0 C-N-CA 124.743 1.163 . . . . 0.0 114.328 176.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 71.9 m80 40.06 65.28 0.76 Allowed 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.994 2.118 . . . . 0.0 113.397 -177.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.6 ptp -131.72 141.85 49.65 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.402 1.481 . . . . 0.0 111.88 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -114.12 144.53 43.01 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.75 1.22 . . . . 0.0 108.522 174.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -127.9 177.55 6.77 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 126.083 1.753 . . . . 0.0 110.625 177.025 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.8 p -54.99 90.89 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.743 2.017 . . . . 0.0 113.363 175.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 -79.25 153.33 30.02 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.136 0.974 . . . . 0.0 110.364 175.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 -80.76 58.78 3.43 Favored 'General case' 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.6 -178.89 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 125.193 1.397 . . . . 0.0 111.385 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -109.0 -28.59 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 125.481 1.512 . . . . 0.0 113.1 177.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -60.29 93.57 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 127.701 2.4 . . . . 0.0 112.548 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.18 86.94 2.11 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.466 1.907 . . . . 0.0 109.703 -175.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -75.9 -176.58 3.46 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 124.329 1.052 . . . . 0.0 111.417 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.252 0 C-N-CA 124.969 1.308 . . . . 0.0 114.008 175.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.421 0.153 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.46 81.55 0.16 Allowed Glycine 0 CA--C 1.534 1.226 0 C-N-CA 124.609 1.1 . . . . 0.0 113.19 -179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 -131.28 36.47 3.8 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.795 1.638 . . . . 0.0 113.844 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.6 mpp? -107.14 97.06 6.87 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.241 1.416 . . . . 0.0 112.308 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -87.42 92.66 9.16 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.081 0.953 . . . . 0.0 110.229 175.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.8 p -141.5 173.22 11.71 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.502 1.921 . . . . 0.0 111.224 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 83.6 p -55.51 148.67 15.1 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.543 0.737 . . . . 0.0 112.325 174.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -127.51 160.34 31.81 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.972 1.309 . . . . 0.0 110.324 176.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -78.97 128.52 33.38 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.3 pt -136.17 -160.92 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.713 1.605 . . . . 0.0 110.023 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -50.67 -32.98 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.032 1.733 . . . . 0.0 114.164 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 96.1 0.97 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.914 1.286 . . . . 0.0 111.782 176.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -130.21 127.21 39.18 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.63 1.972 . . . . 0.0 110.311 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -129.28 -69.28 0.7 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.849 1.66 . . . . 0.0 111.238 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 24.8 t70 . . . . . 0 C--O 1.252 1.234 0 C-N-CA 124.79 1.236 . . . . 0.0 113.77 -176.723 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 120.289 0.09 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.03 50.62 4.8 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 124.244 0.926 . . . . 0.0 114.396 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -155.93 62.49 0.58 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.596 1.559 . . . . 0.0 111.97 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.9 ptp -159.88 41.67 0.2 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.16 109.48 1.12 Allowed 'General case' 0 CA--C 1.544 0.713 0 O-C-N 120.922 -1.111 . . . . 0.0 111.425 -178.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 t -137.87 167.27 22.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.853 1.661 . . . . 0.0 111.075 -178.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.5 p -63.92 162.24 14.18 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.202 1.001 . . . . 0.0 111.148 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -129.4 157.53 41.7 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.516 1.126 . . . . 0.0 110.288 177.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.8 m80 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -70.6 149.18 47.33 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.6 pt -107.97 -16.07 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 N-CA-C 114.328 1.232 . . . . 0.0 114.328 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 8.9 tp -64.33 -17.26 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.938 1.695 . . . . 0.0 112.267 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.3 t -72.75 80.11 1.12 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.746 1.618 . . . . 0.0 110.342 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -123.93 137.34 54.64 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.848 2.059 . . . . 0.0 110.585 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -100.99 -73.21 0.65 Allowed 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.56 1.144 . . . . 0.0 110.398 175.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.254 1.319 0 C-N-CA 126.737 2.015 . . . . 0.0 112.723 -177.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 119.503 -0.284 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.79 125.79 2.57 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.145 1.355 . . . . 0.0 111.697 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -68.97 111.7 5.15 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.752 0.821 . . . . 0.0 110.816 179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 64.5 mtp -112.09 152.91 27.7 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 124.505 1.122 . . . . 0.0 111.678 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 -90.94 140.98 29.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.118 0.967 . . . . 0.0 110.003 175.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 9.7 t -150.08 161.89 41.48 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 125.277 1.431 . . . . 0.0 110.003 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 87.2 p -71.66 -178.31 2.19 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.265 1.026 . . . . 0.0 110.988 175.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -122.48 157.69 31.44 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.077 0.951 . . . . 0.0 110.088 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -79.13 140.66 37.75 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.0 pt -133.21 -162.16 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 126.474 1.91 . . . . 0.0 110.146 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.5 tp -50.03 -32.43 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 C-N-CA 125.752 1.621 . . . . 0.0 114.435 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.4 p -65.51 91.59 0.12 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.067 1.347 . . . . 0.0 112.352 179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.1 tt0 -106.16 140.04 39.75 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.303 1.841 . . . . 0.0 110.766 -179.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -89.05 -173.33 4.02 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.62 1.568 . . . . 0.0 111.573 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.22 0 C-N-CA 126.567 1.947 . . . . 0.0 111.907 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.18 0 CA-C-O 120.857 0.36 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.76 112.74 0.53 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.857 1.217 . . . . 0.0 111.665 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -56.52 107.77 0.42 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.022 1.329 . . . . 0.0 111.193 177.024 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ttt -136.78 144.76 43.92 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.58 1.552 . . . . 0.0 110.452 -178.287 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -92.56 130.35 38.23 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.746 0.818 . . . . 0.0 110.17 176.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -133.87 160.86 36.38 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.812 1.645 . . . . 0.0 111.674 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 t -78.96 155.88 28.75 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.428 0.633 . . . . 0.0 112.655 175.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -134.42 158.28 44.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.317 1.847 . . . . 0.0 109.141 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -81.65 126.92 32.34 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.7 pt -135.53 -162.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.554 1.941 . . . . 0.0 109.956 -178.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -50.4 -30.08 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.121 1.768 . . . . 0.0 114.498 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.69 96.35 0.95 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.446 1.099 . . . . 0.0 112.16 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -129.77 167.96 17.28 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.627 2.371 . . . . 0.0 110.895 -179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.75 -64.57 0.84 Allowed 'General case' 0 CA--C 1.543 0.702 0 O-C-N 121.397 -0.814 . . . . 0.0 112.188 179.264 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 C--O 1.252 1.204 0 C-N-CA 129.38 3.072 . . . . 0.0 116.952 -176.818 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 120.396 0.141 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.81 104.35 0.21 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.056 0.836 . . . . 0.0 112.86 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -65.66 154.54 38.57 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 117.645 0.723 . . . . 0.0 111.371 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.35 159.74 42.2 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.506 1.122 . . . . 0.0 111.223 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -115.57 156.78 25.15 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.467 1.507 . . . . 0.0 111.317 176.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 95.32 2.22 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.282 1.833 . . . . 0.0 109.74 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.1 t -61.17 138.81 58.21 Favored 'General case' 0 N--CA 1.47 0.553 0 O-C-N 121.816 -0.553 . . . . 0.0 109.726 175.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -131.63 156.54 45.64 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.182 1.393 . . . . 0.0 110.057 176.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.06 124.7 27.47 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.7 pt -135.54 -163.97 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 126.145 1.778 . . . . 0.0 110.198 -179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -47.88 -41.26 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.171 1.789 . . . . 0.0 114.177 175.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.0 t -72.37 101.31 2.87 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.116 1.366 . . . . 0.0 110.427 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -152.04 169.84 21.38 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 127.643 2.377 . . . . 0.0 110.132 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -98.94 -68.46 0.8 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.032 0.933 . . . . 0.0 112.278 175.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 C--O 1.252 1.232 0 C-N-CA 125.954 1.702 . . . . 0.0 114.312 -174.695 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 119.612 -0.232 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.13 -159.26 26.08 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.226 1.393 . . . . 0.0 112.066 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -131.39 157.21 44.01 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.38 1.472 . . . . 0.0 110.893 175.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -148.99 175.89 10.91 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.566 1.546 . . . . 0.0 110.457 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tt0 -128.62 84.63 2.25 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.133 0.973 . . . . 0.0 110.769 -177.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.9 p -69.83 165.96 20.41 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.358 1.063 . . . . 0.0 112.37 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 13.2 m -139.88 174.39 10.56 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.391 1.476 . . . . 0.0 112.07 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -136.71 161.13 36.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.322 1.449 . . . . 0.0 110.291 174.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -79.77 67.5 5.57 Favored 'General case' 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -83.59 -176.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 125.333 1.453 . . . . 0.0 111.805 177.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.09 -25.71 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 126.258 1.823 . . . . 0.0 113.521 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.4 m -62.38 97.33 0.09 Allowed 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 127.26 2.224 . . . . 0.0 112.659 -178.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -118.75 168.59 10.6 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 126.112 1.765 . . . . 0.0 112.584 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -66.35 -70.32 0.25 Allowed 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.109 1.363 . . . . 0.0 112.705 178.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.4 t70 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 125.588 1.555 . . . . 0.0 114.1 -179.533 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.97 153.57 9.83 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.679 1.609 . . . . 0.0 113.048 -174.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -123.63 5.14 8.89 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 125.322 1.449 . . . . 0.0 113.858 178.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.49 158.79 34.24 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.726 1.61 . . . . 0.0 112.418 175.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -140.51 124.07 17.02 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.767 2.027 . . . . 0.0 109.997 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.1 p -116.71 -43.08 2.92 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.63 1.572 . . . . 0.0 112.008 175.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 m -68.06 155.67 39.04 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.607 1.163 . . . . 0.0 111.545 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -98.85 161.55 13.57 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.13 0.972 . . . . 0.0 110.474 175.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -74.44 84.57 1.99 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.2 pt -132.39 -166.16 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 126.008 1.723 . . . . 0.0 111.344 -176.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.4 tp -121.43 -27.54 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 126.333 1.853 . . . . 0.0 112.686 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -58.02 121.04 9.64 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.531 1.532 . . . . 0.0 111.973 179.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -133.79 97.9 4.03 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.424 1.89 . . . . 0.0 109.609 -173.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -77.87 -174.64 3.62 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.037 1.335 . . . . 0.0 111.921 175.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 . . . . . 0 C--O 1.253 1.26 0 C-N-CA 126.239 1.816 . . . . 0.0 112.158 177.482 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.411 0.148 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.31 -89.0 0.1 Allowed Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.387 0.994 . . . . 0.0 113.07 177.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.4 p-80 -109.28 161.23 15.45 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.014 1.726 . . . . 0.0 112.392 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -159.71 48.79 0.3 Allowed 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.314 1.445 . . . . 0.0 113.198 -178.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -91.84 22.34 4.28 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.536 1.534 . . . . 0.0 113.285 -177.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -69.86 -71.56 0.23 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 126.055 1.742 . . . . 0.0 112.699 178.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 99.0 p -71.02 156.78 39.23 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.851 0.834 . . . . 0.0 111.965 174.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -143.69 158.44 43.67 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.487 1.515 . . . . 0.0 109.612 174.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -76.41 84.23 3.15 Favored 'General case' 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.7 pt -117.66 -167.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 C-N-CA 125.865 1.666 . . . . 0.0 111.617 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.04 -23.77 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.096 1.758 . . . . 0.0 113.608 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.2 t -57.32 102.08 0.08 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.028 1.731 . . . . 0.0 112.472 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -130.78 94.5 3.63 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.404 1.882 . . . . 0.0 111.036 -178.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 15.1 mt-10 -143.03 -72.33 0.3 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.435 . . . . 0.0 110.33 175.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.255 1.382 0 C-N-CA 125.575 1.55 . . . . 0.0 113.169 -176.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.95 98.08 0.12 Allowed Glycine 0 N--CA 1.476 1.324 0 CA-C-N 119.634 1.106 . . . . 0.0 113.61 -179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -136.56 48.78 2.11 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.636 1.574 . . . . 0.0 113.454 -175.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 ttt -123.64 61.36 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.474 1.509 . . . . 0.0 112.365 -171.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -72.37 159.87 33.3 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.312 1.045 . . . . 0.0 112.746 174.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -132.58 -63.32 0.79 Allowed 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 126.174 1.79 . . . . 0.0 111.502 -177.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 71.7 m -128.78 119.16 24.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 126.575 1.95 . . . . 0.0 111.034 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -103.43 161.0 14.22 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.055 1.342 . . . . 0.0 110.6 175.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -83.54 128.2 34.33 Favored 'General case' 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.45 -174.3 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 125.58 1.552 . . . . 0.0 111.124 -178.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.6 tp -111.02 -35.12 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.949 1.7 . . . . 0.0 113.076 176.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.6 t -75.83 82.73 2.77 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.048 1.339 . . . . 0.0 111.653 177.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -59.94 162.58 5.41 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.427 1.091 . . . . 0.0 112.119 175.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -63.62 -62.88 1.37 Allowed 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.04 -1.038 . . . . 0.0 112.144 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.6 t70 . . . . . 0 C--O 1.252 1.22 0 C-N-CA 125.637 1.575 . . . . 0.0 113.053 178.809 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.98 40.68 0.46 Allowed Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.117 0.865 . . . . 0.0 114.152 -176.292 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -133.15 40.82 3.17 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.984 1.314 . . . . 0.0 113.266 -176.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.55 161.36 14.78 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.855 1.262 . . . . 0.0 111.334 174.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mm-40 -69.63 165.2 21.7 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 123.958 0.903 . . . . 0.0 112.662 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.73 75.18 9.0 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.491 1.516 . . . . 0.0 112.638 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.3 m -92.22 124.55 36.38 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.358 1.063 . . . . 0.0 111.293 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -133.5 159.02 41.64 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 125.472 1.509 . . . . 0.0 109.986 175.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 -69.26 154.12 42.56 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 45.5 pt -107.66 -20.07 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -166.06 -35.05 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 127.397 2.279 . . . . 0.0 112.882 -178.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.81 114.42 1.41 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.877 1.671 . . . . 0.0 112.533 -178.019 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -137.08 128.63 28.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.651 1.58 . . . . 0.0 111.089 -177.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -107.36 -60.01 1.75 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.22 1.808 . . . . 0.0 111.479 178.491 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.254 1.331 0 C-N-CA 126.52 1.928 . . . . 0.0 113.133 -176.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 CA-C-O 119.45 -0.31 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.03 -44.52 23.44 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-N 119.088 0.858 . . . . 0.0 114.25 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.6 m80 54.97 -176.49 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 126.878 2.071 . . . . 0.0 113.434 -170.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -155.46 158.73 39.02 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.451 1.5 . . . . 0.0 111.413 175.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mt-30 -132.84 17.35 4.23 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.73 1.612 . . . . 0.0 112.526 -178.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 p -59.74 144.86 47.1 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 126.43 1.892 . . . . 0.0 113.479 177.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.3 m -78.84 116.79 19.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.321 1.449 . . . . 0.0 112.546 178.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -90.14 163.95 14.64 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.853 0.861 . . . . 0.0 110.297 174.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -79.66 57.17 2.41 Favored 'General case' 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 -176.19 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.548 1.139 . . . . 0.0 112.277 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.7 tp -109.48 -28.38 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.128 1.771 . . . . 0.0 113.112 177.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.3 m -59.4 107.72 0.61 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 127.383 2.273 . . . . 0.0 112.007 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -126.03 148.27 49.35 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.499 1.52 . . . . 0.0 111.648 178.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -71.71 -59.06 2.95 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.313 1.445 . . . . 0.0 112.57 178.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.253 1.283 0 C-N-CA 127.176 2.19 . . . . 0.0 114.64 -175.794 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.527 0.204 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 156.74 164.4 13.46 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 125.683 1.611 . . . . 0.0 112.567 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.5 t-160 -145.53 27.37 1.24 Allowed 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -178.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -90.42 148.23 22.92 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.518 1.527 . . . . 0.0 111.875 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -105.27 -45.78 4.4 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.446 1.099 . . . . 0.0 111.732 175.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 79.0 p -64.26 -36.53 84.38 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.291 1.036 . . . . 0.0 113.192 179.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.98 86.47 6.94 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.949 1.299 . . . . 0.0 111.203 -179.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -73.26 161.7 30.22 Favored 'General case' 0 CA--C 1.546 0.801 0 O-C-N 121.68 -0.638 . . . . 0.0 111.111 175.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -81.94 71.28 8.97 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.8 pt -93.45 -14.87 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -177.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.2 tp -63.78 -12.74 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 125.686 1.594 . . . . 0.0 113.032 176.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.07 84.06 0.23 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.976 1.71 . . . . 0.0 111.772 176.37 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.43 122.59 24.74 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.741 1.616 . . . . 0.0 111.409 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -122.22 -64.54 1.19 Allowed 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.77 1.628 . . . . 0.0 111.618 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 C--O 1.253 1.263 0 C-N-CA 127.11 2.164 . . . . 0.0 112.555 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 121.087 0.47 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.24 -143.79 10.29 Favored Glycine 0 CA--C 1.531 1.067 0 O-C-N 120.793 -1.192 . . . . 0.0 111.963 -173.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -70.68 147.81 48.7 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.41 0.605 . . . . 0.0 112.232 175.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.3 mtm -149.6 160.44 43.49 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 126.935 2.094 . . . . 0.0 109.514 174.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.6 tt0 -135.68 169.47 17.49 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.559 1.544 . . . . 0.0 110.686 -177.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.5 104.42 2.76 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.159 1.384 . . . . 0.0 112.836 -177.37 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.5 t -101.51 121.4 41.9 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 124.718 1.207 . . . . 0.0 110.969 174.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -136.28 159.71 40.92 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.953 1.701 . . . . 0.0 110.149 174.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 -74.61 134.89 42.04 Favored 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.34 178.45 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 126.003 1.721 . . . . 0.0 110.819 176.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 1.3 tp -131.87 2.84 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.792 2.037 . . . . 0.0 113.287 178.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 64.6 m -64.43 87.79 0.05 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 126.406 1.882 . . . . 0.0 112.843 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -128.5 58.03 1.57 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.645 1.978 . . . . 0.0 110.844 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -67.36 0.37 Allowed 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.603 1.161 . . . . 0.0 112.338 175.31 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.252 1.229 0 C-N-CA 125.881 1.672 . . . . 0.0 112.448 176.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.446 0.165 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.93 -68.81 0.01 OUTLIER Glycine 0 N--CA 1.474 1.217 0 C-N-CA 124.832 1.205 . . . . 0.0 112.269 -178.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -75.25 119.64 19.65 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.489 1.116 . . . . 0.0 111.29 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.7 mmt -116.52 88.33 2.87 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.518 1.927 . . . . 0.0 110.022 177.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.98 154.2 38.2 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.322 0.649 . . . . 0.0 111.087 175.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.5 p -96.74 -69.6 0.75 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.612 1.165 . . . . 0.0 110.931 174.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 75.0 m -60.77 110.26 1.27 Allowed 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.996 1.318 . . . . 0.0 111.557 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -132.64 158.26 42.72 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.63 1.572 . . . . 0.0 110.69 177.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -76.88 66.56 2.77 Favored 'General case' 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -77.24 -175.52 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.694 1.198 . . . . 0.0 111.443 177.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -113.62 -24.05 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.756 1.622 . . . . 0.0 113.575 178.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.53 101.13 0.08 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.759 2.024 . . . . 0.0 112.33 177.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -126.22 61.42 1.28 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.26 1.824 . . . . 0.0 111.961 -176.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -62.62 -57.56 10.63 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 120.972 -1.08 . . . . 0.0 112.688 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.275 1.83 . . . . 0.0 113.948 -178.836 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 CA-C-O 119.598 -0.239 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.79 143.37 3.49 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 125.237 1.399 . . . . 0.0 112.766 -173.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -92.72 59.35 3.25 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 124.308 1.043 . . . . 0.0 111.357 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.4 ttm -156.31 99.72 1.94 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.221 1.008 . . . . 0.0 111.574 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -74.0 152.11 40.12 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.376 0.67 . . . . 0.0 111.377 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 t -68.17 -42.66 79.68 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.639 0.776 . . . . 0.0 111.455 176.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.8 p -87.8 134.86 33.6 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.714 2.006 . . . . 0.0 112.606 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -140.29 158.79 43.49 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.275 1.83 . . . . 0.0 109.559 175.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.41 74.76 3.97 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.9 pt -113.47 -165.12 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 126.118 1.767 . . . . 0.0 111.247 -177.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -123.76 -31.87 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 126.082 1.753 . . . . 0.0 112.844 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -60.26 137.22 58.16 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.581 1.152 . . . . 0.0 111.634 176.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -129.89 171.79 12.37 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.097 1.759 . . . . 0.0 111.393 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -57.95 -61.49 2.5 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.477 -0.764 . . . . 0.0 112.59 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.214 0 C-N-CA 125.442 1.497 . . . . 0.0 113.466 -178.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.216 0.055 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.9 57.34 0.32 Allowed Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.071 0.844 . . . . 0.0 114.147 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 57.32 87.71 0.06 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 127.159 2.184 . . . . 0.0 114.137 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.6 mtp -98.63 -32.16 11.56 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.905 1.282 . . . . 0.0 113.782 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -137.28 167.58 21.31 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.255 2.222 . . . . 0.0 111.111 -177.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 8.1 p -122.49 -69.63 0.82 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 126.476 1.911 . . . . 0.0 110.73 -177.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.2 p -71.61 163.46 27.71 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.562 1.145 . . . . 0.0 111.993 175.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -136.08 160.16 39.49 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.794 1.637 . . . . 0.0 110.052 174.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.31 69.04 9.9 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 pt -90.12 -15.21 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -176.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.1 tp -63.6 -15.74 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.012 1.325 . . . . 0.0 111.973 175.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.7 137.07 58.18 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.391 1.476 . . . . 0.0 111.629 175.069 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -146.96 161.88 39.88 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.14 1.376 . . . . 0.0 111.867 -178.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -124.13 -65.29 1.07 Allowed 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.237 1.415 . . . . 0.0 111.466 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.4 t70 . . . . . 0 C--O 1.254 1.329 0 C-N-CA 125.517 1.527 . . . . 0.0 114.003 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.265 0 CA-C-O 120.971 0.415 . . . . 0.0 111.523 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.08 5.19 84.8 Favored Glycine 0 CA--C 1.537 1.429 0 C-N-CA 125.339 1.447 . . . . 0.0 115.186 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -148.88 158.84 44.47 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.76 1.624 . . . . 0.0 111.974 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.18 178.98 6.58 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 127.18 2.192 . . . . 0.0 110.812 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.89 -175.05 1.63 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 124.63 1.172 . . . . 0.0 111.126 174.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -63.47 111.01 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.146 1.378 . . . . 0.0 111.832 174.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.0 m -118.28 159.32 23.57 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.185 1.394 . . . . 0.0 111.975 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -139.6 157.84 45.12 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.384 1.474 . . . . 0.0 109.776 175.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -83.54 93.05 7.75 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 31.7 pt -91.67 -21.28 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -165.59 -30.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 127.345 2.258 . . . . 0.0 113.823 -179.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -60.86 104.27 0.34 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.917 1.287 . . . . 0.0 113.151 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.76 173.52 9.47 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.114 1.365 . . . . 0.0 111.886 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.04 -63.27 0.61 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.107 1.763 . . . . 0.0 111.065 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.0 t70 . . . . . 0 C--O 1.254 1.33 0 C-N-CA 125.082 1.353 . . . . 0.0 113.243 -174.896 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.6 0.238 . . . . 0.0 111.432 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.97 175.63 53.96 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 124.717 1.151 . . . . 0.0 113.607 175.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -146.43 70.17 1.21 Allowed 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.942 1.297 . . . . 0.0 111.576 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.1 mtt -118.93 143.99 46.7 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.845 1.258 . . . . 0.0 112.337 178.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.5 tp60 -153.2 54.46 0.76 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 125.791 1.637 . . . . 0.0 110.972 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -75.19 154.37 37.66 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 120.722 -1.236 . . . . 0.0 111.367 174.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -87.13 177.21 7.26 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.628 0.771 . . . . 0.0 112.688 175.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -96.65 161.97 13.65 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.782 1.233 . . . . 0.0 111.914 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -79.49 73.39 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -94.3 -171.74 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 125.914 1.686 . . . . 0.0 111.693 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.8 tp -119.95 -29.59 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.098 1.759 . . . . 0.0 113.087 176.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.17 124.02 18.57 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 126.521 1.928 . . . . 0.0 112.25 175.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -137.55 143.26 41.49 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.888 1.675 . . . . 0.0 110.937 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -119.43 -64.7 1.24 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.084 1.353 . . . . 0.0 111.498 179.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.068 1.747 . . . . 0.0 113.676 178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 121.093 0.473 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 . . . . . 0 CA--C 1.538 0.517 0 CA-C-O 121.319 0.581 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.679 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.679 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 121.198 0.523 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.639 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 37' ' ' GLN . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.506 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.639 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 . . . . . 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 C--O 1.237 0.424 0 CA-C-O 121.072 0.463 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.739 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.403 HG11 ' HB2' ' A' ' 46' ' ' GLU . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 11.0 m-70 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.403 ' HB2' HG11 ' A' ' 21' ' ' VAL . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 60' ' ' SER . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.587 ' H ' HG12 ' A' ' 58' ' ' VAL . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.739 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.444 ' N ' ' HB1' ' A' ' 14' ' ' ALA . 3.0 tt0 . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 121.133 0.492 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.624 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.407 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.407 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.4 HG23 HG23 ' A' ' 44' ' ' ILE . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.477 HG22 ' HB2' ' A' ' 37' ' ' GLN . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.477 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.4 HG23 HG23 ' A' ' 21' ' ' VAL . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.624 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.409 ' C ' ' HB1' ' A' ' 14' ' ' ALA . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 . . . . . 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 . . . . . 0 CA--C 1.539 0.521 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.532 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.414 HG13 ' CA ' ' A' ' 20' ' ' GLY . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.414 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 . . . . . 0 C--O 1.237 0.399 0 CA-C-O 121.16 0.505 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.688 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 60' ' ' SER . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.497 ' H ' HG12 ' A' ' 58' ' ' VAL . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.688 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 . . . . . 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 CA--C 1.538 0.518 0 CA-C-O 121.054 0.454 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.421 HG13 ' CA ' ' A' ' 20' ' ' GLY . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.421 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 . . . . . 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.639 0 CA-C-O 121.088 0.471 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.53 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.419 HG11 ' HB2' ' A' ' 46' ' ' GLU . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.471 ' HB2' HD13 ' A' ' 55' ' ' ILE . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB2' HG11 ' A' ' 21' ' ' VAL . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.471 HD13 ' HB2' ' A' ' 38' ' ' SER . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.582 HG12 ' H ' ' A' ' 60' ' ' SER . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.582 ' H ' HG12 ' A' ' 58' ' ' VAL . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.53 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 . . . . . 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 . . . . . 0 CA--C 1.538 0.49 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.451 ' HB3' HD12 ' A' ' 63' ' ' LEU . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 60' ' ' SER . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.561 ' H ' HG12 ' A' ' 58' ' ' VAL . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 14' ' ' ALA . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 . . . . . 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 . . . . . 0 CA--C 1.545 0.761 0 CA-C-O 121.002 0.429 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.49 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 60' ' ' SER . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 . . . . . 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.516 ' HB2' HD13 ' A' ' 55' ' ' ILE . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.516 HD13 ' HB2' ' A' ' 38' ' ' SER . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 60' ' ' SER . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.496 ' H ' HG12 ' A' ' 58' ' ' VAL . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.692 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 . . . . . 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 120.978 0.418 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.41 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 . . . . . 0 CA--C 1.546 0.801 0 CA-C-O 121.15 0.5 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.612 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 60' ' ' SER . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 58' ' ' VAL . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.612 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 . . . . . 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 121.061 0.458 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.513 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.513 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 . . . . . 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 . . . . . 0 CA--C 1.537 0.458 0 CA-C-O 121.531 0.681 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.427 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.463 ' HB2' HD13 ' A' ' 55' ' ' ILE . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 38' ' ' SER . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.489 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 . . . . . 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.654 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.483 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.406 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.406 HD13 ' HB2' ' A' ' 38' ' ' SER . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.483 HD23 ' HB3' ' A' ' 14' ' ' ALA . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 CA--C 1.541 0.609 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.415 HG13 ' CA ' ' A' ' 20' ' ' GLY . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.415 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.51 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.068 0.461 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.6 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.6 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 . . . . . 0 CA--C 1.545 0.765 0 CA-C-O 121.325 0.583 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.44 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.44 HD23 ' HB3' ' A' ' 14' ' ' ALA . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 . . . . . 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.257 0 CA-C-O 120.559 0.219 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.61 173.32 39.7 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.121 1.343 . . . . 0.0 112.973 175.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.6 p80 -150.76 152.38 33.76 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.171 1.788 . . . . 0.0 111.157 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.51 178.18 9.84 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.845 1.258 . . . . 0.0 111.99 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -125.68 106.66 9.89 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.31 1.444 . . . . 0.0 111.791 176.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 p -106.69 173.0 6.51 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.981 2.113 . . . . 0.0 110.945 175.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.76 158.76 20.92 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.677 1.191 . . . . 0.0 111.625 175.058 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -124.03 159.87 28.91 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.173 1.389 . . . . 0.0 110.499 175.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -83.48 136.44 34.29 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 36.1 pt -109.75 -6.82 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.904 1.682 . . . . 0.0 114.164 174.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.25 93.6 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 122.648 1.213 . . . . 0.0 109.335 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.0 t -83.36 33.22 0.45 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.219 2.208 . . . . 0.0 112.246 176.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -80.14 118.99 22.33 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.153 1.381 . . . . 0.0 110.975 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -128.47 -171.21 2.41 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.404 1.882 . . . . 0.0 110.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.8 t70 . . . . . 0 CA--C 1.557 1.218 0 C-N-CA 125.42 1.488 . . . . 0.0 113.58 175.334 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.316 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.53 -33.32 1.89 Allowed Glycine 0 N--CA 1.475 1.288 0 C-N-CA 124.743 1.163 . . . . 0.0 114.328 176.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 71.9 m80 40.06 65.28 0.76 Allowed 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.994 2.118 . . . . 0.0 113.397 -177.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.6 ptp -131.72 141.85 49.65 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.402 1.481 . . . . 0.0 111.88 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -114.12 144.53 43.01 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.75 1.22 . . . . 0.0 108.522 174.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -127.9 177.55 6.77 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 126.083 1.753 . . . . 0.0 110.625 177.025 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.8 p -54.99 90.89 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.743 2.017 . . . . 0.0 113.363 175.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 -79.25 153.33 30.02 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.136 0.974 . . . . 0.0 110.364 175.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.679 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.679 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 -80.76 58.78 3.43 Favored 'General case' 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.6 -178.89 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 125.193 1.397 . . . . 0.0 111.385 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -109.0 -28.59 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 125.481 1.512 . . . . 0.0 113.1 177.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -60.29 93.57 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 127.701 2.4 . . . . 0.0 112.548 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.18 86.94 2.11 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.466 1.907 . . . . 0.0 109.703 -175.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -75.9 -176.58 3.46 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 124.329 1.052 . . . . 0.0 111.417 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.252 0 C-N-CA 124.969 1.308 . . . . 0.0 114.008 175.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.421 0.153 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.46 81.55 0.16 Allowed Glycine 0 CA--C 1.534 1.226 0 C-N-CA 124.609 1.1 . . . . 0.0 113.19 -179.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 -131.28 36.47 3.8 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.795 1.638 . . . . 0.0 113.844 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.6 mpp? -107.14 97.06 6.87 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.241 1.416 . . . . 0.0 112.308 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -87.42 92.66 9.16 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.081 0.953 . . . . 0.0 110.229 175.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.8 p -141.5 173.22 11.71 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.502 1.921 . . . . 0.0 111.224 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 83.6 p -55.51 148.67 15.1 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.543 0.737 . . . . 0.0 112.325 174.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -127.51 160.34 31.81 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.972 1.309 . . . . 0.0 110.324 176.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.639 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.527 HG21 HG12 ' A' ' 66' ' ' ILE . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 37' ' ' GLN . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.506 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.639 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -78.97 128.52 33.38 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 15' ' ' VAL . 3.3 pt -136.17 -160.92 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.713 1.605 . . . . 0.0 110.023 -179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -50.67 -32.98 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.032 1.733 . . . . 0.0 114.164 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 96.1 0.97 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.914 1.286 . . . . 0.0 111.782 176.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -130.21 127.21 39.18 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.63 1.972 . . . . 0.0 110.311 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -129.28 -69.28 0.7 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.849 1.66 . . . . 0.0 111.238 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 24.8 t70 . . . . . 0 C--O 1.252 1.234 0 C-N-CA 124.79 1.236 . . . . 0.0 113.77 -176.723 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 120.289 0.09 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.03 50.62 4.8 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 124.244 0.926 . . . . 0.0 114.396 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -155.93 62.49 0.58 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.596 1.559 . . . . 0.0 111.97 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.9 ptp -159.88 41.67 0.2 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.16 109.48 1.12 Allowed 'General case' 0 CA--C 1.544 0.713 0 O-C-N 120.922 -1.111 . . . . 0.0 111.425 -178.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 t -137.87 167.27 22.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.853 1.661 . . . . 0.0 111.075 -178.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.5 p -63.92 162.24 14.18 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.202 1.001 . . . . 0.0 111.148 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -129.4 157.53 41.7 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.516 1.126 . . . . 0.0 110.288 177.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.739 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.403 HG11 ' HB2' ' A' ' 46' ' ' GLU . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 11.0 m-70 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.403 ' HB2' HG11 ' A' ' 21' ' ' VAL . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 60' ' ' SER . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.587 ' H ' HG12 ' A' ' 58' ' ' VAL . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.739 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.444 ' N ' ' HB1' ' A' ' 14' ' ' ALA . 3.0 tt0 -70.6 149.18 47.33 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.6 pt -107.97 -16.07 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 N-CA-C 114.328 1.232 . . . . 0.0 114.328 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 8.9 tp -64.33 -17.26 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.938 1.695 . . . . 0.0 112.267 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.3 t -72.75 80.11 1.12 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.746 1.618 . . . . 0.0 110.342 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -123.93 137.34 54.64 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.848 2.059 . . . . 0.0 110.585 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -100.99 -73.21 0.65 Allowed 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.56 1.144 . . . . 0.0 110.398 175.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.254 1.319 0 C-N-CA 126.737 2.015 . . . . 0.0 112.723 -177.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 119.503 -0.284 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.79 125.79 2.57 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.145 1.355 . . . . 0.0 111.697 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -68.97 111.7 5.15 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.752 0.821 . . . . 0.0 110.816 179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 64.5 mtp -112.09 152.91 27.7 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 124.505 1.122 . . . . 0.0 111.678 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 -90.94 140.98 29.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.118 0.967 . . . . 0.0 110.003 175.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 9.7 t -150.08 161.89 41.48 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 125.277 1.431 . . . . 0.0 110.003 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 87.2 p -71.66 -178.31 2.19 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.265 1.026 . . . . 0.0 110.988 175.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -122.48 157.69 31.44 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.077 0.951 . . . . 0.0 110.088 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.624 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.407 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.407 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.4 HG23 HG23 ' A' ' 44' ' ' ILE . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.477 HG22 ' HB2' ' A' ' 37' ' ' GLN . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.477 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.4 HG23 HG23 ' A' ' 21' ' ' VAL . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.624 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.409 ' C ' ' HB1' ' A' ' 14' ' ' ALA . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -79.13 140.66 37.75 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.0 pt -133.21 -162.16 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 126.474 1.91 . . . . 0.0 110.146 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.5 tp -50.03 -32.43 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 C-N-CA 125.752 1.621 . . . . 0.0 114.435 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.4 p -65.51 91.59 0.12 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.067 1.347 . . . . 0.0 112.352 179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.1 tt0 -106.16 140.04 39.75 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.303 1.841 . . . . 0.0 110.766 -179.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -89.05 -173.33 4.02 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.62 1.568 . . . . 0.0 111.573 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.22 0 C-N-CA 126.567 1.947 . . . . 0.0 111.907 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.18 0 CA-C-O 120.857 0.36 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.76 112.74 0.53 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.857 1.217 . . . . 0.0 111.665 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -56.52 107.77 0.42 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.022 1.329 . . . . 0.0 111.193 177.024 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ttt -136.78 144.76 43.92 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.58 1.552 . . . . 0.0 110.452 -178.287 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -92.56 130.35 38.23 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.746 0.818 . . . . 0.0 110.17 176.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -133.87 160.86 36.38 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.812 1.645 . . . . 0.0 111.674 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 t -78.96 155.88 28.75 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.428 0.633 . . . . 0.0 112.655 175.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -134.42 158.28 44.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.317 1.847 . . . . 0.0 109.141 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.532 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.472 HG21 HG12 ' A' ' 66' ' ' ILE . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.414 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -81.65 126.92 32.34 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.472 HG12 HG21 ' A' ' 15' ' ' VAL . 1.7 pt -135.53 -162.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.554 1.941 . . . . 0.0 109.956 -178.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -50.4 -30.08 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.121 1.768 . . . . 0.0 114.498 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.69 96.35 0.95 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.446 1.099 . . . . 0.0 112.16 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -129.77 167.96 17.28 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.627 2.371 . . . . 0.0 110.895 -179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.75 -64.57 0.84 Allowed 'General case' 0 CA--C 1.543 0.702 0 O-C-N 121.397 -0.814 . . . . 0.0 112.188 179.264 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 C--O 1.252 1.204 0 C-N-CA 129.38 3.072 . . . . 0.0 116.952 -176.818 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 120.396 0.141 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.81 104.35 0.21 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.056 0.836 . . . . 0.0 112.86 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -65.66 154.54 38.57 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 117.645 0.723 . . . . 0.0 111.371 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.35 159.74 42.2 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.506 1.122 . . . . 0.0 111.223 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -115.57 156.78 25.15 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.467 1.507 . . . . 0.0 111.317 176.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 95.32 2.22 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.282 1.833 . . . . 0.0 109.74 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.1 t -61.17 138.81 58.21 Favored 'General case' 0 N--CA 1.47 0.553 0 O-C-N 121.816 -0.553 . . . . 0.0 109.726 175.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -131.63 156.54 45.64 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.182 1.393 . . . . 0.0 110.057 176.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.688 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.44 HG21 HG12 ' A' ' 66' ' ' ILE . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 60' ' ' SER . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.497 ' H ' HG12 ' A' ' 58' ' ' VAL . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.688 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.06 124.7 27.47 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.44 HG12 HG21 ' A' ' 15' ' ' VAL . 1.7 pt -135.54 -163.97 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 126.145 1.778 . . . . 0.0 110.198 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -47.88 -41.26 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.171 1.789 . . . . 0.0 114.177 175.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.0 t -72.37 101.31 2.87 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.116 1.366 . . . . 0.0 110.427 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -152.04 169.84 21.38 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 127.643 2.377 . . . . 0.0 110.132 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -98.94 -68.46 0.8 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.032 0.933 . . . . 0.0 112.278 175.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 C--O 1.252 1.232 0 C-N-CA 125.954 1.702 . . . . 0.0 114.312 -174.695 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 119.612 -0.232 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.13 -159.26 26.08 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.226 1.393 . . . . 0.0 112.066 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -131.39 157.21 44.01 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.38 1.472 . . . . 0.0 110.893 175.02 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -148.99 175.89 10.91 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.566 1.546 . . . . 0.0 110.457 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tt0 -128.62 84.63 2.25 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.133 0.973 . . . . 0.0 110.769 -177.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.9 p -69.83 165.96 20.41 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.358 1.063 . . . . 0.0 112.37 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 13.2 m -139.88 174.39 10.56 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.391 1.476 . . . . 0.0 112.07 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -136.71 161.13 36.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.322 1.449 . . . . 0.0 110.291 174.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.421 HG13 ' CA ' ' A' ' 20' ' ' GLY . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.421 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -79.77 67.5 5.57 Favored 'General case' 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -83.59 -176.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 125.333 1.453 . . . . 0.0 111.805 177.033 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.09 -25.71 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 126.258 1.823 . . . . 0.0 113.521 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.4 m -62.38 97.33 0.09 Allowed 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 127.26 2.224 . . . . 0.0 112.659 -178.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -118.75 168.59 10.6 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 126.112 1.765 . . . . 0.0 112.584 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -66.35 -70.32 0.25 Allowed 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.109 1.363 . . . . 0.0 112.705 178.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.4 t70 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 125.588 1.555 . . . . 0.0 114.1 -179.533 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.97 153.57 9.83 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.679 1.609 . . . . 0.0 113.048 -174.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -123.63 5.14 8.89 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 125.322 1.449 . . . . 0.0 113.858 178.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.49 158.79 34.24 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.726 1.61 . . . . 0.0 112.418 175.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -140.51 124.07 17.02 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.767 2.027 . . . . 0.0 109.997 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.1 p -116.71 -43.08 2.92 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.63 1.572 . . . . 0.0 112.008 175.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 m -68.06 155.67 39.04 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.607 1.163 . . . . 0.0 111.545 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -98.85 161.55 13.57 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.13 0.972 . . . . 0.0 110.474 175.007 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.53 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.419 HG11 ' HB2' ' A' ' 46' ' ' GLU . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.471 ' HB2' HD13 ' A' ' 55' ' ' ILE . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB2' HG11 ' A' ' 21' ' ' VAL . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.471 HD13 ' HB2' ' A' ' 38' ' ' SER . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.582 HG12 ' H ' ' A' ' 60' ' ' SER . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.582 ' H ' HG12 ' A' ' 58' ' ' VAL . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.53 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -74.44 84.57 1.99 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.2 pt -132.39 -166.16 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 126.008 1.723 . . . . 0.0 111.344 -176.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.4 tp -121.43 -27.54 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 126.333 1.853 . . . . 0.0 112.686 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -58.02 121.04 9.64 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.531 1.532 . . . . 0.0 111.973 179.11 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -133.79 97.9 4.03 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.424 1.89 . . . . 0.0 109.609 -173.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -77.87 -174.64 3.62 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.037 1.335 . . . . 0.0 111.921 175.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 . . . . . 0 C--O 1.253 1.26 0 C-N-CA 126.239 1.816 . . . . 0.0 112.158 177.482 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.411 0.148 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.31 -89.0 0.1 Allowed Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.387 0.994 . . . . 0.0 113.07 177.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.4 p-80 -109.28 161.23 15.45 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.014 1.726 . . . . 0.0 112.392 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -159.71 48.79 0.3 Allowed 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.314 1.445 . . . . 0.0 113.198 -178.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -91.84 22.34 4.28 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.536 1.534 . . . . 0.0 113.285 -177.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -69.86 -71.56 0.23 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 126.055 1.742 . . . . 0.0 112.699 178.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 99.0 p -71.02 156.78 39.23 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.851 0.834 . . . . 0.0 111.965 174.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -143.69 158.44 43.67 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.487 1.515 . . . . 0.0 109.612 174.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.451 ' HB3' HD12 ' A' ' 63' ' ' LEU . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 60' ' ' SER . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.561 ' H ' HG12 ' A' ' 58' ' ' VAL . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 14' ' ' ALA . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -76.41 84.23 3.15 Favored 'General case' 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.7 pt -117.66 -167.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 C-N-CA 125.865 1.666 . . . . 0.0 111.617 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.04 -23.77 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.096 1.758 . . . . 0.0 113.608 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.2 t -57.32 102.08 0.08 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.028 1.731 . . . . 0.0 112.472 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -130.78 94.5 3.63 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.404 1.882 . . . . 0.0 111.036 -178.305 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 15.1 mt-10 -143.03 -72.33 0.3 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.435 . . . . 0.0 110.33 175.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.255 1.382 0 C-N-CA 125.575 1.55 . . . . 0.0 113.169 -176.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.95 98.08 0.12 Allowed Glycine 0 N--CA 1.476 1.324 0 CA-C-N 119.634 1.106 . . . . 0.0 113.61 -179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -136.56 48.78 2.11 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.636 1.574 . . . . 0.0 113.454 -175.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 ttt -123.64 61.36 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.474 1.509 . . . . 0.0 112.365 -171.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -72.37 159.87 33.3 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.312 1.045 . . . . 0.0 112.746 174.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -132.58 -63.32 0.79 Allowed 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 126.174 1.79 . . . . 0.0 111.502 -177.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 71.7 m -128.78 119.16 24.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 126.575 1.95 . . . . 0.0 111.034 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -103.43 161.0 14.22 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.055 1.342 . . . . 0.0 110.6 175.056 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.49 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.436 HG21 HG12 ' A' ' 66' ' ' ILE . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 60' ' ' SER . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -83.54 128.2 34.33 Favored 'General case' 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.436 HG12 HG21 ' A' ' 15' ' ' VAL . 1.1 pt -134.45 -174.3 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 125.58 1.552 . . . . 0.0 111.124 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.6 tp -111.02 -35.12 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.949 1.7 . . . . 0.0 113.076 176.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.6 t -75.83 82.73 2.77 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.048 1.339 . . . . 0.0 111.653 177.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -59.94 162.58 5.41 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.427 1.091 . . . . 0.0 112.119 175.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -63.62 -62.88 1.37 Allowed 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.04 -1.038 . . . . 0.0 112.144 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.6 t70 . . . . . 0 C--O 1.252 1.22 0 C-N-CA 125.637 1.575 . . . . 0.0 113.053 178.809 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.98 40.68 0.46 Allowed Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.117 0.865 . . . . 0.0 114.152 -176.292 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -133.15 40.82 3.17 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.984 1.314 . . . . 0.0 113.266 -176.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.55 161.36 14.78 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.855 1.262 . . . . 0.0 111.334 174.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mm-40 -69.63 165.2 21.7 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 123.958 0.903 . . . . 0.0 112.662 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.73 75.18 9.0 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.491 1.516 . . . . 0.0 112.638 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.3 m -92.22 124.55 36.38 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.358 1.063 . . . . 0.0 111.293 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -133.5 159.02 41.64 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 125.472 1.509 . . . . 0.0 109.986 175.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.516 ' HB2' HD13 ' A' ' 55' ' ' ILE . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.516 HD13 ' HB2' ' A' ' 38' ' ' SER . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 60' ' ' SER . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.496 ' H ' HG12 ' A' ' 58' ' ' VAL . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.692 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 -69.26 154.12 42.56 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 45.5 pt -107.66 -20.07 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -166.06 -35.05 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 127.397 2.279 . . . . 0.0 112.882 -178.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.81 114.42 1.41 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.877 1.671 . . . . 0.0 112.533 -178.019 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -137.08 128.63 28.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.651 1.58 . . . . 0.0 111.089 -177.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -107.36 -60.01 1.75 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.22 1.808 . . . . 0.0 111.479 178.491 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.254 1.331 0 C-N-CA 126.52 1.928 . . . . 0.0 113.133 -176.555 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 CA-C-O 119.45 -0.31 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.03 -44.52 23.44 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-N 119.088 0.858 . . . . 0.0 114.25 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.6 m80 54.97 -176.49 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 126.878 2.071 . . . . 0.0 113.434 -170.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -155.46 158.73 39.02 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.451 1.5 . . . . 0.0 111.413 175.025 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mt-30 -132.84 17.35 4.23 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.73 1.612 . . . . 0.0 112.526 -178.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 p -59.74 144.86 47.1 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 126.43 1.892 . . . . 0.0 113.479 177.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.3 m -78.84 116.79 19.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.321 1.449 . . . . 0.0 112.546 178.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -90.14 163.95 14.64 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.853 0.861 . . . . 0.0 110.297 174.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.41 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -79.66 57.17 2.41 Favored 'General case' 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 -176.19 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.548 1.139 . . . . 0.0 112.277 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.7 tp -109.48 -28.38 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.128 1.771 . . . . 0.0 113.112 177.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.3 m -59.4 107.72 0.61 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 127.383 2.273 . . . . 0.0 112.007 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -126.03 148.27 49.35 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.499 1.52 . . . . 0.0 111.648 178.116 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -71.71 -59.06 2.95 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.313 1.445 . . . . 0.0 112.57 178.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.253 1.283 0 C-N-CA 127.176 2.19 . . . . 0.0 114.64 -175.794 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.527 0.204 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 156.74 164.4 13.46 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 125.683 1.611 . . . . 0.0 112.567 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.5 t-160 -145.53 27.37 1.24 Allowed 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -178.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -90.42 148.23 22.92 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.518 1.527 . . . . 0.0 111.875 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -105.27 -45.78 4.4 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.446 1.099 . . . . 0.0 111.732 175.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 79.0 p -64.26 -36.53 84.38 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.291 1.036 . . . . 0.0 113.192 179.255 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.98 86.47 6.94 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.949 1.299 . . . . 0.0 111.203 -179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -73.26 161.7 30.22 Favored 'General case' 0 CA--C 1.546 0.801 0 O-C-N 121.68 -0.638 . . . . 0.0 111.111 175.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.612 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 60' ' ' SER . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 58' ' ' VAL . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.612 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -81.94 71.28 8.97 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.8 pt -93.45 -14.87 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -177.255 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.2 tp -63.78 -12.74 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 125.686 1.594 . . . . 0.0 113.032 176.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.07 84.06 0.23 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.976 1.71 . . . . 0.0 111.772 176.37 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.43 122.59 24.74 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.741 1.616 . . . . 0.0 111.409 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -122.22 -64.54 1.19 Allowed 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.77 1.628 . . . . 0.0 111.618 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 C--O 1.253 1.263 0 C-N-CA 127.11 2.164 . . . . 0.0 112.555 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 121.087 0.47 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.24 -143.79 10.29 Favored Glycine 0 CA--C 1.531 1.067 0 O-C-N 120.793 -1.192 . . . . 0.0 111.963 -173.307 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -70.68 147.81 48.7 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.41 0.605 . . . . 0.0 112.232 175.19 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.3 mtm -149.6 160.44 43.49 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 126.935 2.094 . . . . 0.0 109.514 174.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.6 tt0 -135.68 169.47 17.49 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.559 1.544 . . . . 0.0 110.686 -177.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.5 104.42 2.76 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.159 1.384 . . . . 0.0 112.836 -177.37 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.5 t -101.51 121.4 41.9 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 124.718 1.207 . . . . 0.0 110.969 174.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -136.28 159.71 40.92 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.953 1.701 . . . . 0.0 110.149 174.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.513 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.513 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 -74.61 134.89 42.04 Favored 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.34 178.45 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 126.003 1.721 . . . . 0.0 110.819 176.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 1.3 tp -131.87 2.84 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.792 2.037 . . . . 0.0 113.287 178.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 64.6 m -64.43 87.79 0.05 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 126.406 1.882 . . . . 0.0 112.843 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -128.5 58.03 1.57 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.645 1.978 . . . . 0.0 110.844 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -67.36 0.37 Allowed 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.603 1.161 . . . . 0.0 112.338 175.31 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.252 1.229 0 C-N-CA 125.881 1.672 . . . . 0.0 112.448 176.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.446 0.165 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.93 -68.81 0.01 OUTLIER Glycine 0 N--CA 1.474 1.217 0 C-N-CA 124.832 1.205 . . . . 0.0 112.269 -178.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -75.25 119.64 19.65 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.489 1.116 . . . . 0.0 111.29 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.7 mmt -116.52 88.33 2.87 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.518 1.927 . . . . 0.0 110.022 177.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.98 154.2 38.2 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.322 0.649 . . . . 0.0 111.087 175.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.5 p -96.74 -69.6 0.75 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.612 1.165 . . . . 0.0 110.931 174.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 75.0 m -60.77 110.26 1.27 Allowed 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.996 1.318 . . . . 0.0 111.557 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -132.64 158.26 42.72 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.63 1.572 . . . . 0.0 110.69 177.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.427 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.463 ' HB2' HD13 ' A' ' 55' ' ' ILE . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 38' ' ' SER . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.489 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -76.88 66.56 2.77 Favored 'General case' 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -77.24 -175.52 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.694 1.198 . . . . 0.0 111.443 177.096 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -113.62 -24.05 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.756 1.622 . . . . 0.0 113.575 178.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.53 101.13 0.08 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.759 2.024 . . . . 0.0 112.33 177.362 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -126.22 61.42 1.28 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.26 1.824 . . . . 0.0 111.961 -176.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -62.62 -57.56 10.63 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 120.972 -1.08 . . . . 0.0 112.688 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.275 1.83 . . . . 0.0 113.948 -178.836 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 CA-C-O 119.598 -0.239 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.79 143.37 3.49 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 125.237 1.399 . . . . 0.0 112.766 -173.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -92.72 59.35 3.25 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 124.308 1.043 . . . . 0.0 111.357 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.4 ttm -156.31 99.72 1.94 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.221 1.008 . . . . 0.0 111.574 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -74.0 152.11 40.12 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.376 0.67 . . . . 0.0 111.377 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 t -68.17 -42.66 79.68 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.639 0.776 . . . . 0.0 111.455 176.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.8 p -87.8 134.86 33.6 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.714 2.006 . . . . 0.0 112.606 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -140.29 158.79 43.49 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.275 1.83 . . . . 0.0 109.559 175.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.483 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.406 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.406 HD13 ' HB2' ' A' ' 38' ' ' SER . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.483 HD23 ' HB3' ' A' ' 14' ' ' ALA . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.41 74.76 3.97 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.9 pt -113.47 -165.12 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 126.118 1.767 . . . . 0.0 111.247 -177.331 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -123.76 -31.87 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 126.082 1.753 . . . . 0.0 112.844 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -60.26 137.22 58.16 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.581 1.152 . . . . 0.0 111.634 176.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -129.89 171.79 12.37 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.097 1.759 . . . . 0.0 111.393 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -57.95 -61.49 2.5 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.477 -0.764 . . . . 0.0 112.59 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.214 0 C-N-CA 125.442 1.497 . . . . 0.0 113.466 -178.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.216 0.055 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.9 57.34 0.32 Allowed Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.071 0.844 . . . . 0.0 114.147 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 57.32 87.71 0.06 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 127.159 2.184 . . . . 0.0 114.137 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.6 mtp -98.63 -32.16 11.56 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.905 1.282 . . . . 0.0 113.782 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -137.28 167.58 21.31 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.255 2.222 . . . . 0.0 111.111 -177.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 8.1 p -122.49 -69.63 0.82 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 126.476 1.911 . . . . 0.0 110.73 -177.362 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.2 p -71.61 163.46 27.71 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.562 1.145 . . . . 0.0 111.993 175.002 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -136.08 160.16 39.49 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.794 1.637 . . . . 0.0 110.052 174.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.415 HG13 ' CA ' ' A' ' 20' ' ' GLY . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.415 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.51 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.31 69.04 9.9 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 pt -90.12 -15.21 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -176.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.1 tp -63.6 -15.74 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.012 1.325 . . . . 0.0 111.973 175.029 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.7 137.07 58.18 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.391 1.476 . . . . 0.0 111.629 175.069 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -146.96 161.88 39.88 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.14 1.376 . . . . 0.0 111.867 -178.32 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -124.13 -65.29 1.07 Allowed 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.237 1.415 . . . . 0.0 111.466 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.4 t70 . . . . . 0 C--O 1.254 1.329 0 C-N-CA 125.517 1.527 . . . . 0.0 114.003 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.265 0 CA-C-O 120.971 0.415 . . . . 0.0 111.523 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.08 5.19 84.8 Favored Glycine 0 CA--C 1.537 1.429 0 C-N-CA 125.339 1.447 . . . . 0.0 115.186 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -148.88 158.84 44.47 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.76 1.624 . . . . 0.0 111.974 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.18 178.98 6.58 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 127.18 2.192 . . . . 0.0 110.812 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.89 -175.05 1.63 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 124.63 1.172 . . . . 0.0 111.126 174.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -63.47 111.01 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.146 1.378 . . . . 0.0 111.832 174.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.0 m -118.28 159.32 23.57 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.185 1.394 . . . . 0.0 111.975 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -139.6 157.84 45.12 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.384 1.474 . . . . 0.0 109.776 175.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.6 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.6 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -83.54 93.05 7.75 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 31.7 pt -91.67 -21.28 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -165.59 -30.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 127.345 2.258 . . . . 0.0 113.823 -179.242 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -60.86 104.27 0.34 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.917 1.287 . . . . 0.0 113.151 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.76 173.52 9.47 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.114 1.365 . . . . 0.0 111.886 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.04 -63.27 0.61 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.107 1.763 . . . . 0.0 111.065 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.0 t70 . . . . . 0 C--O 1.254 1.33 0 C-N-CA 125.082 1.353 . . . . 0.0 113.243 -174.896 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.6 0.238 . . . . 0.0 111.432 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.97 175.63 53.96 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 124.717 1.151 . . . . 0.0 113.607 175.497 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -146.43 70.17 1.21 Allowed 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.942 1.297 . . . . 0.0 111.576 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.1 mtt -118.93 143.99 46.7 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.845 1.258 . . . . 0.0 112.337 178.371 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.5 tp60 -153.2 54.46 0.76 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 125.791 1.637 . . . . 0.0 110.972 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -75.19 154.37 37.66 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 120.722 -1.236 . . . . 0.0 111.367 174.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -87.13 177.21 7.26 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.628 0.771 . . . . 0.0 112.688 175.612 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -96.65 161.97 13.65 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.782 1.233 . . . . 0.0 111.914 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.44 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.44 HD23 ' HB3' ' A' ' 14' ' ' ALA . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -79.49 73.39 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -94.3 -171.74 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 125.914 1.686 . . . . 0.0 111.693 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.8 tp -119.95 -29.59 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.098 1.759 . . . . 0.0 113.087 176.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.17 124.02 18.57 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 126.521 1.928 . . . . 0.0 112.25 175.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -137.55 143.26 41.49 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.888 1.675 . . . . 0.0 110.937 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -119.43 -64.7 1.24 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.084 1.353 . . . . 0.0 111.498 179.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.068 1.747 . . . . 0.0 113.676 178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 121.093 0.473 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 . . . . . 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 . . . . . 0 CA--C 1.538 0.517 0 CA-C-O 121.319 0.581 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.679 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.679 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 . . . . . 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 121.198 0.523 . . . . 0.0 110.324 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.639 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 37' ' ' GLN . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.506 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.639 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 . . . . . 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 C--O 1.237 0.424 0 CA-C-O 121.072 0.463 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.739 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.403 HG11 ' HB2' ' A' ' 46' ' ' GLU . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.8 m80 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.403 ' HB2' HG11 ' A' ' 21' ' ' VAL . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 60' ' ' SER . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.587 ' H ' HG12 ' A' ' 58' ' ' VAL . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.739 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.444 ' N ' ' HB1' ' A' ' 14' ' ' ALA . 3.0 tt0 . . . . . 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 121.133 0.492 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.624 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.407 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.407 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.4 HG23 HG23 ' A' ' 44' ' ' ILE . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.477 HG22 ' HB2' ' A' ' 37' ' ' GLN . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.477 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.4 HG23 HG23 ' A' ' 21' ' ' VAL . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.624 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.409 ' C ' ' HB1' ' A' ' 14' ' ' ALA . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 . . . . . 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 . . . . . 0 CA--C 1.539 0.521 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.532 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.414 HG13 ' CA ' ' A' ' 20' ' ' GLY . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.414 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 . . . . . 0 C--O 1.237 0.399 0 CA-C-O 121.16 0.505 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.688 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 60' ' ' SER . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.497 ' H ' HG12 ' A' ' 58' ' ' VAL . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.688 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 . . . . . 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 CA--C 1.538 0.518 0 CA-C-O 121.054 0.454 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.421 HG13 ' CA ' ' A' ' 20' ' ' GLY . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.421 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 . . . . . 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.639 0 CA-C-O 121.088 0.471 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.53 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.419 HG11 ' HB2' ' A' ' 46' ' ' GLU . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.471 ' HB2' HD13 ' A' ' 55' ' ' ILE . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB2' HG11 ' A' ' 21' ' ' VAL . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.471 HD13 ' HB2' ' A' ' 38' ' ' SER . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.582 HG12 ' H ' ' A' ' 60' ' ' SER . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.582 ' H ' HG12 ' A' ' 58' ' ' VAL . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.53 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 . . . . . 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 . . . . . 0 CA--C 1.538 0.49 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.451 ' HB3' HD12 ' A' ' 63' ' ' LEU . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 60' ' ' SER . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.561 ' H ' HG12 ' A' ' 58' ' ' VAL . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 14' ' ' ALA . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 . . . . . 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 . . . . . 0 CA--C 1.545 0.761 0 CA-C-O 121.002 0.429 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.49 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 60' ' ' SER . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 . . . . . 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 . . . . . 0 N--CA 1.472 0.64 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.516 ' HB2' HD13 ' A' ' 55' ' ' ILE . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.516 HD13 ' HB2' ' A' ' 38' ' ' SER . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 60' ' ' SER . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.496 ' H ' HG12 ' A' ' 58' ' ' VAL . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.692 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 . . . . . 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 120.978 0.418 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.41 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 . . . . . 0 CA--C 1.546 0.801 0 CA-C-O 121.15 0.5 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.612 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 60' ' ' SER . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 58' ' ' VAL . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.612 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 . . . . . 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 121.061 0.458 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.513 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.513 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 . . . . . 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 . . . . . 0 CA--C 1.537 0.458 0 CA-C-O 121.531 0.681 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.427 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.463 ' HB2' HD13 ' A' ' 55' ' ' ILE . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 38' ' ' SER . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.489 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 . . . . . 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 . . . . . 0 CA--C 1.542 0.654 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.483 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.406 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.406 HD13 ' HB2' ' A' ' 38' ' ' SER . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.483 HD23 ' HB3' ' A' ' 14' ' ' ALA . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 . . . . . 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 . . . . . 0 CA--C 1.541 0.609 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.415 HG13 ' CA ' ' A' ' 20' ' ' GLY . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.415 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.51 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 . . . . . 0 CA--C 1.539 0.523 0 CA-C-O 121.068 0.461 . . . . 0.0 109.776 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.6 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.6 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 . . . . . 0 CA--C 1.545 0.765 0 CA-C-O 121.325 0.583 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.44 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.44 HD23 ' HB3' ' A' ' 14' ' ' ALA . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 . . . . . 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.257 0 CA-C-O 120.559 0.219 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.61 173.32 39.7 Favored Glycine 0 CA--C 1.534 1.267 0 C-N-CA 125.121 1.343 . . . . 0.0 112.973 175.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.6 p80 -150.76 152.38 33.76 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.171 1.788 . . . . 0.0 111.157 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -152.51 178.18 9.84 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.845 1.258 . . . . 0.0 111.99 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -125.68 106.66 9.89 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.31 1.444 . . . . 0.0 111.791 176.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 p -106.69 173.0 6.51 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.981 2.113 . . . . 0.0 110.945 175.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.76 158.76 20.92 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.677 1.191 . . . . 0.0 111.625 175.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -124.03 159.87 28.91 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.173 1.389 . . . . 0.0 110.499 175.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -72.72 -171.96 0.92 Allowed 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.313 1.445 . . . . 0.0 111.661 175.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -50.83 141.43 13.26 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.22 1.408 . . . . 0.0 111.02 175.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.52 -3.5 50.15 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 125.167 1.365 . . . . 0.0 114.588 -174.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -67.96 142.89 55.84 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 119.054 1.427 . . . . 0.0 111.742 175.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 15.3 ttmt -129.29 127.86 42.02 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.401 1.08 . . . . 0.0 110.182 174.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.95 167.48 18.5 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 125.142 1.377 . . . . 0.0 111.451 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -83.33 100.33 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 125.741 1.616 . . . . 0.0 109.343 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.36 157.7 72.56 Favored Pre-proline 0 CA--C 1.554 1.107 0 C-N-CA 123.274 0.63 . . . . 0.0 111.61 174.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -73.37 87.64 1.05 Allowed 'Trans proline' 0 CA--C 1.542 0.905 0 C-N-CA 124.46 3.44 . . . . 0.0 112.169 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.77 -57.27 0.16 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 124.42 1.01 . . . . 0.0 113.487 175.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -129.21 -36.74 1.71 Allowed 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 124.497 1.119 . . . . 0.0 113.068 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.48 -10.9 69.9 Favored Glycine 0 CA--C 1.535 1.288 0 C-N-CA 124.681 1.134 . . . . 0.0 115.91 -177.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 41.5 t -105.9 124.24 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.999 1.32 . . . . 0.0 110.048 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.35 143.01 3.54 Favored Glycine 0 CA--C 1.531 1.072 0 C-N-CA 125.326 1.441 . . . . 0.0 112.156 178.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -121.0 131.58 54.38 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.12 1.368 . . . . 0.0 108.354 174.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.3 t -59.14 107.11 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 123.671 0.788 . . . . 0.0 109.544 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.29 -19.83 27.69 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.077 1.351 . . . . 0.0 111.705 -176.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.32 -172.47 44.5 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.46 1.505 . . . . 0.0 112.755 175.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.75 143.06 34.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 C-N-CA 125.57 1.548 . . . . 0.0 107.202 175.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -112.58 145.8 39.7 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.332 1.453 . . . . 0.0 111.138 175.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -137.83 113.75 9.86 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 125.108 1.363 . . . . 0.0 109.743 -178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.5 t -141.84 -179.93 6.49 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.704 1.202 . . . . 0.0 111.947 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -123.95 108.51 12.49 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 126.623 1.969 . . . . 0.0 110.275 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.6 m -110.84 144.31 19.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 126.042 1.737 . . . . 0.0 110.007 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.04 27.18 2.36 Favored 'General case' 0 CA--C 1.556 1.211 0 N-CA-C 114.694 1.368 . . . . 0.0 114.694 -175.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.17 12.01 85.01 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 124.933 1.254 . . . . 0.0 115.257 -175.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -124.56 141.14 52.32 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 126.041 1.737 . . . . 0.0 111.218 -178.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -64.1 120.95 13.04 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 124.147 0.979 . . . . 0.0 109.848 174.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -137.94 115.69 11.43 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 124.635 1.174 . . . . 0.0 110.769 178.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.5 m -81.62 157.06 24.83 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 124.574 1.15 . . . . 0.0 112.507 176.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -142.74 158.56 43.52 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 125.788 1.635 . . . . 0.0 110.891 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -102.38 130.18 49.06 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.598 1.559 . . . . 0.0 109.6 174.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.86 99.71 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 124.562 1.145 . . . . 0.0 108.377 175.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -105.89 114.03 27.94 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 123.187 0.595 . . . . 0.0 110.024 178.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.3 ttm180 -89.73 120.09 30.69 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.05 0.94 . . . . 0.0 108.66 174.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 mm -76.67 103.9 4.31 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 126.133 1.773 . . . . 0.0 109.279 177.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.0 mp -57.98 -15.42 8.91 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.288 1.435 . . . . 0.0 114.521 178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -55.03 -54.19 46.19 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.973 1.709 . . . . 0.0 112.256 177.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.46 3.44 3.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 125.199 1.399 . . . . 0.0 114.346 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.8 14.81 80.45 Favored Glycine 0 CA--C 1.537 1.449 0 C-N-CA 124.296 0.951 . . . . 0.0 114.111 -171.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 47.9 mtm -62.38 164.62 7.0 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.556 1.142 . . . . 0.0 112.125 175.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.5 ptp85 -125.16 128.9 49.12 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 126.128 1.771 . . . . 0.0 110.512 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 52.9 mt -130.26 115.26 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 124.546 1.138 . . . . 0.0 109.11 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.6 mtt -70.39 147.84 49.07 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 122.663 0.385 . . . . 0.0 110.752 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.8 mt -131.68 103.7 14.61 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.538 1.135 . . . . 0.0 109.255 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -67.19 123.99 11.59 Favored 'Trans proline' 0 C--N 1.349 0.574 0 C-N-CA 123.191 2.594 . . . . 0.0 111.271 177.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.0 pt -58.17 -18.45 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.144 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -50.68 -40.82 54.69 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 127.627 2.371 . . . . 0.0 112.929 176.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 17.3 ptmt -89.11 -25.19 22.02 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 124.544 1.138 . . . . 0.0 113.519 175.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.4 t -73.46 -57.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 C-N-CA 125.741 1.616 . . . . 0.0 111.661 -175.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.29 -7.39 3.51 Favored Glycine 0 CA--C 1.544 1.874 0 C-N-CA 126.153 1.835 . . . . 0.0 116.848 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 2.9 m -168.15 -79.19 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 127.246 2.218 . . . . 0.0 111.09 177.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.0 m -136.27 -39.01 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 125.259 1.424 . . . . 0.0 114.13 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.67 -3.19 2.08 Favored Glycine 0 CA--C 1.542 1.753 0 C-N-CA 124.885 1.231 . . . . 0.0 115.819 -176.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.4 mp -94.05 145.24 24.81 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 126.817 2.047 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.0 mtt-85 -140.74 117.61 11.08 Favored 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 126.1 1.76 . . . . 0.0 111.579 176.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 -83.48 136.44 34.29 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 120.898 -1.126 . . . . 0.0 111.584 176.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 36.1 pt -109.75 -6.82 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 125.904 1.682 . . . . 0.0 114.164 174.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.0 mp -62.25 93.6 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 CA-C-O 122.648 1.213 . . . . 0.0 109.335 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.0 t -83.36 33.22 0.45 Allowed 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 127.219 2.208 . . . . 0.0 112.246 176.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -80.14 118.99 22.33 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 125.153 1.381 . . . . 0.0 110.975 175.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -128.47 -171.21 2.41 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.404 1.882 . . . . 0.0 110.814 178.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 26.8 t70 . . . . . 0 CA--C 1.557 1.218 0 C-N-CA 125.42 1.488 . . . . 0.0 113.58 175.334 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.316 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 142.53 -33.32 1.89 Allowed Glycine 0 N--CA 1.475 1.288 0 C-N-CA 124.743 1.163 . . . . 0.0 114.328 176.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 71.9 m80 40.06 65.28 0.76 Allowed 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 126.994 2.118 . . . . 0.0 113.397 -177.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.6 ptp -131.72 141.85 49.65 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.402 1.481 . . . . 0.0 111.88 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -114.12 144.53 43.01 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.75 1.22 . . . . 0.0 108.522 174.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 p -127.9 177.55 6.77 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 126.083 1.753 . . . . 0.0 110.625 177.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.8 p -54.99 90.89 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.743 2.017 . . . . 0.0 113.363 175.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 48.3 t80 -79.25 153.33 30.02 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.136 0.974 . . . . 0.0 110.364 175.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -73.01 -173.32 1.23 Allowed 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 124.652 1.181 . . . . 0.0 111.98 174.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 85.9 m -50.05 140.12 12.97 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.969 1.708 . . . . 0.0 110.87 174.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.22 -5.65 45.65 Favored Glycine 0 CA--C 1.533 1.191 0 C-N-CA 124.643 1.116 . . . . 0.0 114.603 -174.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.71 134.33 53.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 119.414 1.607 . . . . 0.0 110.602 175.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.6 ttmt -129.28 127.86 42.03 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.919 0.887 . . . . 0.0 110.308 178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.679 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.92 168.35 10.35 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.894 1.278 . . . . 0.0 111.286 -176.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.29 100.91 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.132 0.973 . . . . 0.0 108.675 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.8 157.94 81.22 Favored Pre-proline 0 CA--C 1.554 1.123 0 O-C-N 121.443 -0.786 . . . . 0.0 111.122 178.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -71.42 87.17 0.78 Allowed 'Trans proline' 0 CA--C 1.543 0.926 0 C-N-CA 124.634 3.556 . . . . 0.0 112.419 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.33 -58.15 0.2 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 124.326 0.965 . . . . 0.0 113.796 174.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -127.63 -43.0 1.59 Allowed 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 124.579 1.152 . . . . 0.0 112.443 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.42 -12.55 51.24 Favored Glycine 0 CA--C 1.533 1.162 0 C-N-CA 125.015 1.293 . . . . 0.0 115.943 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.92 124.59 58.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.98 1.312 . . . . 0.0 110.182 175.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 162.77 137.81 2.27 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 124.986 1.279 . . . . 0.0 112.229 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -117.36 131.64 56.75 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.51 1.124 . . . . 0.0 108.464 175.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -58.3 115.63 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 124.276 1.031 . . . . 0.0 110.076 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.5 tpt -93.71 -21.47 19.32 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.531 1.132 . . . . 0.0 112.561 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.08 -174.18 44.18 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 124.066 0.841 . . . . 0.0 113.252 177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.28 135.66 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 124.941 1.296 . . . . 0.0 107.766 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -105.81 154.39 20.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.642 1.577 . . . . 0.0 111.461 175.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 -137.75 113.84 9.98 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.174 1.389 . . . . 0.0 109.404 -178.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.3 t -141.62 149.03 40.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.356 1.063 . . . . 0.0 111.653 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -89.65 136.97 32.72 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.015 0.926 . . . . 0.0 111.2 178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.9 m -134.03 136.89 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 125.98 1.712 . . . . 0.0 109.902 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.82 27.16 2.94 Favored 'General case' 0 CA--C 1.556 1.187 0 N-CA-C 115.055 1.502 . . . . 0.0 115.055 -176.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.86 13.9 78.65 Favored Glycine 0 CA--C 1.537 1.464 0 C-N-CA 124.8 1.19 . . . . 0.0 115.153 -175.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -124.81 135.0 52.55 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 126.208 1.803 . . . . 0.0 111.167 -178.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -62.58 117.95 6.93 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.682 1.193 . . . . 0.0 111.025 175.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.64 172.18 8.05 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 126.04 1.736 . . . . 0.0 110.572 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.2 m -142.56 155.04 44.95 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 125.114 1.365 . . . . 0.0 110.603 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -142.3 147.58 36.61 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.806 0.842 . . . . 0.0 110.789 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -84.57 126.58 33.45 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.856 0.862 . . . . 0.0 110.603 175.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 t -92.09 99.65 10.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.816 0.846 . . . . 0.0 109.916 177.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.8 tp -105.18 113.88 27.74 Favored 'General case' 0 C--O 1.236 0.35 0 C-N-CA 123.436 0.695 . . . . 0.0 110.826 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.09 108.57 19.32 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 124.031 0.933 . . . . 0.0 109.631 175.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -73.41 101.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 C-N-CA 126.366 1.866 . . . . 0.0 109.355 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 1.1 mt -55.78 -14.33 2.26 Favored 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.054 1.742 . . . . 0.0 114.864 176.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.82 -52.69 64.64 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 126.423 1.889 . . . . 0.0 112.596 178.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -132.45 3.98 3.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.553 1.541 . . . . 0.0 113.735 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.28 16.64 80.56 Favored Glycine 0 CA--C 1.536 1.348 0 C-N-CA 124.266 0.936 . . . . 0.0 113.938 -170.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 52.7 mtm -62.92 163.15 10.06 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 118.396 1.098 . . . . 0.0 111.982 174.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -129.58 105.8 8.31 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 126.19 1.796 . . . . 0.0 109.322 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -100.52 123.81 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 124.198 0.999 . . . . 0.0 108.51 176.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -91.28 144.51 25.53 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 123.322 0.649 . . . . 0.0 110.486 174.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 mp -127.11 122.06 22.97 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 124.76 1.224 . . . . 0.0 110.059 178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.65 125.21 14.46 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 123.453 2.768 . . . . 0.0 111.615 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.17 -15.5 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 177.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -62.85 -23.0 67.08 Favored 'General case' 0 CA--C 1.55 0.954 0 O-C-N 121.036 -1.04 . . . . 0.0 112.76 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.37 7.6 9.61 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 126.301 1.84 . . . . 0.0 114.876 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -57.92 -36.71 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.153 0 C-N-CA 125.941 1.696 . . . . 0.0 114.499 -176.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.71 -20.33 0.38 Allowed Glycine 0 CA--C 1.542 1.759 0 C-N-CA 127.271 2.367 . . . . 0.0 116.054 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -176.69 -60.39 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.07 2.548 . . . . 0.0 110.729 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 12.0 m -142.82 -31.54 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 125.547 1.539 . . . . 0.0 114.369 -177.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 78.27 -10.17 29.91 Favored Glycine 0 CA--C 1.538 1.48 0 C-N-CA 124.516 1.055 . . . . 0.0 114.52 -175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.679 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 3.0 mm? -104.39 111.96 24.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.395 1.878 . . . . 0.0 109.451 175.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.0 ttm-85 -113.08 117.71 32.74 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.199 0.999 . . . . 0.0 110.188 -177.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.3 tt0 -80.76 58.78 3.43 Favored 'General case' 0 N--CA 1.48 1.061 0 O-C-N 119.995 -1.691 . . . . 0.0 111.743 -175.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.6 -178.89 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 125.193 1.397 . . . . 0.0 111.385 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -109.0 -28.59 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 125.481 1.512 . . . . 0.0 113.1 177.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -60.29 93.57 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 127.701 2.4 . . . . 0.0 112.548 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.18 86.94 2.11 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.466 1.907 . . . . 0.0 109.703 -175.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -75.9 -176.58 3.46 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 124.329 1.052 . . . . 0.0 111.417 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.253 1.252 0 C-N-CA 124.969 1.308 . . . . 0.0 114.008 175.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.421 0.153 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.46 81.55 0.16 Allowed Glycine 0 CA--C 1.534 1.226 0 C-N-CA 124.609 1.1 . . . . 0.0 113.19 -179.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 -131.28 36.47 3.8 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.795 1.638 . . . . 0.0 113.844 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 4.6 mpp? -107.14 97.06 6.87 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.241 1.416 . . . . 0.0 112.308 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -87.42 92.66 9.16 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.081 0.953 . . . . 0.0 110.229 175.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.8 p -141.5 173.22 11.71 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 126.502 1.921 . . . . 0.0 111.224 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 83.6 p -55.51 148.67 15.1 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.543 0.737 . . . . 0.0 112.325 174.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -127.51 160.34 31.81 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 124.972 1.309 . . . . 0.0 110.324 176.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -71.63 -171.8 0.71 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.207 1.403 . . . . 0.0 112.08 175.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 55.5 m -51.06 138.67 19.3 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.008 1.723 . . . . 0.0 110.07 175.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.87 -4.02 41.97 Favored Glycine 0 CA--C 1.533 1.2 0 C-N-CA 124.133 0.873 . . . . 0.0 114.82 -174.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -73.31 134.33 44.13 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 119.308 1.554 . . . . 0.0 109.579 175.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.97 127.78 50.73 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.81 1.244 . . . . 0.0 110.038 175.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.639 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.82 174.64 13.58 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.175 1.39 . . . . 0.0 110.255 -176.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.527 HG21 HG12 ' A' ' 66' ' ' ILE . 21.3 t -92.01 100.23 10.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 125.125 1.37 . . . . 0.0 108.886 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -76.52 158.0 81.71 Favored Pre-proline 0 CA--C 1.555 1.136 0 O-C-N 121.639 -0.663 . . . . 0.0 110.907 175.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -72.41 87.91 0.9 Allowed 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 124.559 3.506 . . . . 0.0 112.55 177.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.7 -50.82 0.22 Allowed Glycine 0 CA--C 1.532 1.119 0 C-N-CA 124.118 0.866 . . . . 0.0 114.416 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.2 -47.25 1.0 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.651 1.18 . . . . 0.0 112.165 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 98.29 -8.7 62.71 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.771 1.176 . . . . 0.0 115.724 -177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -106.05 129.33 59.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 126.176 1.79 . . . . 0.0 110.93 175.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 149.55 145.97 4.23 Favored Glycine 0 CA--C 1.532 1.116 0 C-N-CA 125.843 1.687 . . . . 0.0 112.024 -177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -124.11 131.98 53.6 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.912 1.285 . . . . 0.0 108.503 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 55.7 t -58.25 116.59 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.924 0.889 . . . . 0.0 110.05 -176.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 56.0 tpp -94.52 -20.03 20.01 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.879 1.272 . . . . 0.0 112.405 178.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -174.82 44.14 Favored Glycine 0 CA--C 1.527 0.782 0 O-C-N 121.309 -0.869 . . . . 0.0 114.118 175.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.07 134.55 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 C-N-CA 125.145 1.378 . . . . 0.0 107.467 175.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -99.98 142.8 30.97 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -134.51 113.79 12.17 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 124.674 1.19 . . . . 0.0 110.469 -178.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.4 t -139.58 -178.01 5.2 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.599 1.16 . . . . 0.0 111.776 178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -135.99 110.32 8.44 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.163 1.785 . . . . 0.0 109.665 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 37' ' ' GLN . 24.6 m -116.53 146.99 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 125.665 1.586 . . . . 0.0 110.115 -179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.57 26.95 2.65 Favored 'General case' 0 CA--C 1.557 1.219 0 N-CA-C 114.714 1.375 . . . . 0.0 114.714 -175.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.7 11.14 84.71 Favored Glycine 0 CA--C 1.541 1.665 0 C-N-CA 124.747 1.165 . . . . 0.0 115.376 -175.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.37 141.41 52.01 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 126.504 1.921 . . . . 0.0 112.053 179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.1 mtt-85 -63.64 113.32 3.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.476 1.51 . . . . 0.0 109.831 176.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.506 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -126.3 113.18 16.59 Favored 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 124.891 1.276 . . . . 0.0 109.983 177.438 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.71 156.91 18.23 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.676 0.751 . . . . 0.0 110.054 174.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -140.53 168.63 19.35 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.988 1.315 . . . . 0.0 110.44 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.59 124.9 49.66 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.744 1.217 . . . . 0.0 111.18 175.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.77 99.6 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -106.82 113.81 27.53 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.798 0.839 . . . . 0.0 108.807 176.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 23.2 ttm-85 -90.36 111.88 23.26 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.651 1.181 . . . . 0.0 109.095 177.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.4 mm -74.27 96.15 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.777 1.631 . . . . 0.0 109.949 -177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 31.1 mt -56.03 -18.06 8.54 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 126.304 1.842 . . . . 0.0 114.573 178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -55.64 -56.62 18.22 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 126.804 2.042 . . . . 0.0 112.277 178.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -133.39 5.32 3.75 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.087 1.355 . . . . 0.0 113.892 -177.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.96 15.18 79.57 Favored Glycine 0 CA--C 1.538 1.478 0 O-C-N 121.18 -0.95 . . . . 0.0 114.338 -172.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 67.6 mtm -66.13 169.19 7.32 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.447 1.123 . . . . 0.0 111.42 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.1 ptp85 -134.29 131.51 38.49 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 126.527 1.931 . . . . 0.0 110.326 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.7 mt -135.42 110.36 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.818 0.847 . . . . 0.0 110.737 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 38.6 mtt -76.43 149.16 36.89 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 122.744 0.418 . . . . 0.0 110.08 175.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 63.3 mt -136.34 125.39 15.59 Favored Pre-proline 0 N--CA 1.473 0.705 0 C-N-CA 125.551 1.54 . . . . 0.0 109.834 178.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.7 126.28 14.48 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.451 2.768 . . . . 0.0 112.67 178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.2 pt -65.27 -14.84 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -80.04 -6.34 57.44 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 124.436 1.094 . . . . 0.0 112.808 177.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 48.6 tttm -118.65 -24.07 6.85 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 126.416 1.886 . . . . 0.0 113.775 -178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 22.9 m -63.62 -20.26 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 114.349 1.24 . . . . 0.0 114.349 174.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.63 -20.73 0.47 Allowed Glycine 0 CA--C 1.541 1.699 0 C-N-CA 127.327 2.394 . . . . 0.0 116.436 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -167.71 -54.3 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 127.966 2.507 . . . . 0.0 111.213 175.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 13.9 m -137.42 -44.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 C-N-CA 125.386 1.474 . . . . 0.0 113.401 -176.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.81 -8.9 70.66 Favored Glycine 0 CA--C 1.535 1.292 0 C-N-CA 124.921 1.248 . . . . 0.0 114.045 -177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.639 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.21 134.54 47.28 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.669 1.987 . . . . 0.0 110.195 176.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -137.14 120.65 17.12 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 125.522 1.529 . . . . 0.0 112.077 177.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -78.97 128.52 33.38 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 120.572 -1.33 . . . . 0.0 110.153 177.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 15' ' ' VAL . 3.3 pt -136.17 -160.92 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.713 1.605 . . . . 0.0 110.023 -179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -50.67 -32.98 11.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.032 1.733 . . . . 0.0 114.164 175.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 96.1 0.97 Allowed 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 124.914 1.286 . . . . 0.0 111.782 176.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -130.21 127.21 39.18 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.63 1.972 . . . . 0.0 110.311 -178.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -129.28 -69.28 0.7 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.849 1.66 . . . . 0.0 111.238 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 24.8 t70 . . . . . 0 C--O 1.252 1.234 0 C-N-CA 124.79 1.236 . . . . 0.0 113.77 -176.723 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.313 0 CA-C-O 120.289 0.09 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 82.03 50.62 4.8 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 124.244 0.926 . . . . 0.0 114.396 175.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -155.93 62.49 0.58 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.596 1.559 . . . . 0.0 111.97 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.9 ptp -159.88 41.67 0.2 Allowed 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.16 109.48 1.12 Allowed 'General case' 0 CA--C 1.544 0.713 0 O-C-N 120.922 -1.111 . . . . 0.0 111.425 -178.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.9 t -137.87 167.27 22.09 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.853 1.661 . . . . 0.0 111.075 -178.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.5 p -63.92 162.24 14.18 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.202 1.001 . . . . 0.0 111.148 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -129.4 157.53 41.7 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.516 1.126 . . . . 0.0 110.288 177.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -69.1 -175.38 0.74 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 124.405 1.082 . . . . 0.0 111.456 174.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.0 m -50.26 141.12 12.05 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.88 1.272 . . . . 0.0 111.302 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.43 -2.45 50.05 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 124.251 0.929 . . . . 0.0 114.399 -175.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -67.6 134.32 50.98 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.985 1.393 . . . . 0.0 110.518 174.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.3 ttmt -140.37 127.74 21.28 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 124.227 1.011 . . . . 0.0 109.979 179.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.739 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.11 167.87 8.6 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.13 0.972 . . . . 0.0 111.94 -175.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.0 t -82.25 100.22 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 C-N-CA 124.698 1.199 . . . . 0.0 110.06 -175.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.91 157.74 71.19 Favored Pre-proline 0 CA--C 1.548 0.896 0 C-N-CA 123.299 0.64 . . . . 0.0 112.066 176.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -72.41 85.15 1.1 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.424 3.416 . . . . 0.0 111.728 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.53 -49.25 0.16 Allowed Glycine 0 CA--C 1.53 0.991 0 C-N-CA 124.298 0.952 . . . . 0.0 114.024 175.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -140.74 -38.34 0.43 Allowed 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.373 1.069 . . . . 0.0 113.467 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.66 -10.82 57.71 Favored Glycine 0 CA--C 1.533 1.209 0 C-N-CA 124.999 1.285 . . . . 0.0 115.506 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.403 HG11 ' HB2' ' A' ' 46' ' ' GLU . 7.1 p -106.13 145.64 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.772 2.029 . . . . 0.0 111.151 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 143.33 119.26 1.38 Allowed Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.354 1.454 . . . . 0.0 110.97 -177.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 75.5 tt0 -108.38 127.02 53.52 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.406 1.083 . . . . 0.0 109.647 175.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -60.35 131.65 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 124.16 0.984 . . . . 0.0 110.717 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.58 -26.43 10.89 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.624 1.57 . . . . 0.0 114.099 -179.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.0 -172.02 43.66 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 124.513 1.054 . . . . 0.0 113.351 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -111.17 134.33 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.299 1.44 . . . . 0.0 108.169 174.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -135.65 156.0 49.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.584 1.153 . . . . 0.0 111.869 178.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.8 m80 -136.52 116.23 13.02 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.656 1.182 . . . . 0.0 109.218 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.7 t -123.55 167.85 13.37 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.653 1.181 . . . . 0.0 111.233 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -99.0 140.59 32.93 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.698 1.199 . . . . 0.0 110.691 175.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.6 t -133.2 116.36 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.816 1.647 . . . . 0.0 109.096 -177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 53.47 31.73 12.75 Favored 'General case' 0 CA--C 1.555 1.138 0 N-CA-C 114.597 1.332 . . . . 0.0 114.597 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.92 11.75 78.48 Favored Glycine 0 CA--C 1.539 1.559 0 C-N-CA 124.707 1.146 . . . . 0.0 114.97 -176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -122.0 114.99 21.73 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 127.417 2.287 . . . . 0.0 110.61 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -70.7 137.98 50.22 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.503 1.121 . . . . 0.0 110.406 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -150.26 159.2 44.62 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 123.47 0.708 . . . . 0.0 111.343 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 34.5 m -89.28 150.45 22.6 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 122.011 0.91 . . . . 0.0 112.246 174.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -140.63 172.35 12.83 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.317 1.447 . . . . 0.0 111.457 -178.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -119.18 124.85 47.79 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 125.787 1.635 . . . . 0.0 110.884 175.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.3 t -75.35 103.54 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 174.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 19.5 tp -118.9 113.96 21.84 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 123.601 0.761 . . . . 0.0 110.029 176.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.8 ttt180 -92.32 115.33 27.99 Favored 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 175.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.7 mm -72.73 104.97 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 124.117 0.967 . . . . 0.0 108.936 175.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.86 -20.0 20.61 Favored 'General case' 0 CA--C 1.547 0.846 0 N-CA-C 114.671 1.36 . . . . 0.0 114.671 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.403 ' HB2' HG11 ' A' ' 21' ' ' VAL . 3.2 tm-20 -53.87 -61.71 2.13 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 126.095 1.758 . . . . 0.0 111.745 178.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.29 -16.88 16.14 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 124.701 1.2 . . . . 0.0 113.353 177.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.05 12.9 65.13 Favored Glycine 0 CA--C 1.538 1.482 0 C-N-CA 125.414 1.483 . . . . 0.0 114.898 -177.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 32.7 mtm -93.0 159.72 15.18 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.151 1.38 . . . . 0.0 111.905 -178.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtm180 -95.26 139.46 31.55 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 125.64 1.576 . . . . 0.0 111.48 176.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.6 mt -136.64 115.02 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 C-N-CA 126.493 1.917 . . . . 0.0 108.386 177.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.09 128.77 34.1 Favored 'General case' 0 CA--C 1.538 0.516 0 O-C-N 121.759 -0.588 . . . . 0.0 110.327 174.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.3 mp -106.05 126.27 31.01 Favored Pre-proline 0 N--CA 1.477 0.898 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.983 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.44 122.04 9.02 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 123.74 2.96 . . . . 0.0 112.443 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -59.05 -22.29 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 -178.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -54.14 -28.9 42.92 Favored 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.479 2.312 . . . . 0.0 113.094 176.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -100.78 -28.0 13.05 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 126.072 1.749 . . . . 0.0 113.541 175.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 60' ' ' SER . 59.8 t -64.21 -60.57 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 125.192 1.397 . . . . 0.0 111.156 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.4 -4.8 4.62 Favored Glycine 0 CA--C 1.544 1.849 0 C-N-CA 124.864 1.221 . . . . 0.0 115.982 -178.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.587 ' H ' HG12 ' A' ' 58' ' ' VAL . 1.1 m -171.41 -77.61 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 128.279 2.632 . . . . 0.0 110.527 -174.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.2 p -145.07 -37.76 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 C-N-CA 125.38 1.472 . . . . 0.0 113.939 -177.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.15 -14.12 5.19 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 124.851 1.215 . . . . 0.0 114.938 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.739 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.9 mp -100.93 124.9 47.34 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.754 1.621 . . . . 0.0 109.56 178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 53.9 mtp180 -123.52 117.53 25.31 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 125.014 1.326 . . . . 0.0 112.021 176.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.444 ' N ' ' HB1' ' A' ' 14' ' ' ALA . 3.0 tt0 -70.6 149.18 47.33 Favored 'General case' 0 N--CA 1.473 0.689 0 O-C-N 121.265 -0.897 . . . . 0.0 111.4 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.6 pt -107.97 -16.07 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 N-CA-C 114.328 1.232 . . . . 0.0 114.328 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 8.9 tp -64.33 -17.26 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 125.938 1.695 . . . . 0.0 112.267 177.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.3 t -72.75 80.11 1.12 Allowed 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.746 1.618 . . . . 0.0 110.342 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -123.93 137.34 54.64 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.848 2.059 . . . . 0.0 110.585 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -100.99 -73.21 0.65 Allowed 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.56 1.144 . . . . 0.0 110.398 175.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.254 1.319 0 C-N-CA 126.737 2.015 . . . . 0.0 112.723 -177.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 119.503 -0.284 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 134.79 125.79 2.57 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 125.145 1.355 . . . . 0.0 111.697 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -68.97 111.7 5.15 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 123.752 0.821 . . . . 0.0 110.816 179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 64.5 mtp -112.09 152.91 27.7 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 124.505 1.122 . . . . 0.0 111.678 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 -90.94 140.98 29.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.118 0.967 . . . . 0.0 110.003 175.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 9.7 t -150.08 161.89 41.48 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 125.277 1.431 . . . . 0.0 110.003 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 87.2 p -71.66 -178.31 2.19 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.265 1.026 . . . . 0.0 110.988 175.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -122.48 157.69 31.44 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.077 0.951 . . . . 0.0 110.088 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.5 mmtt -70.7 -172.62 0.65 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 124.777 1.231 . . . . 0.0 111.257 175.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 99.1 m -48.33 140.34 7.74 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.544 1.137 . . . . 0.0 111.224 175.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.19 -7.4 43.82 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 125.431 1.491 . . . . 0.0 113.861 -174.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.7 154.76 41.53 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 119.138 1.469 . . . . 0.0 111.518 174.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.8 130.54 29.86 Favored 'General case' 0 C--O 1.234 0.242 0 C-N-CA 124.729 1.211 . . . . 0.0 110.39 177.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.624 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -160.08 166.13 30.45 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.296 1.038 . . . . 0.0 111.078 -175.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.407 HG13 ' CA ' ' A' ' 20' ' ' GLY . 21.7 t -78.4 100.52 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 124.414 1.085 . . . . 0.0 108.804 178.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -80.37 157.54 72.74 Favored Pre-proline 0 CA--C 1.553 1.066 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 175.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.99 88.51 0.81 Allowed 'Trans proline' 0 CA--C 1.542 0.891 0 C-N-CA 124.622 3.548 . . . . 0.0 112.105 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.09 -55.67 0.19 Allowed Glycine 0 CA--C 1.533 1.186 0 C-N-CA 124.163 0.887 . . . . 0.0 114.132 175.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.61 -39.26 1.47 Allowed 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 124.726 1.21 . . . . 0.0 112.302 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.407 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.31 -10.93 65.43 Favored Glycine 0 CA--C 1.53 0.978 0 C-N-CA 125.023 1.297 . . . . 0.0 115.28 -177.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.4 HG23 HG23 ' A' ' 44' ' ' ILE . 11.8 m -105.91 124.19 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.716 1.206 . . . . 0.0 111.694 175.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 169.42 142.59 3.59 Favored Glycine 0 CA--C 1.527 0.804 0 C-N-CA 123.915 0.769 . . . . 0.0 112.707 174.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -118.65 130.36 55.81 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 124.892 1.277 . . . . 0.0 109.885 174.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 37.7 t -64.4 107.32 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.563 0.745 . . . . 0.0 109.086 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 77.2 mmm -86.37 -18.97 30.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.304 1.042 . . . . 0.0 112.915 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.04 -175.94 43.93 Favored Glycine 0 CA--C 1.527 0.828 0 C-N-CA 125.344 1.449 . . . . 0.0 112.427 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -113.28 141.88 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 C-N-CA 124.596 1.158 . . . . 0.0 108.031 174.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -111.24 144.32 40.59 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.354 1.061 . . . . 0.0 111.542 175.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -131.94 113.76 13.82 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.009 1.324 . . . . 0.0 109.259 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -141.33 145.83 35.94 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 124.529 1.132 . . . . 0.0 111.737 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -87.42 125.51 34.32 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.943 0.897 . . . . 0.0 110.102 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.477 HG22 ' HB2' ' A' ' 37' ' ' GLN . 33.1 m -124.47 142.97 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 125.318 1.447 . . . . 0.0 110.066 177.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.27 29.31 6.52 Favored 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -177.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.35 14.7 81.7 Favored Glycine 0 CA--C 1.538 1.525 0 C-N-CA 124.562 1.077 . . . . 0.0 114.844 -175.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -128.16 130.31 47.86 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 126.694 1.997 . . . . 0.0 111.066 -176.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.4 mtm-85 -60.76 113.84 2.71 Favored 'General case' 0 N--CA 1.474 0.731 0 O-C-N 121.241 -0.912 . . . . 0.0 111.029 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.477 ' HB2' HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -114.73 171.85 7.39 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 125.383 1.473 . . . . 0.0 110.461 175.03 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 23.9 m -142.58 155.57 45.0 Favored 'General case' 0 C--O 1.237 0.4 0 C-N-CA 125.019 1.328 . . . . 0.0 110.688 176.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -143.76 160.94 39.85 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.933 1.293 . . . . 0.0 110.686 -179.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -100.27 126.22 46.56 Favored 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 125.274 1.43 . . . . 0.0 110.849 175.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.7 99.76 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.675 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 23.7 tp -107.51 113.85 27.46 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.369 0.667 . . . . 0.0 109.995 178.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.3 ttt180 -89.6 114.73 26.36 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 123.523 0.729 . . . . 0.0 109.976 176.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.4 HG23 HG23 ' A' ' 21' ' ' VAL . 20.5 mm -69.68 111.02 3.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 126.237 1.815 . . . . 0.0 109.866 178.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 12.1 mt -60.95 -15.09 27.32 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.624 1.569 . . . . 0.0 114.006 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -53.44 -61.06 2.54 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 126.047 1.739 . . . . 0.0 112.076 177.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -134.36 13.9 3.81 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.432 1.893 . . . . 0.0 113.86 -177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.87 19.73 79.75 Favored Glycine 0 CA--C 1.536 1.363 0 C-N-CA 124.252 0.929 . . . . 0.0 113.84 -173.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.3 ttp -60.54 165.87 3.51 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 124.941 1.296 . . . . 0.0 111.688 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -130.76 115.09 16.16 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.558 1.143 . . . . 0.0 110.683 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.7 mt -115.43 123.65 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 124.471 1.108 . . . . 0.0 108.766 176.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 30.8 mmt -87.49 146.57 25.76 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 123.821 0.848 . . . . 0.0 110.205 175.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.01 125.23 18.98 Favored Pre-proline 0 N--CA 1.473 0.689 0 C-N-CA 124.25 1.02 . . . . 0.0 110.547 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -67.46 123.61 11.03 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.856 3.037 . . . . 0.0 112.567 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -65.41 -13.69 15.68 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -83.67 -3.78 58.04 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 124.651 1.18 . . . . 0.0 112.639 177.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -118.28 -27.33 6.06 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.722 1.609 . . . . 0.0 113.663 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.6 m -57.89 -28.88 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 175.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -19.45 1.11 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 126.315 1.912 . . . . 0.0 115.88 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -167.66 -51.78 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 127.721 2.408 . . . . 0.0 111.382 175.013 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 15.5 m -143.19 -38.06 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 C-N-CA 125.663 1.585 . . . . 0.0 113.939 -174.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.4 -11.25 39.07 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.051 1.31 . . . . 0.0 114.082 178.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.624 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.5 mp -104.55 146.81 28.36 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.538 1.935 . . . . 0.0 109.914 177.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.409 ' C ' ' HB1' ' A' ' 14' ' ' ALA . 5.2 ttt180 -143.57 117.57 9.43 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 123.847 0.859 . . . . 0.0 112.062 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -79.13 140.66 37.75 Favored 'General case' 0 N--CA 1.476 0.864 0 O-C-N 120.655 -1.278 . . . . 0.0 110.643 176.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 3.0 pt -133.21 -162.16 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 126.474 1.91 . . . . 0.0 110.146 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 9.5 tp -50.03 -32.43 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 C-N-CA 125.752 1.621 . . . . 0.0 114.435 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.4 p -65.51 91.59 0.12 Allowed 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.067 1.347 . . . . 0.0 112.352 179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.1 tt0 -106.16 140.04 39.75 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 126.303 1.841 . . . . 0.0 110.766 -179.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -89.05 -173.33 4.02 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.62 1.568 . . . . 0.0 111.573 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.252 1.22 0 C-N-CA 126.567 1.947 . . . . 0.0 111.907 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.18 0 CA-C-O 120.857 0.36 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.76 112.74 0.53 Allowed Glycine 0 CA--C 1.528 0.898 0 C-N-CA 124.857 1.217 . . . . 0.0 111.665 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -56.52 107.77 0.42 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 125.022 1.329 . . . . 0.0 111.193 177.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ttt -136.78 144.76 43.92 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.58 1.552 . . . . 0.0 110.452 -178.287 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -92.56 130.35 38.23 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.746 0.818 . . . . 0.0 110.17 176.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -133.87 160.86 36.38 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.812 1.645 . . . . 0.0 111.674 178.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 t -78.96 155.88 28.75 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.428 0.633 . . . . 0.0 112.655 175.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -134.42 158.28 44.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 126.317 1.847 . . . . 0.0 109.141 175.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.01 -173.35 1.02 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.858 1.663 . . . . 0.0 111.892 175.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 87.7 m -50.65 139.57 16.03 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.216 1.406 . . . . 0.0 110.875 174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.88 -4.28 49.47 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.538 1.066 . . . . 0.0 114.615 -175.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -66.95 134.34 51.79 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 119.554 1.677 . . . . 0.0 109.963 175.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.59 127.89 28.23 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.984 0.914 . . . . 0.0 110.177 179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.532 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -170.17 169.47 7.83 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 125.054 1.342 . . . . 0.0 110.368 -177.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.472 HG21 HG12 ' A' ' 66' ' ' ILE . 26.3 t -81.58 100.32 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 C-N-CA 124.831 1.252 . . . . 0.0 109.115 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -77.09 156.96 81.79 Favored Pre-proline 0 CA--C 1.553 1.083 0 O-C-N 121.791 -0.568 . . . . 0.0 111.435 175.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.02 86.32 0.94 Allowed 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 124.647 3.564 . . . . 0.0 112.184 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.1 -58.54 0.15 Allowed Glycine 0 CA--C 1.53 1.006 0 C-N-CA 124.574 1.083 . . . . 0.0 113.161 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.94 -37.85 1.48 Allowed 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.359 1.063 . . . . 0.0 113.4 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.414 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.76 -10.09 64.31 Favored Glycine 0 CA--C 1.533 1.215 0 C-N-CA 124.782 1.182 . . . . 0.0 115.891 -178.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -105.93 132.79 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 126.52 1.928 . . . . 0.0 110.354 175.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 150.82 127.61 1.44 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.653 1.597 . . . . 0.0 111.866 -177.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -115.6 131.69 56.86 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.88 1.272 . . . . 0.0 109.474 175.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.4 t -60.85 124.19 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 124.049 0.94 . . . . 0.0 110.568 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.01 -21.49 15.01 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 126.367 1.867 . . . . 0.0 113.414 -178.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.15 -176.32 43.89 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.901 1.239 . . . . 0.0 113.231 176.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -116.59 141.21 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.272 1.429 . . . . 0.0 107.647 174.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.15 139.74 52.94 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 125.285 1.434 . . . . 0.0 110.745 -178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -130.29 113.76 14.8 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 125.167 1.387 . . . . 0.0 110.693 -175.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.85 -177.69 5.32 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 124.274 1.03 . . . . 0.0 112.418 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 49.0 tt0 -135.54 109.39 8.12 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.621 1.969 . . . . 0.0 109.494 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.83 146.24 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 125.584 1.554 . . . . 0.0 109.564 -178.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.16 26.99 2.36 Favored 'General case' 0 CA--C 1.558 1.274 0 N-CA-C 114.781 1.4 . . . . 0.0 114.781 -176.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.61 21.14 79.73 Favored Glycine 0 CA--C 1.539 1.589 0 C-N-CA 124.598 1.094 . . . . 0.0 114.863 -175.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -132.42 133.68 44.19 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.518 1.927 . . . . 0.0 110.996 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -60.08 115.72 3.66 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 121.207 -0.933 . . . . 0.0 110.263 175.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -137.09 113.13 9.74 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.471 1.109 . . . . 0.0 108.953 178.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 12.1 m -91.19 162.76 14.52 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.578 1.151 . . . . 0.0 111.307 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.9 m-85 -139.96 155.76 46.98 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 123.968 0.907 . . . . 0.0 111.42 -177.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -96.53 125.47 41.03 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 124.811 1.244 . . . . 0.0 110.974 174.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.0 t -83.93 99.68 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 175.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -113.69 113.92 25.67 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 124.476 1.11 . . . . 0.0 109.915 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 46.6 ttt180 -91.98 116.72 29.17 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 123.704 0.802 . . . . 0.0 109.726 175.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.2 mm -76.58 104.63 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 C-N-CA 124.685 1.194 . . . . 0.0 109.435 176.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.0 tp -58.19 -23.08 54.29 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.404 1.082 . . . . 0.0 113.795 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -52.02 -54.03 34.75 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 126.221 1.809 . . . . 0.0 112.684 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -110.86 -14.5 13.97 Favored 'General case' 0 CA--C 1.546 0.827 0 C-N-CA 125.366 1.466 . . . . 0.0 113.186 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.28 9.67 72.58 Favored Glycine 0 CA--C 1.538 1.526 0 C-N-CA 125.714 1.626 . . . . 0.0 115.1 -178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 38.8 mtm -92.09 158.88 15.96 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.063 1.345 . . . . 0.0 112.392 -175.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.32 140.4 29.63 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.333 1.453 . . . . 0.0 111.229 175.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.1 mt -135.96 113.1 13.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 126.15 1.78 . . . . 0.0 109.244 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 34.2 mtt -76.97 146.72 37.31 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 123.173 0.589 . . . . 0.0 110.684 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 58.6 mt -131.32 125.26 20.77 Favored Pre-proline 0 N--CA 1.477 0.887 0 C-N-CA 124.677 1.191 . . . . 0.0 110.339 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.74 123.12 10.09 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.681 2.921 . . . . 0.0 111.791 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.9 pt -59.59 -19.72 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 113.947 1.091 . . . . 0.0 113.947 -177.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.85 -34.79 60.38 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 127.228 2.211 . . . . 0.0 113.147 178.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 52.8 mttp -93.34 -29.1 15.8 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.426 1.491 . . . . 0.0 113.558 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 85.8 t -67.58 -51.45 51.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 C-N-CA 126.588 1.955 . . . . 0.0 111.961 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.06 -20.53 0.9 Allowed Glycine 0 CA--C 1.541 1.705 0 C-N-CA 126.649 2.071 . . . . 0.0 116.258 -176.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 44.2 p -164.01 -69.4 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 126.556 1.942 . . . . 0.0 110.739 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -136.88 -38.28 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 127.099 2.16 . . . . 0.0 113.358 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 64.95 0.83 5.74 Favored Glycine 0 CA--C 1.541 1.698 0 C-N-CA 124.125 0.869 . . . . 0.0 115.191 -174.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 6.3 mp -91.78 147.47 22.96 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.588 1.955 . . . . 0.0 111.02 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.1 ptt180 -142.73 117.66 9.97 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 126.279 1.832 . . . . 0.0 111.771 177.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 60.3 tt0 -81.65 126.92 32.34 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.209 -1.557 . . . . 0.0 110.783 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.472 HG12 HG21 ' A' ' 15' ' ' VAL . 1.7 pt -135.53 -162.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 126.554 1.941 . . . . 0.0 109.956 -178.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -50.4 -30.08 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 C-N-CA 126.121 1.768 . . . . 0.0 114.498 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.69 96.35 0.95 Allowed 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.446 1.099 . . . . 0.0 112.16 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -129.77 167.96 17.28 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.627 2.371 . . . . 0.0 110.895 -179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.75 -64.57 0.84 Allowed 'General case' 0 CA--C 1.543 0.702 0 O-C-N 121.397 -0.814 . . . . 0.0 112.188 179.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 C--O 1.252 1.204 0 C-N-CA 129.38 3.072 . . . . 0.0 116.952 -176.818 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 120.396 0.141 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.81 104.35 0.21 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.056 0.836 . . . . 0.0 112.86 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -65.66 154.54 38.57 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 117.645 0.723 . . . . 0.0 111.371 175.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -144.35 159.74 42.2 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.506 1.122 . . . . 0.0 111.223 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -115.57 156.78 25.15 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 125.467 1.507 . . . . 0.0 111.317 176.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 95.32 2.22 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.282 1.833 . . . . 0.0 109.74 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.1 t -61.17 138.81 58.21 Favored 'General case' 0 N--CA 1.47 0.553 0 O-C-N 121.816 -0.553 . . . . 0.0 109.726 175.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -131.63 156.54 45.64 Favored 'General case' 0 C--O 1.237 0.399 0 C-N-CA 125.182 1.393 . . . . 0.0 110.057 176.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -174.36 0.77 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.822 1.249 . . . . 0.0 111.828 174.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 48.5 m -49.57 142.46 8.14 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.346 1.459 . . . . 0.0 111.451 174.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.05 -2.89 56.82 Favored Glycine 0 CA--C 1.532 1.153 0 C-N-CA 124.746 1.165 . . . . 0.0 114.417 -173.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -64.24 146.11 54.87 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 119.22 1.51 . . . . 0.0 111.623 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -137.6 130.21 29.81 Favored 'General case' 0 N--CA 1.469 0.493 0 C-N-CA 124.322 1.049 . . . . 0.0 110.583 178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.688 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -168.89 170.07 9.34 Favored 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.422 1.089 . . . . 0.0 111.314 -174.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.44 HG21 HG12 ' A' ' 66' ' ' ILE . 19.7 t -83.64 100.3 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 124.465 1.106 . . . . 0.0 109.864 -176.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -76.13 156.63 83.85 Favored Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 122.756 0.422 . . . . 0.0 111.965 175.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -71.91 85.69 0.96 Allowed 'Trans proline' 0 CA--C 1.543 0.953 0 C-N-CA 124.082 3.188 . . . . 0.0 111.856 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.53 -62.07 0.12 Allowed Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.744 1.164 . . . . 0.0 113.033 176.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -128.16 -41.48 1.59 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.825 1.25 . . . . 0.0 112.802 -177.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.65 -12.41 58.03 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 125.538 1.542 . . . . 0.0 115.523 -177.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -106.16 124.22 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.705 1.202 . . . . 0.0 110.775 176.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 167.05 125.77 0.79 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.512 1.529 . . . . 0.0 111.418 179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -109.02 131.87 54.65 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 124.182 0.993 . . . . 0.0 108.758 174.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.1 t -59.57 107.12 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 C-N-CA 123.728 0.811 . . . . 0.0 109.349 179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 10.8 tpt -78.27 -27.57 47.49 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 125.052 1.341 . . . . 0.0 111.948 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.31 -175.93 44.74 Favored Glycine 0 CA--C 1.526 0.722 0 C-N-CA 125.14 1.352 . . . . 0.0 112.798 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -117.32 141.75 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 124.995 1.318 . . . . 0.0 107.544 175.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.75 146.68 39.52 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.734 1.214 . . . . 0.0 111.43 176.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -132.99 113.77 13.2 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.152 1.381 . . . . 0.0 110.144 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 t -141.86 178.68 7.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.343 1.057 . . . . 0.0 112.256 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.1 mt-10 -129.46 108.21 10.09 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 126.372 1.869 . . . . 0.0 109.894 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.27 125.92 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.956 1.702 . . . . 0.0 109.696 178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 52.71 27.07 4.91 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 124.733 1.213 . . . . 0.0 114.25 -174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.19 -15.89 51.24 Favored Glycine 0 CA--C 1.538 1.47 0 C-N-CA 126.313 1.911 . . . . 0.0 115.02 -175.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -84.7 130.77 34.65 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.88 1.34 . . . . 0.0 110.87 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 73.0 mtp180 -61.29 116.18 4.42 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.264 1.026 . . . . 0.0 110.174 175.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -136.18 113.18 10.4 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 123.992 0.917 . . . . 0.0 109.461 175.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 m -84.97 162.04 19.55 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.922 0.889 . . . . 0.0 111.519 176.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -138.65 158.82 43.53 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 124.634 1.173 . . . . 0.0 111.542 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -97.62 125.66 42.5 Favored 'General case' 0 N--CA 1.464 0.275 0 C-N-CA 125.214 1.406 . . . . 0.0 110.984 174.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -89.76 99.92 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.05 0.94 . . . . 0.0 108.873 175.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.4 tp -108.14 113.89 27.36 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.811 0.845 . . . . 0.0 110.185 179.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 7.2 mmt85 -86.5 108.73 18.67 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 124.331 1.052 . . . . 0.0 108.471 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.4 mm -77.8 90.37 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 125.037 1.335 . . . . 0.0 108.9 175.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.6 mp -54.86 -21.36 11.16 Favored 'General case' 0 CA--C 1.547 0.837 0 C-N-CA 124.51 1.124 . . . . 0.0 113.668 176.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -57.2 -57.66 11.64 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 126.209 1.804 . . . . 0.0 112.493 178.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -94.8 -18.44 21.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 124.242 1.017 . . . . 0.0 113.381 174.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.9 19.39 56.16 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.297 1.427 . . . . 0.0 114.704 -176.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 39.8 mtm -110.75 170.33 8.17 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.591 1.556 . . . . 0.0 111.869 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 37.3 ptt180 -106.61 150.5 26.13 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 124.982 1.313 . . . . 0.0 111.092 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 38.7 mt -136.72 134.44 48.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.703 1.601 . . . . 0.0 109.056 175.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mtt -98.93 141.6 31.5 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 124.374 1.07 . . . . 0.0 110.789 175.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 59.0 mt -132.82 127.27 20.25 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 124.634 1.174 . . . . 0.0 110.268 -178.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.65 121.91 8.62 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 123.821 3.014 . . . . 0.0 111.988 179.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 27.4 pt -59.02 -21.44 19.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -177.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -54.03 -37.07 63.72 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 127.13 2.172 . . . . 0.0 112.416 178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.6 mttp -90.5 -31.43 16.77 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.64 1.576 . . . . 0.0 113.363 175.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.497 HG12 ' H ' ' A' ' 60' ' ' SER . 96.3 t -62.76 -52.91 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 126.159 1.783 . . . . 0.0 112.077 -179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.7 -20.51 2.81 Favored Glycine 0 CA--C 1.542 1.746 0 C-N-CA 125.487 1.517 . . . . 0.0 116.129 -178.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.497 ' H ' HG12 ' A' ' 58' ' ' VAL . 27.4 t -163.63 -71.54 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 125.891 1.677 . . . . 0.0 111.209 177.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -131.69 -38.01 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.825 1.65 . . . . 0.0 113.325 -175.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.45 -9.89 13.37 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 124.824 1.202 . . . . 0.0 114.807 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.688 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.6 mp -104.17 155.73 18.48 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 126.331 1.852 . . . . 0.0 110.416 175.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -143.83 117.61 9.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 125.544 1.538 . . . . 0.0 112.087 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.06 124.7 27.47 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 120.882 -1.136 . . . . 0.0 110.348 178.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.44 HG12 HG21 ' A' ' 15' ' ' VAL . 1.7 pt -135.54 -163.97 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 126.145 1.778 . . . . 0.0 110.198 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.0 tp -47.88 -41.26 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.171 1.789 . . . . 0.0 114.177 175.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.0 t -72.37 101.31 2.87 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 125.116 1.366 . . . . 0.0 110.427 175.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -152.04 169.84 21.38 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 127.643 2.377 . . . . 0.0 110.132 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -98.94 -68.46 0.8 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 124.032 0.933 . . . . 0.0 112.278 175.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 C--O 1.252 1.232 0 C-N-CA 125.954 1.702 . . . . 0.0 114.312 -174.695 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 119.612 -0.232 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.13 -159.26 26.08 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.226 1.393 . . . . 0.0 112.066 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -131.39 157.21 44.01 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.38 1.472 . . . . 0.0 110.893 175.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -148.99 175.89 10.91 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 125.566 1.546 . . . . 0.0 110.457 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tt0 -128.62 84.63 2.25 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 124.133 0.973 . . . . 0.0 110.769 -177.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.9 p -69.83 165.96 20.41 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.358 1.063 . . . . 0.0 112.37 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 13.2 m -139.88 174.39 10.56 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.391 1.476 . . . . 0.0 112.07 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -136.71 161.13 36.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 125.322 1.449 . . . . 0.0 110.291 174.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.8 mmtt -73.42 -168.25 0.52 Allowed 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.781 1.633 . . . . 0.0 111.908 175.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.0 m -52.0 141.55 17.77 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.871 1.268 . . . . 0.0 110.589 175.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.69 -8.98 43.93 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.182 1.372 . . . . 0.0 114.792 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.91 159.69 32.43 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 119.241 1.52 . . . . 0.0 112.589 175.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -126.33 127.85 46.19 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 125.196 1.398 . . . . 0.0 110.01 176.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.35 164.2 38.98 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.911 1.285 . . . . 0.0 111.218 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.421 HG13 ' CA ' ' A' ' 20' ' ' GLY . 29.8 t -85.85 100.26 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 C-N-CA 124.671 1.188 . . . . 0.0 109.411 -172.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -71.21 156.45 91.78 Favored Pre-proline 0 CA--C 1.549 0.938 0 O-C-N 121.535 -0.728 . . . . 0.0 111.395 177.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -71.3 85.21 0.87 Allowed 'Trans proline' 0 CA--C 1.546 1.08 0 C-N-CA 123.823 3.016 . . . . 0.0 112.873 177.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.43 -56.81 0.19 Allowed Glycine 0 CA--C 1.535 1.322 0 C-N-CA 124.266 0.936 . . . . 0.0 114.932 174.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -129.13 -36.88 1.72 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 124.566 1.147 . . . . 0.0 112.751 -179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.421 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 97.95 -10.48 64.06 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 116.218 1.247 . . . . 0.0 116.218 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.6 t -101.63 124.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.522 1.129 . . . . 0.0 110.499 177.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 168.05 149.37 6.08 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.469 1.509 . . . . 0.0 111.375 175.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.39 129.57 51.47 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.463 1.105 . . . . 0.0 109.308 175.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t -61.07 107.17 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 C-N-CA 123.787 0.835 . . . . 0.0 109.998 -174.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.54 -25.47 28.72 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.917 1.287 . . . . 0.0 112.947 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.05 -166.15 39.4 Favored Glycine 0 CA--C 1.527 0.842 0 C-N-CA 124.306 0.955 . . . . 0.0 113.081 177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mp -117.36 138.33 48.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 C-N-CA 125.667 1.587 . . . . 0.0 107.131 174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -109.21 154.98 21.63 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 126.307 1.843 . . . . 0.0 111.169 177.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 -137.76 113.77 9.91 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 124.67 1.188 . . . . 0.0 109.4 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.0 t -141.89 148.48 38.81 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.956 0.902 . . . . 0.0 111.713 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -88.2 129.16 35.42 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.843 1.257 . . . . 0.0 110.84 -179.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.15 142.42 43.53 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 C-N-CA 125.096 1.358 . . . . 0.0 110.396 177.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.49 27.06 1.89 Allowed 'General case' 0 CA--C 1.557 1.24 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.96 18.02 73.38 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 124.543 1.068 . . . . 0.0 115.067 -176.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -131.65 131.32 43.08 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 126.88 2.072 . . . . 0.0 110.931 -177.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 2.8 mtt180 -61.28 119.06 7.73 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.037 0.935 . . . . 0.0 110.507 175.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.26 175.24 6.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.815 1.646 . . . . 0.0 111.107 176.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.5 m -142.6 150.8 40.8 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.831 1.252 . . . . 0.0 110.889 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -142.21 162.0 36.59 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.287 1.035 . . . . 0.0 110.773 -177.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -96.12 124.91 40.31 Favored 'General case' 0 N--CA 1.47 0.528 0 O-C-N 120.862 -1.149 . . . . 0.0 110.528 175.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.6 t -81.72 100.69 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.844 1.258 . . . . 0.0 109.546 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 40.7 tp -106.69 113.99 27.82 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-O 121.03 0.443 . . . . 0.0 110.979 175.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 ttt85 -82.65 110.4 17.69 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 124.713 1.205 . . . . 0.0 107.754 174.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.8 mm -80.41 90.16 1.65 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 C-N-CA 125.147 1.379 . . . . 0.0 109.521 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.5 mp -56.53 -14.5 3.16 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 125.025 1.33 . . . . 0.0 114.214 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.84 -51.46 69.93 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.993 1.317 . . . . 0.0 113.035 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -134.41 2.31 3.24 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.725 1.61 . . . . 0.0 113.689 -175.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.29 13.91 81.13 Favored Glycine 0 CA--C 1.537 1.462 0 C-N-CA 124.573 1.083 . . . . 0.0 114.137 -171.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 64.2 mtm -65.13 168.76 6.28 Favored 'General case' 0 CA--C 1.544 0.743 0 CA-C-N 118.466 1.133 . . . . 0.0 111.677 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -139.48 127.65 22.52 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 125.635 1.574 . . . . 0.0 110.433 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 69.8 mt -128.15 143.68 40.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.272 1.029 . . . . 0.0 109.456 -178.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.7 mtt -119.96 95.13 4.63 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.857 2.063 . . . . 0.0 109.077 -173.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.0 mp -76.31 123.5 87.91 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 117.981 -1.009 . . . . 0.0 109.321 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -66.53 126.34 15.35 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 123.48 2.787 . . . . 0.0 111.37 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.0 pt -63.2 -13.69 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -46.11 -37.27 6.68 Favored 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 128.217 2.607 . . . . 0.0 113.887 -170.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -153.21 50.75 0.72 Allowed 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 126.453 1.901 . . . . 0.0 113.201 175.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -67.05 -23.43 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.45 -20.8 0.34 Allowed Glycine 0 CA--C 1.539 1.567 0 C-N-CA 126.565 2.031 . . . . 0.0 115.418 -174.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 m -172.59 -61.61 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 128.308 2.643 . . . . 0.0 111.153 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.8 m -136.22 -29.5 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 C-N-CA 126.256 1.822 . . . . 0.0 113.365 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 -11.42 68.47 Favored Glycine 0 CA--C 1.536 1.374 0 C-N-CA 125.675 1.607 . . . . 0.0 114.543 -178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -104.82 109.0 20.78 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.426 1.89 . . . . 0.0 109.379 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -75.86 118.75 18.99 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 124.061 0.944 . . . . 0.0 111.452 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -79.77 67.5 5.57 Favored 'General case' 0 CA--C 1.551 0.996 0 O-C-N 119.949 -1.719 . . . . 0.0 111.762 177.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -83.59 -176.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 125.333 1.453 . . . . 0.0 111.805 177.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.09 -25.71 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 126.258 1.823 . . . . 0.0 113.521 177.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.4 m -62.38 97.33 0.09 Allowed 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 127.26 2.224 . . . . 0.0 112.659 -178.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.3 mm-40 -118.75 168.59 10.6 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 126.112 1.765 . . . . 0.0 112.584 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -66.35 -70.32 0.25 Allowed 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.109 1.363 . . . . 0.0 112.705 178.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.4 t70 . . . . . 0 C--O 1.253 1.285 0 C-N-CA 125.588 1.555 . . . . 0.0 114.1 -179.533 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.97 153.57 9.83 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.679 1.609 . . . . 0.0 113.048 -174.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -123.63 5.14 8.89 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 125.322 1.449 . . . . 0.0 113.858 178.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.49 158.79 34.24 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.726 1.61 . . . . 0.0 112.418 175.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -140.51 124.07 17.02 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.767 2.027 . . . . 0.0 109.997 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.1 p -116.71 -43.08 2.92 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 125.63 1.572 . . . . 0.0 112.008 175.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 m -68.06 155.67 39.04 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.607 1.163 . . . . 0.0 111.545 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -98.85 161.55 13.57 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.13 0.972 . . . . 0.0 110.474 175.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 4.0 mmtm -73.09 -171.59 0.93 Allowed 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.071 1.348 . . . . 0.0 111.607 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 53.3 m -49.49 142.0 8.51 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.479 1.512 . . . . 0.0 111.24 174.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.75 -7.06 49.13 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 124.748 1.166 . . . . 0.0 114.459 -174.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -75.65 151.45 37.74 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 119.036 1.418 . . . . 0.0 112.356 176.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 ttpt -134.38 127.86 32.45 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 125.111 1.364 . . . . 0.0 110.644 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.53 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.04 167.72 29.4 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 124.527 1.131 . . . . 0.0 111.955 -174.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 39.4 t -78.32 100.35 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 124.447 1.099 . . . . 0.0 110.005 -176.074 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.5 p90 -75.35 156.29 85.51 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 123.739 0.815 . . . . 0.0 112.355 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.36 95.63 0.86 Allowed 'Trans proline' 0 CA--C 1.541 0.853 0 C-N-CA 124.393 3.396 . . . . 0.0 111.896 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.91 -23.86 0.81 Allowed Glycine 0 CA--C 1.534 1.227 0 C-N-CA 124.681 1.134 . . . . 0.0 115.178 175.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -166.26 -38.64 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.984 1.313 . . . . 0.0 113.402 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.43 2.6 50.6 Favored Glycine 0 CA--C 1.535 1.329 0 N-CA-C 116.815 1.486 . . . . 0.0 116.815 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.419 HG11 ' HB2' ' A' ' 46' ' ' GLU . 6.1 p -106.12 144.16 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 125.797 1.639 . . . . 0.0 111.752 179.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.11 136.74 3.78 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 124.258 0.933 . . . . 0.0 111.879 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -117.31 134.58 54.65 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 124.94 1.296 . . . . 0.0 110.18 176.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.1 t -63.29 107.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.3 ttt -86.35 -20.72 27.88 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.651 1.18 . . . . 0.0 112.575 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.93 -178.24 43.5 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 124.401 1.001 . . . . 0.0 113.3 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.24 130.77 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -96.22 149.07 22.06 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 125.197 1.399 . . . . 0.0 110.644 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -136.24 113.83 10.97 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.865 1.266 . . . . 0.0 109.961 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.08 -179.3 6.01 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.176 0.99 . . . . 0.0 111.63 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.1 tt0 -128.4 108.19 10.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.51 1.524 . . . . 0.0 109.432 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -109.7 140.07 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 C-N-CA 125.608 1.563 . . . . 0.0 109.759 -177.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.13 27.09 3.18 Favored 'General case' 0 CA--C 1.557 1.214 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -175.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.15 15.57 81.46 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 124.77 1.176 . . . . 0.0 115.051 -174.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -129.49 134.51 47.83 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 126.9 2.08 . . . . 0.0 111.265 -176.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -66.9 117.51 9.08 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.9 0.88 . . . . 0.0 110.528 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.42 113.18 11.59 Favored 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.708 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.471 ' HB2' HD13 ' A' ' 55' ' ' ILE . 15.3 m -80.14 159.93 25.88 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 123.736 0.814 . . . . 0.0 111.329 175.019 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -137.23 160.0 40.29 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 125.209 1.403 . . . . 0.0 110.629 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -102.8 129.86 49.6 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 125.447 1.499 . . . . 0.0 109.94 174.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.2 t -94.47 99.76 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.113 1.365 . . . . 0.0 107.92 175.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.5 tp -103.86 113.94 27.83 Favored 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.335 0.654 . . . . 0.0 109.981 179.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.0 ttt180 -85.91 111.64 20.42 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.372 0.669 . . . . 0.0 110.575 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 38.6 mm -77.89 91.95 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 C-N-CA 126.405 1.882 . . . . 0.0 110.544 -178.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 20.3 mt -56.09 -15.64 3.94 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 125.861 1.665 . . . . 0.0 115.002 176.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.419 ' HB2' HG11 ' A' ' 21' ' ' VAL . 2.6 tm-20 -54.42 -47.78 72.4 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 125.877 1.671 . . . . 0.0 112.973 177.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -134.4 -8.76 2.55 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.335 1.454 . . . . 0.0 113.966 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.08 -0.1 58.78 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.987 1.756 . . . . 0.0 115.511 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 17.0 mtm -66.25 172.8 3.59 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 119.079 1.44 . . . . 0.0 113.809 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.86 151.91 37.24 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 127.327 2.251 . . . . 0.0 111.104 174.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 53.5 mt -140.4 132.78 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 125.504 1.521 . . . . 0.0 107.785 175.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.68 140.65 29.3 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.827 1.251 . . . . 0.0 109.737 175.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -131.25 108.36 14.92 Favored Pre-proline 0 CA--C 1.547 0.851 0 C-N-CA 124.182 0.993 . . . . 0.0 109.974 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.14 122.16 9.21 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 123.776 2.984 . . . . 0.0 112.022 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.471 HD13 ' HB2' ' A' ' 38' ' ' SER . 22.8 pt -58.9 -20.65 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 119.593 1.088 . . . . 0.0 113.907 -177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -49.8 -33.49 16.76 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 127.565 2.346 . . . . 0.0 114.026 175.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.4 -21.65 15.32 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 124.689 1.196 . . . . 0.0 113.999 176.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.582 HG12 ' H ' ' A' ' 60' ' ' SER . 45.0 t -71.34 -59.26 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 126.259 1.824 . . . . 0.0 110.805 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.25 -6.49 7.44 Favored Glycine 0 CA--C 1.543 1.814 0 C-N-CA 125.598 1.571 . . . . 0.0 116.222 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.582 ' H ' HG12 ' A' ' 58' ' ' VAL . 40.8 p -164.81 -79.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 125.807 1.643 . . . . 0.0 111.82 -177.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.33 -34.67 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 127.564 2.346 . . . . 0.0 113.133 -178.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 68.83 -13.96 0.83 Allowed Glycine 0 CA--C 1.541 1.711 0 C-N-CA 125.719 1.628 . . . . 0.0 115.917 -178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.53 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.6 mp -99.39 146.77 25.94 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 126.395 1.878 . . . . 0.0 110.513 175.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.7 mtt-85 -138.77 123.8 18.97 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 125.147 1.379 . . . . 0.0 111.594 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -74.44 84.57 1.99 Allowed 'General case' 0 N--CA 1.476 0.873 0 O-C-N 120.942 -1.099 . . . . 0.0 111.226 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 4.2 pt -132.39 -166.16 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 126.008 1.723 . . . . 0.0 111.344 -176.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.4 tp -121.43 -27.54 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 126.333 1.853 . . . . 0.0 112.686 174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 t -58.02 121.04 9.64 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 125.531 1.532 . . . . 0.0 111.973 179.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -133.79 97.9 4.03 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 126.424 1.89 . . . . 0.0 109.609 -173.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -77.87 -174.64 3.62 Favored 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 125.037 1.335 . . . . 0.0 111.921 175.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 . . . . . 0 C--O 1.253 1.26 0 C-N-CA 126.239 1.816 . . . . 0.0 112.158 177.482 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 120.411 0.148 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 163.31 -89.0 0.1 Allowed Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.387 0.994 . . . . 0.0 113.07 177.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.4 p-80 -109.28 161.23 15.45 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 126.014 1.726 . . . . 0.0 112.392 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -159.71 48.79 0.3 Allowed 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 125.314 1.445 . . . . 0.0 113.198 -178.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -91.84 22.34 4.28 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.536 1.534 . . . . 0.0 113.285 -177.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -69.86 -71.56 0.23 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 126.055 1.742 . . . . 0.0 112.699 178.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 99.0 p -71.02 156.78 39.23 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.851 0.834 . . . . 0.0 111.965 174.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -143.69 158.44 43.67 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.487 1.515 . . . . 0.0 109.612 174.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.1 mmtm -72.17 -172.87 0.96 Allowed 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 124.941 1.296 . . . . 0.0 111.465 175.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.6 m -50.52 141.99 11.42 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 125.294 1.438 . . . . 0.0 111.328 174.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.35 -0.09 55.78 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.76 1.171 . . . . 0.0 114.501 -172.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -72.07 147.75 46.47 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 119.273 1.537 . . . . 0.0 111.802 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -135.39 127.85 30.51 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.673 1.189 . . . . 0.0 110.753 175.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.451 ' HB3' HD12 ' A' ' 63' ' ' LEU . . . -160.42 172.65 16.9 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.282 1.433 . . . . 0.0 111.007 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.9 t -84.68 100.34 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 125.349 1.46 . . . . 0.0 109.116 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -76.72 158.06 81.23 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 121.711 -0.618 . . . . 0.0 111.629 176.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.96 87.1 0.87 Allowed 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 124.211 3.274 . . . . 0.0 112.205 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.3 -55.4 0.19 Allowed Glycine 0 CA--C 1.532 1.126 0 C-N-CA 124.316 0.96 . . . . 0.0 114.082 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.8 mm100 -129.76 -43.99 1.22 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.623 1.169 . . . . 0.0 112.555 -178.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.7 -12.89 59.54 Favored Glycine 0 CA--C 1.535 1.299 0 C-N-CA 125.274 1.416 . . . . 0.0 115.682 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.6 t -106.03 124.2 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.699 1.2 . . . . 0.0 110.076 177.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 163.88 135.03 1.75 Allowed Glycine 0 CA--C 1.532 1.129 0 C-N-CA 125.093 1.33 . . . . 0.0 111.847 178.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 51.0 tt0 -116.45 130.01 56.53 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.009 1.324 . . . . 0.0 108.75 174.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -60.29 107.17 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 C-N-CA 123.763 0.825 . . . . 0.0 109.59 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 8.2 tpt -87.88 -18.23 29.67 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 124.947 1.299 . . . . 0.0 112.316 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.96 -172.64 44.84 Favored Glycine 0 CA--C 1.531 1.056 0 C-N-CA 125.155 1.359 . . . . 0.0 112.953 176.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mp -120.2 141.84 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 125.565 1.546 . . . . 0.0 107.682 174.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.63 142.92 40.08 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 125.108 1.363 . . . . 0.0 110.556 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -137.96 113.88 9.89 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 124.914 1.285 . . . . 0.0 110.14 -178.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.4 t -140.12 -179.1 5.78 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.679 1.191 . . . . 0.0 111.32 179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -128.28 108.25 10.44 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 125.937 1.695 . . . . 0.0 109.37 178.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.7 m -110.44 146.07 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 125.347 1.459 . . . . 0.0 110.525 178.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.8 27.05 2.87 Favored 'General case' 0 CA--C 1.556 1.202 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.4 13.46 83.36 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.776 1.179 . . . . 0.0 115.166 -175.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -127.3 135.07 50.05 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.112 1.765 . . . . 0.0 111.272 -177.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 12.3 mtp180 -62.19 126.63 28.01 Favored 'General case' 0 N--CA 1.477 0.892 0 O-C-N 120.946 -1.096 . . . . 0.0 110.218 175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -137.47 117.45 13.32 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.724 1.21 . . . . 0.0 109.823 178.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.6 m -82.76 155.54 24.2 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.734 1.214 . . . . 0.0 111.967 176.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -143.76 163.19 34.04 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 125.317 1.447 . . . . 0.0 110.511 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -106.16 131.11 53.81 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.589 1.556 . . . . 0.0 110.416 175.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.1 t -93.44 99.68 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.625 1.17 . . . . 0.0 108.71 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 25.7 tp -110.23 113.92 26.98 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.92 0.888 . . . . 0.0 109.645 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -89.56 114.61 26.19 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 124.077 0.951 . . . . 0.0 108.619 175.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 mm -73.8 100.18 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 124.839 1.256 . . . . 0.0 109.651 176.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 29.8 mt -57.0 -14.75 3.91 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.447 1.499 . . . . 0.0 114.586 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -53.97 -55.01 31.07 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.194 1.398 . . . . 0.0 112.241 176.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -134.42 3.68 3.35 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 125.436 1.494 . . . . 0.0 114.492 -178.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.2 4.82 90.08 Favored Glycine 0 CA--C 1.539 1.546 0 C-N-CA 125.298 1.428 . . . . 0.0 114.633 -174.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.4 mtp -61.65 129.61 41.9 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.68 1.592 . . . . 0.0 111.656 176.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -90.21 135.89 33.39 Favored 'General case' 0 N--CA 1.474 0.769 0 O-C-N 121.319 -0.863 . . . . 0.0 110.326 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.2 mt -128.76 128.72 67.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 124.778 1.231 . . . . 0.0 109.129 176.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 15.5 mmt -84.69 144.65 28.41 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.277 1.031 . . . . 0.0 109.924 175.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 mp -130.06 106.08 16.53 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 124.301 1.04 . . . . 0.0 109.801 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.36 126.28 14.04 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 123.577 2.851 . . . . 0.0 111.781 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.1 pt -59.03 -21.6 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -52.28 -34.05 44.81 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.351 2.261 . . . . 0.0 113.261 175.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -97.37 -25.16 15.32 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 125.154 1.382 . . . . 0.0 113.589 175.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.561 HG12 ' H ' ' A' ' 60' ' ' SER . 84.8 t -67.23 -53.35 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.557 1.543 . . . . 0.0 112.334 177.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.98 -20.92 0.84 Allowed Glycine 0 CA--C 1.542 1.78 0 C-N-CA 126.335 1.921 . . . . 0.0 116.179 -174.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.561 ' H ' HG12 ' A' ' 58' ' ' VAL . 33.5 p -168.15 -62.83 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 126.424 1.889 . . . . 0.0 112.101 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -141.35 -58.3 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 127.463 2.305 . . . . 0.0 112.511 -177.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 69.75 -8.11 3.57 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.74 1.162 . . . . 0.0 115.491 -175.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.451 HD12 ' HB3' ' A' ' 14' ' ' ALA . 4.0 mm? -88.91 141.11 28.77 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 127.568 2.347 . . . . 0.0 110.731 177.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -139.81 120.2 13.98 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 126.293 1.837 . . . . 0.0 111.098 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -76.41 84.23 3.15 Favored 'General case' 0 CA--C 1.55 0.947 0 O-C-N 120.604 -1.31 . . . . 0.0 111.518 178.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.7 pt -117.66 -167.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 C-N-CA 125.865 1.666 . . . . 0.0 111.617 -178.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.4 tp -117.04 -23.77 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 126.096 1.758 . . . . 0.0 113.608 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.2 t -57.32 102.08 0.08 Allowed 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 126.028 1.731 . . . . 0.0 112.472 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -130.78 94.5 3.63 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.404 1.882 . . . . 0.0 111.036 -178.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 15.1 mt-10 -143.03 -72.33 0.3 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 125.289 1.435 . . . . 0.0 110.33 175.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.255 1.382 0 C-N-CA 125.575 1.55 . . . . 0.0 113.169 -176.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.95 98.08 0.12 Allowed Glycine 0 N--CA 1.476 1.324 0 CA-C-N 119.634 1.106 . . . . 0.0 113.61 -179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.8 p80 -136.56 48.78 2.11 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 125.636 1.574 . . . . 0.0 113.454 -175.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 ttt -123.64 61.36 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.474 1.509 . . . . 0.0 112.365 -171.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -72.37 159.87 33.3 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 124.312 1.045 . . . . 0.0 112.746 174.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -132.58 -63.32 0.79 Allowed 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 126.174 1.79 . . . . 0.0 111.502 -177.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 71.7 m -128.78 119.16 24.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 126.575 1.95 . . . . 0.0 111.034 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -103.43 161.0 14.22 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 125.055 1.342 . . . . 0.0 110.6 175.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.02 -171.3 1.09 Allowed 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 125.417 1.487 . . . . 0.0 112.112 174.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.3 m -49.33 141.72 8.41 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.804 1.642 . . . . 0.0 111.146 175.012 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.21 -6.43 53.51 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.845 1.212 . . . . 0.0 114.458 -174.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -67.53 138.71 56.73 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 119.049 1.425 . . . . 0.0 111.405 174.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt -121.73 127.76 51.05 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.868 1.267 . . . . 0.0 109.594 175.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.49 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -162.23 170.11 19.57 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 124.552 1.141 . . . . 0.0 111.209 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.436 HG21 HG12 ' A' ' 66' ' ' ILE . 21.6 t -82.3 100.44 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 C-N-CA 124.67 1.188 . . . . 0.0 109.401 -178.014 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.07 157.39 73.63 Favored Pre-proline 0 CA--C 1.553 1.06 0 C-N-CA 123.726 0.81 . . . . 0.0 111.533 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -73.61 85.45 1.3 Allowed 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 124.287 3.325 . . . . 0.0 112.083 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.96 -57.95 0.12 Allowed Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.378 0.99 . . . . 0.0 113.485 175.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -131.08 -34.66 1.43 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.579 1.151 . . . . 0.0 113.356 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.43 -14.59 64.38 Favored Glycine 0 CA--C 1.534 1.247 0 N-CA-C 115.818 1.087 . . . . 0.0 115.818 -178.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 t -104.72 124.11 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.716 0 CA-C-N 118.63 1.215 . . . . 0.0 109.371 177.128 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.59 139.8 2.74 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 125.039 1.304 . . . . 0.0 111.626 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -117.99 132.17 56.41 Favored 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 124.603 1.161 . . . . 0.0 108.241 174.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.7 t -61.13 108.24 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.664 -0.647 . . . . 0.0 110.009 -178.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.0 tpt -85.07 -19.59 31.67 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.618 1.167 . . . . 0.0 112.675 -177.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.8 179.51 42.11 Favored Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.865 1.221 . . . . 0.0 114.036 176.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -112.66 135.64 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 C-N-CA 125.648 1.579 . . . . 0.0 108.289 174.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -122.3 128.44 51.07 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.715 1.206 . . . . 0.0 110.63 -176.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -134.45 115.39 13.92 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.858 1.263 . . . . 0.0 110.136 -175.285 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -137.72 -178.36 5.21 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 124.827 1.251 . . . . 0.0 111.735 -177.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -115.93 138.33 51.28 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 125.761 1.624 . . . . 0.0 110.797 175.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.21 111.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 C-N-CA 127.174 2.189 . . . . 0.0 107.984 -174.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.76 40.99 25.75 Favored 'General case' 0 CA--C 1.554 1.102 0 C-N-CA 125.358 1.463 . . . . 0.0 114.382 -177.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.36 8.06 88.04 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 124.787 1.184 . . . . 0.0 114.923 -178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -116.33 151.04 36.68 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 126.536 1.934 . . . . 0.0 110.94 -177.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.25 123.54 24.74 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 124.118 0.967 . . . . 0.0 111.142 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -145.54 113.2 6.34 Favored 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 121.486 0.66 . . . . 0.0 111.085 174.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.6 m -100.57 159.56 15.06 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.006 1.322 . . . . 0.0 112.214 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -144.45 162.1 37.38 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.522 1.529 . . . . 0.0 111.744 -176.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -104.23 124.86 49.9 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.849 1.26 . . . . 0.0 111.589 175.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 t -81.08 99.66 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.0 tp -107.35 113.9 27.57 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 9.5 ttp180 -86.42 116.86 24.84 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.5 87.25 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 C-N-CA 125.353 1.461 . . . . 0.0 108.619 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.6 mp -58.58 -18.16 27.68 Favored 'General case' 0 CA--C 1.55 0.945 0 O-C-N 121.325 -0.86 . . . . 0.0 113.194 177.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -56.28 -39.06 72.06 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 126.637 1.975 . . . . 0.0 113.106 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -128.16 -9.38 5.33 Favored 'General case' 0 CA--C 1.548 0.871 0 C-N-CA 126.14 1.776 . . . . 0.0 113.639 -179.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.83 2.49 81.37 Favored Glycine 0 CA--C 1.536 1.4 0 C-N-CA 126.26 1.886 . . . . 0.0 115.063 178.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.9 mtm -87.92 171.81 10.06 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 119.005 1.402 . . . . 0.0 112.548 -179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -114.49 142.01 46.95 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 125.429 1.491 . . . . 0.0 110.298 175.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 29.1 mt -133.58 141.75 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 125.446 1.499 . . . . 0.0 109.7 177.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.5 mtt -103.65 143.59 32.57 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.475 1.11 . . . . 0.0 110.673 175.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 68.7 mt -128.15 124.19 22.93 Favored Pre-proline 0 N--CA 1.475 0.801 0 C-N-CA 125.355 1.462 . . . . 0.0 109.822 -178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -68.78 124.5 11.55 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 123.916 3.077 . . . . 0.0 112.187 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 16.1 pt -60.11 -20.69 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -55.42 -32.54 62.77 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.413 1.885 . . . . 0.0 113.79 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -96.15 -21.53 17.86 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 124.551 1.14 . . . . 0.0 112.979 175.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 60' ' ' SER . 95.9 t -73.33 -52.08 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 126.795 2.038 . . . . 0.0 112.193 179.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.63 -20.9 0.97 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 126.784 2.135 . . . . 0.0 116.453 -176.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -165.74 -62.94 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.16 1.784 . . . . 0.0 111.577 175.087 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 2.1 m -138.36 -38.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 C-N-CA 125.623 1.569 . . . . 0.0 113.864 176.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 66.39 -2.28 4.45 Favored Glycine 0 CA--C 1.541 1.712 0 C-N-CA 124.58 1.086 . . . . 0.0 115.259 -177.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 5.3 mp -90.01 146.93 24.0 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 127.021 2.129 . . . . 0.0 111.09 179.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -144.89 117.56 8.66 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.083 1.353 . . . . 0.0 110.839 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 tt0 -83.54 128.2 34.33 Favored 'General case' 0 N--CA 1.478 0.944 0 O-C-N 120.53 -1.356 . . . . 0.0 110.778 -177.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.436 HG12 HG21 ' A' ' 15' ' ' VAL . 1.1 pt -134.45 -174.3 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 125.58 1.552 . . . . 0.0 111.124 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.6 tp -111.02 -35.12 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 125.949 1.7 . . . . 0.0 113.076 176.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.6 t -75.83 82.73 2.77 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 125.048 1.339 . . . . 0.0 111.653 177.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -59.94 162.58 5.41 Favored 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 124.427 1.091 . . . . 0.0 112.119 175.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -63.62 -62.88 1.37 Allowed 'General case' 0 N--CA 1.475 0.801 0 O-C-N 121.04 -1.038 . . . . 0.0 112.144 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.6 t70 . . . . . 0 C--O 1.252 1.22 0 C-N-CA 125.637 1.575 . . . . 0.0 113.053 178.809 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.98 40.68 0.46 Allowed Glycine 0 N--CA 1.475 1.272 0 C-N-CA 124.117 0.865 . . . . 0.0 114.152 -176.292 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -133.15 40.82 3.17 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.984 1.314 . . . . 0.0 113.266 -176.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.55 161.36 14.78 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.855 1.262 . . . . 0.0 111.334 174.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mm-40 -69.63 165.2 21.7 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 123.958 0.903 . . . . 0.0 112.662 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -87.73 75.18 9.0 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 125.491 1.516 . . . . 0.0 112.638 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.3 m -92.22 124.55 36.38 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 124.358 1.063 . . . . 0.0 111.293 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -133.5 159.02 41.64 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 125.472 1.509 . . . . 0.0 109.986 175.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.2 mmmt -71.71 -173.31 0.94 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.861 1.264 . . . . 0.0 112.146 174.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.4 m -49.59 139.74 11.99 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 125.74 1.616 . . . . 0.0 111.171 175.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.26 -7.58 43.79 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.503 1.049 . . . . 0.0 114.476 -176.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -67.99 134.25 50.41 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 119.079 1.44 . . . . 0.0 110.514 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.2 ttpp -130.85 127.77 39.26 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.157 0.983 . . . . 0.0 110.376 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -164.59 175.58 9.69 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.447 1.099 . . . . 0.0 111.525 -173.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.1 t -98.41 100.32 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 C-N-CA 125.367 1.467 . . . . 0.0 109.035 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -82.83 160.77 60.26 Favored Pre-proline 0 CA--C 1.551 0.983 0 O-C-N 121.55 -0.719 . . . . 0.0 111.641 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -73.42 101.92 1.42 Allowed 'Trans proline' 0 CA--C 1.539 0.751 0 C-N-CA 124.633 3.555 . . . . 0.0 112.061 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.46 -41.22 0.71 Allowed Glycine 0 CA--C 1.528 0.866 0 C-N-CA 124.094 0.854 . . . . 0.0 113.534 175.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -141.79 -52.21 0.42 Allowed 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.37 1.068 . . . . 0.0 112.655 -177.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.91 -11.32 60.7 Favored Glycine 0 CA--C 1.534 1.236 0 C-N-CA 125.01 1.29 . . . . 0.0 115.628 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.2 t -106.14 124.23 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 CA-C-N 118.712 1.256 . . . . 0.0 109.802 175.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.86 138.04 2.33 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.747 1.641 . . . . 0.0 111.648 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -120.11 133.37 55.53 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.593 1.157 . . . . 0.0 110.301 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.0 t -59.85 121.26 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 123.714 0.806 . . . . 0.0 110.154 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 7.2 ttt -101.0 -21.97 14.89 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 125.751 1.62 . . . . 0.0 112.902 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.95 -175.78 43.92 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 124.731 1.158 . . . . 0.0 113.344 177.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -122.18 137.72 54.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.531 1.533 . . . . 0.0 107.37 174.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.81 149.1 28.64 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 125.306 1.443 . . . . 0.0 111.216 175.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 87.8 m-70 -135.23 113.84 11.71 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.172 1.389 . . . . 0.0 110.251 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.9 t -141.81 -178.93 5.91 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.565 1.146 . . . . 0.0 111.57 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -123.27 128.03 49.39 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.829 1.652 . . . . 0.0 110.216 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -130.41 119.18 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 125.947 1.699 . . . . 0.0 109.471 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 54.61 27.09 8.07 Favored 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.316 1.446 . . . . 0.0 114.234 -174.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.64 -11.94 66.92 Favored Glycine 0 CA--C 1.535 1.33 0 C-N-CA 126.096 1.807 . . . . 0.0 114.989 -177.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -96.3 135.49 38.06 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 118.719 1.26 . . . . 0.0 109.979 174.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 81.0 mtt-85 -62.51 122.1 14.93 Favored 'General case' 0 N--CA 1.473 0.712 0 O-C-N 120.889 -1.132 . . . . 0.0 109.761 175.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -128.81 113.19 14.99 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.411 1.084 . . . . 0.0 108.969 175.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.516 ' HB2' HD13 ' A' ' 55' ' ' ILE . 12.2 m -85.6 164.35 17.79 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.999 0.92 . . . . 0.0 111.121 175.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -140.31 157.77 45.06 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.886 1.274 . . . . 0.0 111.218 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -98.56 125.3 43.76 Favored 'General case' 0 N--CA 1.466 0.371 0 C-N-CA 125.124 1.37 . . . . 0.0 110.754 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.9 t -85.4 99.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.691 1.196 . . . . 0.0 108.098 175.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.3 tp -109.3 113.84 27.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 123.988 0.915 . . . . 0.0 110.145 179.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -87.1 115.1 24.26 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.242 0.617 . . . . 0.0 109.569 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.2 mm -78.89 99.07 2.98 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.368 0 C-N-CA 124.395 1.078 . . . . 0.0 109.523 176.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.7 mp -57.19 -20.67 28.13 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 114.036 1.125 . . . . 0.0 114.036 176.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -55.2 -58.58 7.1 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 125.527 1.531 . . . . 0.0 111.645 177.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.95 -16.54 17.14 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 124.621 1.168 . . . . 0.0 113.661 177.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.54 9.62 68.9 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.849 1.69 . . . . 0.0 115.032 -177.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 49.5 mtm -93.54 166.43 12.26 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.221 1.408 . . . . 0.0 112.155 -176.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mtm180 -104.67 140.39 38.11 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.027 1.331 . . . . 0.0 110.919 174.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 27.6 mt -133.56 120.68 38.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 126.195 1.798 . . . . 0.0 109.193 179.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.1 147.03 29.3 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 122.897 0.479 . . . . 0.0 110.161 174.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.9 mm -131.11 126.22 21.45 Favored Pre-proline 0 N--CA 1.475 0.812 0 C-N-CA 124.533 1.133 . . . . 0.0 110.754 178.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.96 124.7 11.68 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 123.543 2.829 . . . . 0.0 111.756 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.516 HD13 ' HB2' ' A' ' 38' ' ' SER . 31.9 pt -60.19 -19.49 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -178.597 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.05 -38.39 73.15 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 126.338 1.855 . . . . 0.0 112.88 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.8 ptmt -88.57 -28.45 20.71 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.019 0.928 . . . . 0.0 113.279 174.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 60' ' ' SER . 54.9 t -62.37 -47.03 94.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.494 1.918 . . . . 0.0 111.571 -177.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.98 -20.74 1.43 Allowed Glycine 0 CA--C 1.539 1.578 0 C-N-CA 125.721 1.629 . . . . 0.0 115.453 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.496 ' H ' HG12 ' A' ' 58' ' ' VAL . 42.7 t -165.52 -70.67 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 126.156 1.782 . . . . 0.0 111.933 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -127.98 -38.65 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 C-N-CA 125.499 1.52 . . . . 0.0 113.435 -173.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.04 -14.02 5.12 Favored Glycine 0 CA--C 1.536 1.376 0 C-N-CA 125.255 1.407 . . . . 0.0 114.722 178.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.692 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.1 mp -99.78 139.54 35.29 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.892 2.077 . . . . 0.0 109.815 176.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 ttt180 -141.54 123.74 15.59 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.067 1.347 . . . . 0.0 111.224 176.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.0 mp0 -69.26 154.12 42.56 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 120.19 -1.569 . . . . 0.0 111.43 177.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 45.5 pt -107.66 -20.07 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 N-CA-C 113.896 1.072 . . . . 0.0 113.896 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -166.06 -35.05 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 127.397 2.279 . . . . 0.0 112.882 -178.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.81 114.42 1.41 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.877 1.671 . . . . 0.0 112.533 -178.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -137.08 128.63 28.52 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.651 1.58 . . . . 0.0 111.089 -177.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -107.36 -60.01 1.75 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 126.22 1.808 . . . . 0.0 111.479 178.491 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.254 1.331 0 C-N-CA 126.52 1.928 . . . . 0.0 113.133 -176.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 CA-C-O 119.45 -0.31 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -75.03 -44.52 23.44 Favored Glycine 0 CA--C 1.536 1.368 0 CA-C-N 119.088 0.858 . . . . 0.0 114.25 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.6 m80 54.97 -176.49 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 126.878 2.071 . . . . 0.0 113.434 -170.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -155.46 158.73 39.02 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.451 1.5 . . . . 0.0 111.413 175.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 69.1 mt-30 -132.84 17.35 4.23 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 125.73 1.612 . . . . 0.0 112.526 -178.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.7 p -59.74 144.86 47.1 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 126.43 1.892 . . . . 0.0 113.479 177.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 50.3 m -78.84 116.79 19.41 Favored 'General case' 0 N--CA 1.47 0.564 0 C-N-CA 125.321 1.449 . . . . 0.0 112.546 178.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -90.14 163.95 14.64 Favored 'General case' 0 CA--C 1.546 0.805 0 C-N-CA 123.853 0.861 . . . . 0.0 110.297 174.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.19 -170.72 1.79 Allowed 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.094 1.358 . . . . 0.0 111.266 175.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 75.7 m -48.06 138.92 8.68 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 125.487 1.515 . . . . 0.0 111.352 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.19 -9.48 42.63 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 125.376 1.465 . . . . 0.0 114.32 -173.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.3 148.44 49.74 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 119.442 1.621 . . . . 0.0 112.095 174.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.6 ttmt -126.73 127.82 45.69 Favored 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.976 1.31 . . . . 0.0 109.482 175.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -155.93 177.97 10.8 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.825 1.25 . . . . 0.0 111.206 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.39 100.22 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 C-N-CA 125.048 1.339 . . . . 0.0 108.904 177.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -78.78 158.37 75.58 Favored Pre-proline 0 CA--C 1.553 1.094 0 O-C-N 121.613 -0.679 . . . . 0.0 111.374 177.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -72.82 87.16 1.0 Allowed 'Trans proline' 0 CA--C 1.543 0.957 0 C-N-CA 124.556 3.504 . . . . 0.0 112.515 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.94 -55.99 0.19 Allowed Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.149 0.881 . . . . 0.0 113.869 175.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -125.06 -48.85 1.73 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.66 1.184 . . . . 0.0 111.773 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.18 -13.66 58.59 Favored Glycine 0 CA--C 1.534 1.242 0 C-N-CA 125.386 1.47 . . . . 0.0 115.603 -177.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.09 124.25 61.24 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.981 1.312 . . . . 0.0 110.647 175.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.47 147.73 5.02 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 125.662 1.601 . . . . 0.0 111.889 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -121.07 131.87 54.54 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 124.949 1.3 . . . . 0.0 107.65 174.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 36.9 t -62.72 107.2 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 13.9 ttt -87.55 -18.21 30.29 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.373 0.669 . . . . 0.0 112.652 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.06 179.79 42.44 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 123.904 0.764 . . . . 0.0 113.606 176.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.14 124.57 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 175.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.98 143.9 31.27 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 124.731 1.212 . . . . 0.0 109.677 175.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 -130.8 113.76 14.49 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.777 1.231 . . . . 0.0 109.606 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.1 t -138.68 179.25 6.59 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.17 0.988 . . . . 0.0 111.853 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -128.12 108.78 10.92 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.825 1.65 . . . . 0.0 109.953 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.9 m -111.78 136.52 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.924 1.69 . . . . 0.0 109.638 -177.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.38 27.49 1.99 Allowed 'General case' 0 CA--C 1.557 1.234 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 -174.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.31 18.66 75.8 Favored Glycine 0 CA--C 1.538 1.514 0 C-N-CA 124.676 1.131 . . . . 0.0 115.207 -175.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -127.68 135.84 50.76 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 126.032 1.733 . . . . 0.0 111.156 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 ttp180 -62.22 116.53 5.08 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.215 174.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -136.43 113.2 10.25 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.158 0.983 . . . . 0.0 109.46 176.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.0 m -81.82 163.5 22.3 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.388 1.075 . . . . 0.0 111.729 176.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -140.63 128.21 21.48 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 124.579 1.152 . . . . 0.0 110.029 178.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -65.78 125.02 24.02 Favored 'General case' 0 CA--C 1.538 0.487 0 O-C-N 120.99 -1.069 . . . . 0.0 109.547 175.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.2 t -96.39 99.65 9.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.866 0.866 . . . . 0.0 109.304 176.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -102.31 113.99 27.77 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.954 177.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.1 mmt180 -85.79 114.39 22.7 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 124.682 1.193 . . . . 0.0 108.207 175.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.4 mm -77.99 90.97 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 125.81 1.644 . . . . 0.0 108.868 179.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -54.34 -21.11 8.57 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 126.034 1.734 . . . . 0.0 113.761 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -44.63 -61.57 1.51 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 127.644 2.377 . . . . 0.0 113.324 175.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -134.43 8.34 3.65 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 127.018 2.127 . . . . 0.0 113.363 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.05 16.31 75.0 Favored Glycine 0 CA--C 1.537 1.413 0 C-N-CA 124.941 1.258 . . . . 0.0 114.481 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 ttm -64.6 167.11 7.61 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-N 118.818 1.309 . . . . 0.0 112.322 175.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.9 mtp180 -137.29 114.59 10.92 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 125.949 1.7 . . . . 0.0 108.912 -174.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 74.6 mt -120.04 115.53 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.992 0.917 . . . . 0.0 110.096 -177.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -89.06 139.15 30.76 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.134 1.374 . . . . 0.0 110.975 177.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 73.0 mt -132.36 124.87 19.47 Favored Pre-proline 0 N--CA 1.479 0.993 0 C-N-CA 125.162 1.385 . . . . 0.0 110.036 179.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -64.35 124.72 13.79 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 123.401 2.734 . . . . 0.0 111.72 178.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 pt -66.07 -15.02 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -63.7 -16.15 60.31 Favored 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 125.48 1.512 . . . . 0.0 113.352 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.4 mtpp -126.94 28.7 5.76 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 127.485 2.314 . . . . 0.0 112.616 -173.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.5 -51.73 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 126.19 1.796 . . . . 0.0 113.533 -178.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.03 -20.55 1.88 Allowed Glycine 0 CA--C 1.544 1.866 0 C-N-CA 126.529 2.014 . . . . 0.0 116.844 179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -169.69 -58.92 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 127.621 2.368 . . . . 0.0 110.551 175.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.0 p -155.46 -35.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 C-N-CA 125.022 1.329 . . . . 0.0 113.198 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.36 -11.73 36.37 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 125.071 1.32 . . . . 0.0 114.882 -178.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.41 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.9 mm? -104.63 144.06 32.22 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.727 2.011 . . . . 0.0 110.12 175.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -145.97 123.13 11.5 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 124.335 1.054 . . . . 0.0 111.57 178.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -79.66 57.17 2.41 Favored 'General case' 0 N--CA 1.481 1.101 0 O-C-N 120.368 -1.458 . . . . 0.0 112.437 -174.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 -176.19 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.548 1.139 . . . . 0.0 112.277 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.7 tp -109.48 -28.38 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 126.128 1.771 . . . . 0.0 113.112 177.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.3 m -59.4 107.72 0.61 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 127.383 2.273 . . . . 0.0 112.007 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -126.03 148.27 49.35 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 125.499 1.52 . . . . 0.0 111.648 178.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -71.71 -59.06 2.95 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.313 1.445 . . . . 0.0 112.57 178.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.253 1.283 0 C-N-CA 127.176 2.19 . . . . 0.0 114.64 -175.794 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.183 0 CA-C-O 120.527 0.204 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 156.74 164.4 13.46 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 125.683 1.611 . . . . 0.0 112.567 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.5 t-160 -145.53 27.37 1.24 Allowed 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -178.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -90.42 148.23 22.92 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 125.518 1.527 . . . . 0.0 111.875 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -105.27 -45.78 4.4 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.446 1.099 . . . . 0.0 111.732 175.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 79.0 p -64.26 -36.53 84.38 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 124.291 1.036 . . . . 0.0 113.192 179.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.98 86.47 6.94 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.949 1.299 . . . . 0.0 111.203 -179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -73.26 161.7 30.22 Favored 'General case' 0 CA--C 1.546 0.801 0 O-C-N 121.68 -0.638 . . . . 0.0 111.111 175.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.7 mmtt -75.07 -169.27 0.9 Allowed 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 125.117 1.367 . . . . 0.0 111.431 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 47.9 m -51.71 144.07 11.67 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 125.404 1.482 . . . . 0.0 111.101 174.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.79 -2.23 55.62 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 124.923 1.249 . . . . 0.0 114.317 -173.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.95 149.5 32.29 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 119.225 1.513 . . . . 0.0 111.839 175.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -123.8 130.99 53.49 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.82 1.248 . . . . 0.0 110.224 175.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.612 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -158.54 177.38 11.28 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.877 1.271 . . . . 0.0 110.964 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.3 t -89.98 100.26 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 C-N-CA 125.016 1.326 . . . . 0.0 109.443 -178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -73.27 156.7 88.99 Favored Pre-proline 0 CA--C 1.554 1.114 0 O-C-N 121.361 -0.837 . . . . 0.0 111.767 175.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.14 85.58 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 124.774 3.65 . . . . 0.0 112.148 177.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.53 -60.75 0.17 Allowed Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.694 1.14 . . . . 0.0 112.882 176.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 26.9 mm100 -126.16 -45.08 1.71 Allowed 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 124.591 1.156 . . . . 0.0 112.901 -176.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.19 -5.75 52.96 Favored Glycine 0 CA--C 1.533 1.216 0 C-N-CA 124.957 1.265 . . . . 0.0 116.103 -177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 126.23 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.715 2.006 . . . . 0.0 110.798 176.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.56 130.99 1.53 Allowed Glycine 0 CA--C 1.533 1.201 0 C-N-CA 124.863 1.221 . . . . 0.0 112.261 -177.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -111.84 130.4 55.83 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 124.829 1.252 . . . . 0.0 108.296 175.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -62.36 107.22 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 C-N-CA 123.376 0.671 . . . . 0.0 109.669 -178.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 16.5 tpt -86.78 -20.95 26.85 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.935 1.294 . . . . 0.0 112.42 -178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.5 -171.91 44.59 Favored Glycine 0 CA--C 1.529 0.934 0 C-N-CA 124.4 1.0 . . . . 0.0 113.723 176.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 mp -115.58 143.64 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 C-N-CA 125.508 1.523 . . . . 0.0 107.348 175.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.84 140.53 48.26 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 125.562 1.545 . . . . 0.0 109.983 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -135.82 113.87 11.3 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 124.098 0.959 . . . . 0.0 110.121 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.5 t -140.98 -177.67 5.2 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 124.724 1.21 . . . . 0.0 111.827 -178.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -135.79 114.74 12.16 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 126.529 1.932 . . . . 0.0 109.52 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 m -121.31 149.77 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 125.74 1.616 . . . . 0.0 110.109 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.41 26.98 2.54 Favored 'General case' 0 CA--C 1.557 1.224 0 N-CA-C 114.979 1.474 . . . . 0.0 114.979 -176.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.05 15.81 81.13 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 124.682 1.134 . . . . 0.0 115.045 -176.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -130.25 136.13 48.86 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 126.545 1.938 . . . . 0.0 111.548 -179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -63.38 117.39 6.59 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.83 0.852 . . . . 0.0 109.174 174.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 23.9 tt0 -128.91 113.15 14.87 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 124.274 1.03 . . . . 0.0 108.613 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 14.5 m -80.28 156.16 26.95 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 123.978 0.911 . . . . 0.0 111.358 177.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -142.68 168.05 20.64 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.808 1.243 . . . . 0.0 110.728 178.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -107.12 135.93 47.82 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 125.122 1.369 . . . . 0.0 110.563 175.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 t -94.73 99.77 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.472 1.109 . . . . 0.0 109.03 176.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.7 tp -111.31 114.02 26.9 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.21 1.004 . . . . 0.0 109.454 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.2 mtm180 -89.9 114.47 26.26 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.099 0.56 . . . . 0.0 109.883 175.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.1 mm -73.4 98.12 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 125.32 1.448 . . . . 0.0 109.873 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 6.0 mt -55.71 -16.18 3.97 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 126.484 1.914 . . . . 0.0 114.887 177.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 6.7 tm-20 -58.43 -46.94 85.49 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.941 1.696 . . . . 0.0 112.726 177.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -134.4 0.91 3.11 Favored 'General case' 0 CA--C 1.549 0.912 0 N-CA-C 114.646 1.351 . . . . 0.0 114.646 178.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.11 3.05 90.69 Favored Glycine 0 CA--C 1.539 1.563 0 C-N-CA 125.421 1.486 . . . . 0.0 114.657 -173.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 74.2 mtm -64.82 131.47 46.85 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.834 1.253 . . . . 0.0 111.723 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 14.3 mtm-85 -89.46 134.27 34.17 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.206 1.002 . . . . 0.0 110.278 175.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.0 mt -131.31 128.63 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.775 1.23 . . . . 0.0 109.606 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -92.72 145.22 24.58 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.554 0.742 . . . . 0.0 110.59 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.82 125.66 24.33 Favored Pre-proline 0 N--CA 1.474 0.753 0 C-N-CA 125.149 1.379 . . . . 0.0 109.752 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -68.91 125.12 12.18 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 123.632 2.888 . . . . 0.0 111.985 178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.3 pt -58.96 -23.38 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -61.79 -29.61 70.26 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 125.421 1.489 . . . . 0.0 112.538 -178.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.0 mtpt -93.36 -27.3 16.85 Favored 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.771 1.228 . . . . 0.0 112.678 174.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 60' ' ' SER . 53.5 t -61.78 -51.98 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 126.733 2.013 . . . . 0.0 112.609 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 77.42 -20.73 3.21 Favored Glycine 0 CA--C 1.542 1.777 0 C-N-CA 125.456 1.503 . . . . 0.0 116.345 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 58' ' ' VAL . 3.4 m -162.58 -69.07 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 126.605 1.962 . . . . 0.0 111.339 175.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -133.39 -36.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 C-N-CA 125.142 1.377 . . . . 0.0 113.459 -172.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 75.29 -11.09 9.31 Favored Glycine 0 CA--C 1.535 1.338 0 C-N-CA 124.875 1.226 . . . . 0.0 114.591 176.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.612 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.5 mm? -104.71 134.36 47.99 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 126.929 2.092 . . . . 0.0 109.8 177.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 ptp180 -134.97 118.35 16.75 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.485 1.914 . . . . 0.0 111.448 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -81.94 71.28 8.97 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 119.954 -1.716 . . . . 0.0 112.655 -173.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 7.8 pt -93.45 -14.87 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -177.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.2 tp -63.78 -12.74 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 125.686 1.594 . . . . 0.0 113.032 176.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.07 84.06 0.23 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.976 1.71 . . . . 0.0 111.772 176.37 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.43 122.59 24.74 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.741 1.616 . . . . 0.0 111.409 178.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -122.22 -64.54 1.19 Allowed 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 125.77 1.628 . . . . 0.0 111.618 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 C--O 1.253 1.263 0 C-N-CA 127.11 2.164 . . . . 0.0 112.555 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 121.087 0.47 . . . . 0.0 111.512 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.24 -143.79 10.29 Favored Glycine 0 CA--C 1.531 1.067 0 O-C-N 120.793 -1.192 . . . . 0.0 111.963 -173.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -70.68 147.81 48.7 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.41 0.605 . . . . 0.0 112.232 175.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.3 mtm -149.6 160.44 43.49 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 126.935 2.094 . . . . 0.0 109.514 174.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.6 tt0 -135.68 169.47 17.49 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.559 1.544 . . . . 0.0 110.686 -177.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.5 104.42 2.76 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 125.159 1.384 . . . . 0.0 112.836 -177.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 15.5 t -101.51 121.4 41.9 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 124.718 1.207 . . . . 0.0 110.969 174.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -136.28 159.71 40.92 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.953 1.701 . . . . 0.0 110.149 174.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 9.8 mmtt -71.76 -174.1 1.1 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.301 1.441 . . . . 0.0 112.304 175.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 91.1 m -48.79 138.25 11.37 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 126.16 1.784 . . . . 0.0 111.205 175.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.25 -9.16 42.16 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 124.667 1.127 . . . . 0.0 114.639 -174.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -67.03 139.48 57.64 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 118.986 1.393 . . . . 0.0 111.604 177.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -131.95 127.78 37.08 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.387 1.075 . . . . 0.0 110.559 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.513 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 166.53 17.14 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.529 1.132 . . . . 0.0 111.82 -173.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.4 t -82.05 100.37 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 C-N-CA 124.755 1.222 . . . . 0.0 109.344 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -80.48 157.81 72.13 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 123.35 0.66 . . . . 0.0 111.605 175.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -73.17 85.87 1.18 Allowed 'Trans proline' 0 CA--C 1.541 0.862 0 C-N-CA 124.867 3.712 . . . . 0.0 112.09 179.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.47 -57.31 0.13 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.32 0.962 . . . . 0.0 113.278 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -130.39 -40.64 1.26 Allowed 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.556 1.142 . . . . 0.0 113.124 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 98.63 -11.83 62.91 Favored Glycine 0 CA--C 1.532 1.13 0 C-N-CA 124.839 1.209 . . . . 0.0 115.636 -177.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.9 t -105.44 124.17 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.713 1.256 . . . . 0.0 110.543 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 164.71 150.72 6.27 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 125.257 1.408 . . . . 0.0 112.516 177.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -126.46 131.05 51.75 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.991 1.316 . . . . 0.0 109.451 174.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -60.26 116.67 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.145 0.978 . . . . 0.0 110.028 -178.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 6.8 tpt -96.64 -19.73 18.81 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.162 0.985 . . . . 0.0 112.994 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.02 -176.02 43.89 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.034 0.825 . . . . 0.0 113.719 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.04 134.74 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 C-N-CA 125.281 1.432 . . . . 0.0 108.164 175.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.32 149.39 23.66 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.052 1.741 . . . . 0.0 110.997 175.165 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -137.89 113.84 9.9 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 126.291 1.837 . . . . 0.0 109.412 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.4 t -141.98 177.73 8.0 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.122 0.969 . . . . 0.0 112.175 -178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -122.51 108.45 13.17 Favored 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 125.964 1.706 . . . . 0.0 110.259 177.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.2 m -110.85 141.55 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 126.269 1.827 . . . . 0.0 109.684 176.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.71 27.38 2.2 Favored 'General case' 0 CA--C 1.556 1.2 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -174.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.43 12.7 84.3 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 124.84 1.21 . . . . 0.0 115.402 -176.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -123.53 139.64 53.81 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 126.172 1.789 . . . . 0.0 112.544 178.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -63.46 114.74 4.07 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.866 1.667 . . . . 0.0 110.241 175.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -136.82 116.16 12.67 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 124.532 1.133 . . . . 0.0 110.429 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.7 m -82.95 161.73 21.71 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 112.984 176.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -143.1 154.05 43.53 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 124.713 1.205 . . . . 0.0 111.399 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -92.55 126.17 37.52 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.84 1.256 . . . . 0.0 110.35 174.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -90.05 99.65 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 C-N-CA 124.189 0.996 . . . . 0.0 109.118 175.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.3 tp -107.39 113.83 27.45 Favored 'General case' 0 CA--C 1.539 0.519 0 C-N-CA 123.584 0.754 . . . . 0.0 110.296 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.8 mtt180 -86.97 117.98 26.05 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.112 0.965 . . . . 0.0 108.503 175.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.6 mm -79.57 95.09 2.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.204 1.802 . . . . 0.0 109.342 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.99 -16.71 5.22 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 124.821 1.248 . . . . 0.0 113.914 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -55.83 -50.07 71.53 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 125.415 1.486 . . . . 0.0 112.554 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -134.22 3.46 3.39 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 125.383 1.473 . . . . 0.0 114.906 178.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.12 13.33 81.14 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 124.436 1.017 . . . . 0.0 114.181 -170.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 50.1 mtm -63.57 165.78 7.64 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.377 1.071 . . . . 0.0 111.975 175.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 79.9 mtt180 -134.03 123.15 24.05 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.444 1.498 . . . . 0.0 109.574 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 73.3 mt -129.87 123.04 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.978 0.911 . . . . 0.0 109.498 -179.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -88.95 149.66 23.2 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 124.251 1.02 . . . . 0.0 111.053 175.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.6 mp -133.74 124.27 17.72 Favored Pre-proline 0 N--CA 1.474 0.761 0 C-N-CA 124.833 1.253 . . . . 0.0 110.444 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.29 123.95 11.5 Favored 'Trans proline' 0 C--N 1.35 0.657 0 C-N-CA 123.696 2.931 . . . . 0.0 112.579 178.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.46 -14.21 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 113.777 1.028 . . . . 0.0 113.777 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -85.04 -3.28 58.73 Favored 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.515 1.126 . . . . 0.0 112.615 177.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? -116.27 -26.97 6.99 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.936 1.695 . . . . 0.0 113.439 178.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.7 m -60.49 -23.05 27.2 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 177.098 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 69.92 -20.84 0.51 Allowed Glycine 0 CA--C 1.543 1.796 0 C-N-CA 127.347 2.403 . . . . 0.0 116.275 -176.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 m -166.15 -46.21 0.03 OUTLIER 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 128.168 2.587 . . . . 0.0 112.308 175.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.4 p -152.77 -39.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 124.804 1.242 . . . . 0.0 113.642 -174.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 81.89 -9.71 55.38 Favored Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.462 1.03 . . . . 0.0 114.286 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.513 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 9.2 mp -104.73 140.1 38.57 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.733 1.613 . . . . 0.0 109.937 174.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -140.36 117.67 11.36 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.17 0.988 . . . . 0.0 111.782 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.5 tm-20 -74.61 134.89 42.04 Favored 'General case' 0 N--CA 1.477 0.877 0 O-C-N 120.569 -1.332 . . . . 0.0 111.465 175.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.34 178.45 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 126.003 1.721 . . . . 0.0 110.819 176.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 1.3 tp -131.87 2.84 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.792 2.037 . . . . 0.0 113.287 178.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 64.6 m -64.43 87.79 0.05 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 126.406 1.882 . . . . 0.0 112.843 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -128.5 58.03 1.57 Allowed 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 126.645 1.978 . . . . 0.0 110.844 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.69 -67.36 0.37 Allowed 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.603 1.161 . . . . 0.0 112.338 175.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.252 1.229 0 C-N-CA 125.881 1.672 . . . . 0.0 112.448 176.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.446 0.165 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.93 -68.81 0.01 OUTLIER Glycine 0 N--CA 1.474 1.217 0 C-N-CA 124.832 1.205 . . . . 0.0 112.269 -178.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -75.25 119.64 19.65 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 124.489 1.116 . . . . 0.0 111.29 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.7 mmt -116.52 88.33 2.87 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.518 1.927 . . . . 0.0 110.022 177.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -74.98 154.2 38.2 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.322 0.649 . . . . 0.0 111.087 175.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.5 p -96.74 -69.6 0.75 Allowed 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 124.612 1.165 . . . . 0.0 110.931 174.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 75.0 m -60.77 110.26 1.27 Allowed 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 124.996 1.318 . . . . 0.0 111.557 -178.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -132.64 158.26 42.72 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 125.63 1.572 . . . . 0.0 110.69 177.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 3.0 mptt -70.63 -172.83 0.67 Allowed 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 126.289 1.836 . . . . 0.0 111.876 175.007 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.0 m -49.94 137.96 16.04 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 125.03 1.332 . . . . 0.0 111.131 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.62 -9.13 34.91 Favored Glycine 0 CA--C 1.533 1.193 0 C-N-CA 124.761 1.172 . . . . 0.0 114.652 -176.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -65.22 134.29 53.34 Favored 'General case' 0 CA--C 1.54 0.559 0 CA-C-N 119.012 1.406 . . . . 0.0 109.984 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.4 ttpp -130.26 127.77 40.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.601 1.16 . . . . 0.0 109.758 176.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -165.47 172.41 12.16 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.86 1.264 . . . . 0.0 110.737 -177.044 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.427 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.9 t -88.04 100.28 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 124.675 1.19 . . . . 0.0 109.132 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -74.29 158.52 85.3 Favored Pre-proline 0 CA--C 1.555 1.149 0 O-C-N 121.065 -1.022 . . . . 0.0 111.621 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.78 88.04 0.8 Allowed 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 124.693 3.595 . . . . 0.0 112.15 176.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.69 -52.24 0.23 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 123.889 0.757 . . . . 0.0 114.387 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -132.67 -45.02 0.89 Allowed 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.65 1.18 . . . . 0.0 111.988 -179.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 102.11 -10.14 56.7 Favored Glycine 0 CA--C 1.531 1.04 0 C-N-CA 124.852 1.215 . . . . 0.0 116.016 -179.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 24.3 t -106.14 124.31 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 124.351 1.061 . . . . 0.0 110.167 176.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.95 135.33 1.8 Allowed Glycine 0 CA--C 1.53 1.019 0 C-N-CA 125.014 1.292 . . . . 0.0 111.668 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -114.62 132.22 56.44 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 124.348 1.059 . . . . 0.0 109.276 174.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -58.9 122.81 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 124.069 0.947 . . . . 0.0 110.061 179.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 30.2 ttp -103.11 -19.55 14.5 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 125.112 1.365 . . . . 0.0 113.092 -178.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 169.96 -176.97 43.58 Favored Glycine 0 CA--C 1.53 1.016 0 C-N-CA 125.082 1.325 . . . . 0.0 113.307 175.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.22 131.14 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 125.179 1.392 . . . . 0.0 107.577 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -98.04 147.39 24.58 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 124.997 1.319 . . . . 0.0 111.643 174.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -133.85 113.8 12.64 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.345 1.458 . . . . 0.0 110.462 -177.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.1 t -140.25 -179.42 5.98 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.401 1.08 . . . . 0.0 111.799 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -129.92 108.26 9.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 125.993 1.717 . . . . 0.0 109.644 179.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.7 m -109.67 141.28 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 125.916 1.687 . . . . 0.0 109.48 -178.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 50.19 29.92 3.97 Favored 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 114.696 1.369 . . . . 0.0 114.696 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.28 12.67 83.4 Favored Glycine 0 CA--C 1.539 1.551 0 C-N-CA 124.93 1.252 . . . . 0.0 115.222 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -126.02 134.59 51.4 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.123 2.169 . . . . 0.0 111.35 -177.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 35.4 mtp180 -63.9 112.8 3.08 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.059 1.344 . . . . 0.0 109.479 179.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.4 tt0 -135.18 113.15 11.07 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.869 0.842 . . . . 0.0 108.916 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.463 ' HB2' HD13 ' A' ' 55' ' ' ILE . 31.0 m -89.93 164.28 14.63 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.476 1.11 . . . . 0.0 110.531 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -139.47 157.93 45.01 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.377 1.071 . . . . 0.0 110.752 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -94.0 126.93 39.5 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 124.588 1.155 . . . . 0.0 110.482 175.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.05 99.65 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 124.435 1.094 . . . . 0.0 108.745 175.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 27.7 tp -109.33 113.89 27.1 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.833 0.853 . . . . 0.0 110.507 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -86.3 107.02 17.78 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 124.586 1.154 . . . . 0.0 109.839 175.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.0 mm -76.8 91.16 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.941 1.296 . . . . 0.0 109.581 175.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -54.73 -25.12 25.55 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 125.112 1.365 . . . . 0.0 113.458 177.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -52.45 -62.01 1.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 126.316 1.846 . . . . 0.0 111.729 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -92.87 -17.85 23.54 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.358 1.063 . . . . 0.0 113.448 176.047 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 86.57 18.16 59.04 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 125.447 1.498 . . . . 0.0 114.899 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 44.1 mtm -106.99 173.23 6.41 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 125.595 1.558 . . . . 0.0 111.659 -177.146 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -113.38 148.38 35.91 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.252 1.021 . . . . 0.0 110.995 175.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.0 mt -134.76 131.0 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.605 1.562 . . . . 0.0 108.739 177.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 32.2 mtt -88.57 140.8 29.09 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.67 1.588 . . . . 0.0 109.461 175.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 mp -130.0 125.92 22.2 Favored Pre-proline 0 N--CA 1.475 0.818 0 C-N-CA 124.139 0.976 . . . . 0.0 110.408 178.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.19 123.55 11.04 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 123.463 2.776 . . . . 0.0 112.596 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 38' ' ' SER . 17.3 pt -65.3 -11.66 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 114.162 1.171 . . . . 0.0 114.162 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -83.13 -5.52 59.14 Favored 'General case' 0 CA--C 1.552 1.05 0 O-C-N 120.962 -1.086 . . . . 0.0 112.691 175.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 10.7 mmtt -115.64 -26.34 7.5 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.899 1.68 . . . . 0.0 113.67 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 28.1 m -60.89 -20.97 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 114.606 1.336 . . . . 0.0 114.606 176.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.64 -20.74 0.79 Allowed Glycine 0 CA--C 1.54 1.605 0 C-N-CA 127.594 2.521 . . . . 0.0 115.767 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.0 -52.87 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 128.222 2.609 . . . . 0.0 110.309 174.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.33 -37.54 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 N-CA-C 114.806 1.41 . . . . 0.0 114.806 -175.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 79.55 -9.48 42.48 Favored Glycine 0 CA--C 1.532 1.146 0 C-N-CA 124.338 0.971 . . . . 0.0 113.928 -178.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.489 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 4.4 mm? -104.75 139.65 39.23 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 126.292 1.837 . . . . 0.0 110.242 175.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -144.29 117.64 9.05 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 126.17 1.788 . . . . 0.0 110.764 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -76.88 66.56 2.77 Favored 'General case' 0 N--CA 1.479 0.979 0 O-C-N 120.583 -1.323 . . . . 0.0 110.93 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -77.24 -175.52 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.694 1.198 . . . . 0.0 111.443 177.096 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.9 tp -113.62 -24.05 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 125.756 1.622 . . . . 0.0 113.575 178.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.53 101.13 0.08 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.759 2.024 . . . . 0.0 112.33 177.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -126.22 61.42 1.28 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.26 1.824 . . . . 0.0 111.961 -176.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -62.62 -57.56 10.63 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 120.972 -1.08 . . . . 0.0 112.688 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 . . . . . 0 C--O 1.254 1.312 0 C-N-CA 126.275 1.83 . . . . 0.0 113.948 -178.836 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 CA-C-O 119.598 -0.239 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 80.79 143.37 3.49 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 125.237 1.399 . . . . 0.0 112.766 -173.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -92.72 59.35 3.25 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 124.308 1.043 . . . . 0.0 111.357 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.4 ttm -156.31 99.72 1.94 Allowed 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.221 1.008 . . . . 0.0 111.574 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -74.0 152.11 40.12 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.376 0.67 . . . . 0.0 111.377 175.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 t -68.17 -42.66 79.68 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.639 0.776 . . . . 0.0 111.455 176.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.8 p -87.8 134.86 33.6 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.714 2.006 . . . . 0.0 112.606 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -140.29 158.79 43.49 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 126.275 1.83 . . . . 0.0 109.559 175.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.1 mmtm -71.71 -173.89 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 C-N-CA 124.975 1.31 . . . . 0.0 111.95 175.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 93.2 m -49.69 140.87 10.63 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.359 1.463 . . . . 0.0 111.172 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -5.1 48.72 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 124.642 1.115 . . . . 0.0 114.254 -175.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -66.93 134.75 52.63 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 119.315 1.558 . . . . 0.0 110.631 177.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.97 127.88 39.28 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.43 1.092 . . . . 0.0 109.711 178.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.483 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -165.22 172.7 12.13 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 125.121 1.368 . . . . 0.0 110.663 177.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HA3' ' A' ' 20' ' ' GLY . 21.5 t -88.64 100.58 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.957 1.303 . . . . 0.0 109.085 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -79.01 158.36 74.98 Favored Pre-proline 0 CA--C 1.554 1.13 0 O-C-N 121.585 -0.697 . . . . 0.0 111.741 175.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -72.48 86.43 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.958 0 C-N-CA 124.634 3.556 . . . . 0.0 112.041 178.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 172.68 -53.87 0.17 Allowed Glycine 0 CA--C 1.532 1.098 0 C-N-CA 124.041 0.829 . . . . 0.0 113.814 175.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -133.33 -38.67 0.94 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.152 0.981 . . . . 0.0 112.873 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 15' ' ' VAL . . . 91.71 -12.25 69.91 Favored Glycine 0 CA--C 1.533 1.175 0 C-N-CA 124.479 1.038 . . . . 0.0 115.629 -177.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 t -106.07 128.71 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 125.088 1.355 . . . . 0.0 109.996 175.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 153.09 125.31 1.07 Allowed Glycine 0 CA--C 1.532 1.121 0 C-N-CA 125.419 1.485 . . . . 0.0 111.791 -178.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -109.32 132.71 53.86 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.207 1.003 . . . . 0.0 108.856 175.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.52 124.83 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 124.069 0.948 . . . . 0.0 110.576 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 9.2 tpt -101.92 -20.75 14.72 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.35 1.46 . . . . 0.0 113.279 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.19 -174.41 44.26 Favored Glycine 0 CA--C 1.529 0.95 0 C-N-CA 124.447 1.022 . . . . 0.0 113.204 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.2 mp -118.75 138.85 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 C-N-CA 125.196 1.398 . . . . 0.0 107.537 175.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -108.98 146.07 34.46 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 125.333 1.453 . . . . 0.0 111.455 175.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 88.1 m-70 -134.0 114.15 12.92 Favored 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 124.927 1.291 . . . . 0.0 109.914 -178.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.8 t -141.61 179.01 7.07 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.749 1.22 . . . . 0.0 111.729 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 67.2 tt0 -130.13 108.16 9.85 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.585 1.954 . . . . 0.0 109.552 179.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.9 m -111.46 142.76 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.111 1.764 . . . . 0.0 109.278 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.6 27.09 3.7 Favored 'General case' 0 CA--C 1.558 1.262 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -177.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.07 15.72 81.19 Favored Glycine 0 CA--C 1.54 1.596 0 O-C-N 120.977 -1.077 . . . . 0.0 114.903 -174.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 11.8 mt-30 -128.99 127.98 42.77 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 126.899 2.08 . . . . 0.0 111.803 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 42.4 mtt85 -60.94 114.29 2.99 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.661 1.185 . . . . 0.0 109.631 175.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.85 113.54 15.4 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 124.92 1.288 . . . . 0.0 108.833 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.406 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -78.26 157.02 29.39 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.914 0.864 . . . . 0.0 111.902 175.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -137.09 162.49 33.22 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.362 1.465 . . . . 0.0 110.247 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -107.44 127.55 53.69 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 126.06 1.744 . . . . 0.0 110.039 175.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.1 t -86.31 99.84 8.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 124.934 1.294 . . . . 0.0 108.608 175.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.5 tp -111.57 113.94 26.68 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.05 0.94 . . . . 0.0 110.138 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 39.0 mtp85 -94.36 113.57 25.47 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.875 0.87 . . . . 0.0 109.872 174.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.0 mm -75.85 97.96 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 C-N-CA 125.5 1.52 . . . . 0.0 109.433 176.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.9 mt -58.92 -23.75 61.63 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.907 1.283 . . . . 0.0 113.211 177.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -57.73 -59.29 5.44 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 125.481 1.512 . . . . 0.0 112.399 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -93.14 -16.98 24.29 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.352 1.061 . . . . 0.0 113.445 177.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.92 23.77 59.02 Favored Glycine 0 CA--C 1.537 1.434 0 C-N-CA 125.282 1.42 . . . . 0.0 114.516 -176.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 43.4 mtm -112.81 166.31 11.49 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.417 1.487 . . . . 0.0 111.867 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 16.7 ptt-85 -99.41 151.36 21.18 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.15 0.98 . . . . 0.0 110.743 175.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 37.2 mt -140.11 124.46 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.473 1.509 . . . . 0.0 109.034 175.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.9 mtt -75.29 144.82 42.28 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.081 0.553 . . . . 0.0 110.586 175.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.2 mm -130.32 101.77 17.45 Favored Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 124.679 1.191 . . . . 0.0 109.314 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -68.47 127.5 15.74 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 123.237 2.624 . . . . 0.0 110.886 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.406 HD13 ' HB2' ' A' ' 38' ' ' SER . 28.8 pt -59.96 -16.76 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.05 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -177.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -52.42 -32.31 38.58 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 126.853 2.061 . . . . 0.0 114.043 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -100.51 -29.11 12.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 126.421 1.889 . . . . 0.0 113.266 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 36.7 t -65.29 -52.75 48.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 126.354 1.862 . . . . 0.0 111.257 -179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.18 -20.4 1.18 Allowed Glycine 0 CA--C 1.541 1.703 0 C-N-CA 126.336 1.922 . . . . 0.0 116.207 -176.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 1.8 t -165.39 -61.72 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.428 1.491 . . . . 0.0 111.335 175.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 1.6 m -144.82 -37.04 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 126.057 1.743 . . . . 0.0 114.516 175.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 59.76 7.54 6.42 Favored Glycine 0 CA--C 1.541 1.689 0 CA-C-N 119.501 1.046 . . . . 0.0 115.685 -176.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.483 HD23 ' HB3' ' A' ' 14' ' ' ALA . 4.7 mp -96.86 141.97 29.41 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.272 1.829 . . . . 0.0 110.613 -179.299 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.7 mtt-85 -140.21 117.99 11.69 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 125.441 1.496 . . . . 0.0 110.651 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.41 74.76 3.97 Favored 'General case' 0 N--CA 1.477 0.921 0 O-C-N 120.368 -1.458 . . . . 0.0 111.378 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 2.9 pt -113.47 -165.12 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 126.118 1.767 . . . . 0.0 111.247 -177.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.1 tp -123.76 -31.87 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 126.082 1.753 . . . . 0.0 112.844 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.9 t -60.26 137.22 58.16 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.581 1.152 . . . . 0.0 111.634 176.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.5 pt-20 -129.89 171.79 12.37 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.097 1.759 . . . . 0.0 111.393 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -57.95 -61.49 2.5 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 121.477 -0.764 . . . . 0.0 112.59 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.252 1.214 0 C-N-CA 125.442 1.497 . . . . 0.0 113.466 -178.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.216 0.055 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.9 57.34 0.32 Allowed Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.071 0.844 . . . . 0.0 114.147 -177.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 57.32 87.71 0.06 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 127.159 2.184 . . . . 0.0 114.137 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 11.6 mtp -98.63 -32.16 11.56 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.905 1.282 . . . . 0.0 113.782 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -137.28 167.58 21.31 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 127.255 2.222 . . . . 0.0 111.111 -177.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 8.1 p -122.49 -69.63 0.82 Allowed 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 126.476 1.911 . . . . 0.0 110.73 -177.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 72.2 p -71.61 163.46 27.71 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.562 1.145 . . . . 0.0 111.993 175.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -136.08 160.16 39.49 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 125.794 1.637 . . . . 0.0 110.052 174.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -72.6 -172.35 0.96 Allowed 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 125.103 1.361 . . . . 0.0 112.177 175.074 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 40.3 m -49.04 141.13 8.24 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 126.026 1.73 . . . . 0.0 111.018 174.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.2 -8.48 53.23 Favored Glycine 0 CA--C 1.533 1.197 0 C-N-CA 124.746 1.165 . . . . 0.0 114.656 -174.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -66.36 152.31 45.29 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 119.04 1.42 . . . . 0.0 111.87 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 ttmt -134.39 127.79 32.3 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.434 1.094 . . . . 0.0 109.958 177.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.06 167.97 15.95 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.899 1.28 . . . . 0.0 111.504 -173.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.415 HG13 ' CA ' ' A' ' 20' ' ' GLY . 22.5 t -82.62 100.08 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 124.705 1.202 . . . . 0.0 109.055 -175.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.1 p90 -79.89 159.42 71.19 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 121.639 -0.663 . . . . 0.0 111.468 177.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -71.24 86.32 0.8 Allowed 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 124.566 3.511 . . . . 0.0 112.702 177.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 173.82 -60.3 0.13 Allowed Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.243 0.925 . . . . 0.0 113.294 174.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -129.35 -37.83 1.61 Allowed 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.415 ' CA ' HG13 ' A' ' 15' ' ' VAL . . . 100.81 -11.07 59.13 Favored Glycine 0 CA--C 1.532 1.153 0 N-CA-C 116.172 1.229 . . . . 0.0 116.172 178.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 46.8 t -106.07 131.76 54.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 118.615 1.207 . . . . 0.0 109.751 175.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 158.62 147.61 4.9 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 124.812 1.196 . . . . 0.0 112.091 178.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -120.12 133.74 55.43 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 124.884 1.273 . . . . 0.0 108.473 175.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.5 t -60.58 107.15 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.603 0.761 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.11 -25.77 34.15 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.502 1.121 . . . . 0.0 111.955 -178.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.82 -175.62 45.15 Favored Glycine 0 CA--C 1.527 0.803 0 C-N-CA 124.767 1.175 . . . . 0.0 113.102 175.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.9 mp -116.63 135.25 57.53 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -102.56 150.01 23.83 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 125.354 1.462 . . . . 0.0 111.42 174.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -137.24 113.79 10.24 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 125.489 1.516 . . . . 0.0 109.423 -177.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -139.69 179.91 6.3 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.892 0.877 . . . . 0.0 112.101 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -126.42 108.22 11.0 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.953 1.701 . . . . 0.0 109.895 177.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.9 m -106.32 141.61 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 C-N-CA 125.564 1.546 . . . . 0.0 109.429 177.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 48.61 27.84 1.61 Allowed 'General case' 0 CA--C 1.558 1.27 0 N-CA-C 114.649 1.351 . . . . 0.0 114.649 -174.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.95 83.57 Favored Glycine 0 CA--C 1.54 1.594 0 C-N-CA 124.933 1.254 . . . . 0.0 115.578 -176.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 -126.82 141.38 51.84 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 126.478 1.911 . . . . 0.0 112.509 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 18.8 mtt-85 -59.19 117.46 4.77 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 125.606 1.562 . . . . 0.0 111.5 175.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.38 114.18 11.93 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.692 1.597 . . . . 0.0 110.506 174.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 27.4 m -88.99 158.96 17.84 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.462 0.705 . . . . 0.0 110.348 174.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -144.16 153.15 41.82 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 124.619 1.168 . . . . 0.0 111.113 -178.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -91.06 128.16 36.77 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.429 1.092 . . . . 0.0 110.057 175.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.6 t -94.76 99.74 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 124.607 1.163 . . . . 0.0 109.408 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 31.3 tp -102.78 113.85 27.61 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.791 0.837 . . . . 0.0 110.263 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 48.2 ttm-85 -84.3 110.71 18.79 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 124.438 1.095 . . . . 0.0 109.108 174.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 29.7 mm -80.11 89.37 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 C-N-CA 124.589 1.156 . . . . 0.0 109.782 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -19.17 53.46 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.028 1.331 . . . . 0.0 114.016 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -59.91 -51.43 69.73 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 126.29 1.836 . . . . 0.0 112.8 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -121.03 -10.32 9.07 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 126.959 2.104 . . . . 0.0 113.446 -175.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.58 2.2 79.58 Favored Glycine 0 CA--C 1.538 1.488 0 C-N-CA 126.428 1.966 . . . . 0.0 115.203 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.3 mtp -76.54 168.97 19.13 Favored 'General case' 0 CA--C 1.544 0.729 0 CA-C-N 119.073 1.437 . . . . 0.0 113.257 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.38 138.17 50.46 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 127.223 2.209 . . . . 0.0 110.955 176.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 71.5 mt -137.49 125.54 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.226 1.01 . . . . 0.0 109.871 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 36.4 mtt -96.23 146.64 24.53 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 124.473 1.109 . . . . 0.0 111.032 174.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 80.0 mt -133.65 125.53 18.52 Favored Pre-proline 0 N--CA 1.475 0.792 0 C-N-CA 124.935 1.294 . . . . 0.0 110.339 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -68.3 123.92 11.11 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 123.974 3.116 . . . . 0.0 112.739 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -64.72 -15.07 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 113.888 1.07 . . . . 0.0 113.888 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.76 -7.36 56.45 Favored 'General case' 0 CA--C 1.551 1.0 0 O-C-N 120.935 -1.103 . . . . 0.0 112.389 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 25.6 tttt -119.41 -22.09 7.18 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 126.22 1.808 . . . . 0.0 113.668 -174.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -66.36 -23.17 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 114.919 1.451 . . . . 0.0 114.919 175.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.5 -20.23 0.36 Allowed Glycine 0 CA--C 1.544 1.904 0 C-N-CA 128.469 2.938 . . . . 0.0 116.055 -175.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 m -163.03 -60.12 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 128.392 2.677 . . . . 0.0 111.061 175.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 16.1 m -137.95 -35.71 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 125.349 1.46 . . . . 0.0 114.074 -174.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.26 -12.77 30.37 Favored Glycine 0 CA--C 1.532 1.131 0 C-N-CA 124.911 1.244 . . . . 0.0 114.543 177.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.51 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 8.7 mp -103.42 132.34 49.76 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.308 1.843 . . . . 0.0 109.709 177.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -129.79 117.78 20.77 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.325 1.45 . . . . 0.0 111.737 -177.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.31 69.04 9.9 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 119.837 -1.789 . . . . 0.0 112.152 -170.314 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 pt -90.12 -15.21 8.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.2 0 N-CA-C 115.327 1.602 . . . . 0.0 115.327 -176.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 11.1 tp -63.6 -15.74 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 125.012 1.325 . . . . 0.0 111.973 175.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.7 137.07 58.18 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 125.391 1.476 . . . . 0.0 111.629 175.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -146.96 161.88 39.88 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.14 1.376 . . . . 0.0 111.867 -178.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -124.13 -65.29 1.07 Allowed 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.237 1.415 . . . . 0.0 111.466 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 30.4 t70 . . . . . 0 C--O 1.254 1.329 0 C-N-CA 125.517 1.527 . . . . 0.0 114.003 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.265 0 CA-C-O 120.971 0.415 . . . . 0.0 111.523 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -86.08 5.19 84.8 Favored Glycine 0 CA--C 1.537 1.429 0 C-N-CA 125.339 1.447 . . . . 0.0 115.186 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.1 t-80 -148.88 158.84 44.47 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.76 1.624 . . . . 0.0 111.974 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -165.18 178.98 6.58 Favored 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 127.18 2.192 . . . . 0.0 110.812 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.89 -175.05 1.63 Allowed 'General case' 0 CA--C 1.551 0.997 0 C-N-CA 124.63 1.172 . . . . 0.0 111.126 174.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -63.47 111.01 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 125.146 1.378 . . . . 0.0 111.832 174.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.0 m -118.28 159.32 23.57 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 125.185 1.394 . . . . 0.0 111.975 175.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -139.6 157.84 45.12 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 125.384 1.474 . . . . 0.0 109.776 175.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 7.9 mmtt -71.83 -173.8 1.06 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 125.487 1.515 . . . . 0.0 112.324 174.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 89.6 m -49.27 139.4 11.34 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.652 1.581 . . . . 0.0 110.881 174.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 103.28 -0.87 46.89 Favored Glycine 0 CA--C 1.533 1.183 0 C-N-CA 124.357 0.979 . . . . 0.0 114.63 -174.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -72.42 134.35 45.35 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 119.145 1.472 . . . . 0.0 110.14 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 ttpt -125.48 128.09 47.48 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 124.587 1.155 . . . . 0.0 110.329 176.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.6 ' HB3' ' HB3' ' A' ' 63' ' ' LEU . . . -166.79 167.88 14.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.508 1.123 . . . . 0.0 111.805 -174.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.5 t -83.25 100.33 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 124.956 1.302 . . . . 0.0 109.292 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -76.65 156.92 82.74 Favored Pre-proline 0 CA--C 1.551 1.017 0 O-C-N 121.884 -0.51 . . . . 0.0 111.693 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -72.0 86.61 0.91 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.7 3.6 . . . . 0.0 111.964 177.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.96 -58.47 0.18 Allowed Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.35 0.976 . . . . 0.0 113.666 175.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -128.33 -42.41 1.5 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.772 1.229 . . . . 0.0 112.362 -178.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.15 -9.62 61.4 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 125.094 1.331 . . . . 0.0 115.732 -178.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.01 124.32 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 125.21 1.404 . . . . 0.0 109.652 176.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 161.66 137.63 2.24 Favored Glycine 0 CA--C 1.532 1.095 0 C-N-CA 125.109 1.337 . . . . 0.0 112.045 179.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -117.64 130.53 56.42 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.919 1.288 . . . . 0.0 108.708 174.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -59.02 116.1 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 123.464 0.706 . . . . 0.0 109.622 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 2.6 tpt -98.78 -17.17 18.63 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.615 1.166 . . . . 0.0 112.682 -178.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.12 -173.04 44.13 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.988 1.28 . . . . 0.0 112.99 175.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.0 138.48 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 C-N-CA 125.22 1.408 . . . . 0.0 107.451 175.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -104.94 143.9 32.53 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.976 1.31 . . . . 0.0 111.307 176.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -135.43 113.76 11.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 125.038 1.335 . . . . 0.0 110.045 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.6 t -139.68 -178.73 5.54 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.698 1.199 . . . . 0.0 111.353 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -128.32 115.03 17.66 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.275 1.83 . . . . 0.0 109.204 176.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 17.5 m -115.44 142.15 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 125.849 1.66 . . . . 0.0 109.491 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 51.67 27.08 3.77 Favored 'General case' 0 CA--C 1.558 1.258 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.88 9.99 84.67 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 124.622 1.106 . . . . 0.0 115.022 -175.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -129.01 129.68 45.66 Favored 'General case' 0 CA--C 1.543 0.702 0 C-N-CA 126.471 1.908 . . . . 0.0 111.329 -173.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 52.1 mtt85 -60.06 119.02 7.0 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 124.309 1.044 . . . . 0.0 110.67 174.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.16 116.19 14.23 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 125.237 1.415 . . . . 0.0 109.671 -177.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.6 m -87.56 155.79 19.81 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 124.25 1.02 . . . . 0.0 111.735 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -142.68 160.35 40.48 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.534 1.134 . . . . 0.0 111.169 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -98.37 126.13 43.77 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 124.706 1.202 . . . . 0.0 110.198 175.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.9 t -86.87 99.63 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 123.611 0.764 . . . . 0.0 109.005 175.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 29.4 tp -107.96 113.87 27.38 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.087 0.955 . . . . 0.0 109.733 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -90.53 118.97 30.4 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.184 0.994 . . . . 0.0 109.37 175.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.6 mm -77.43 100.58 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 126.518 1.927 . . . . 0.0 109.157 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 11.0 mp -57.08 -17.79 11.86 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 125.161 1.385 . . . . 0.0 113.956 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -54.08 -54.61 36.98 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 126.182 1.793 . . . . 0.0 112.624 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 10.9 p30 -134.49 7.65 3.59 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.559 1.544 . . . . 0.0 114.352 178.143 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.42 74.31 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.541 1.067 . . . . 0.0 114.266 -174.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.6 mtp -61.67 167.17 3.71 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.15 1.38 . . . . 0.0 112.243 175.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.27 120.42 19.95 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 126.047 1.739 . . . . 0.0 110.157 -178.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.1 mt -127.76 116.29 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 C-N-CA 124.157 0.983 . . . . 0.0 109.616 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 26.2 mmt -80.71 147.64 30.5 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 123.489 0.716 . . . . 0.0 110.653 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.5 mm -133.16 125.8 19.14 Favored Pre-proline 0 N--CA 1.473 0.71 0 C-N-CA 124.598 1.159 . . . . 0.0 110.802 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -68.41 124.43 11.64 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.889 3.059 . . . . 0.0 112.388 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.1 pt -64.81 -13.58 14.91 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -83.14 -6.1 59.36 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.724 1.21 . . . . 0.0 112.735 178.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 2.1 ttmp? -112.9 -32.24 6.45 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 126.622 1.969 . . . . 0.0 112.955 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.9 m -57.82 -24.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.3 -18.86 1.15 Allowed Glycine 0 CA--C 1.539 1.548 0 C-N-CA 126.212 1.863 . . . . 0.0 115.4 -177.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.3 t -171.41 -60.49 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.84 2.456 . . . . 0.0 110.845 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.97 -43.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 125.518 1.527 . . . . 0.0 113.718 -175.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.28 -7.21 76.77 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 124.585 1.088 . . . . 0.0 113.82 -178.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.6 ' HB3' ' HB3' ' A' ' 14' ' ' ALA . 2.6 mm? -104.57 142.66 34.24 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 126.007 1.723 . . . . 0.0 110.482 174.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 -143.18 117.57 9.66 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.265 1.026 . . . . 0.0 112.272 176.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -83.54 93.05 7.75 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 120.377 -1.452 . . . . 0.0 111.72 -177.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 31.7 pt -91.67 -21.28 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 179.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.3 tp -165.59 -30.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 127.345 2.258 . . . . 0.0 113.823 -179.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -60.86 104.27 0.34 Allowed 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 124.917 1.287 . . . . 0.0 113.151 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -126.76 173.52 9.47 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 125.114 1.365 . . . . 0.0 111.886 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -137.04 -63.27 0.61 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 126.107 1.763 . . . . 0.0 111.065 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.0 t70 . . . . . 0 C--O 1.254 1.33 0 C-N-CA 125.082 1.353 . . . . 0.0 113.243 -174.896 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 120.6 0.238 . . . . 0.0 111.432 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.97 175.63 53.96 Favored Glycine 0 CA--C 1.538 1.473 0 C-N-CA 124.717 1.151 . . . . 0.0 113.607 175.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -146.43 70.17 1.21 Allowed 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 124.942 1.297 . . . . 0.0 111.576 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.1 mtt -118.93 143.99 46.7 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 124.845 1.258 . . . . 0.0 112.337 178.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.5 tp60 -153.2 54.46 0.76 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 125.791 1.637 . . . . 0.0 110.972 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 p -75.19 154.37 37.66 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 120.722 -1.236 . . . . 0.0 111.367 174.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -87.13 177.21 7.26 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.628 0.771 . . . . 0.0 112.688 175.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -96.65 161.97 13.65 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 124.782 1.233 . . . . 0.0 111.914 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.6 mmtp -75.39 -169.83 1.08 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.346 1.858 . . . . 0.0 111.798 174.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 97.1 m -50.73 141.25 13.27 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.434 1.493 . . . . 0.0 110.937 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 104.25 -8.98 49.48 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 125.525 1.535 . . . . 0.0 114.385 -174.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -69.62 150.3 47.19 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 118.996 1.398 . . . . 0.0 112.368 177.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.5 ttpp -132.19 127.8 36.61 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.904 1.281 . . . . 0.0 110.522 177.287 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.44 ' HB3' HD23 ' A' ' 63' ' ' LEU . . . -156.09 173.53 16.69 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.721 1.209 . . . . 0.0 111.057 177.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.8 t -91.31 100.38 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.834 1.254 . . . . 0.0 108.885 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -78.52 157.12 77.77 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 121.61 -0.681 . . . . 0.0 111.671 175.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.92 87.52 0.99 Allowed 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.265 3.31 . . . . 0.0 112.254 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.5 -56.38 0.18 Allowed Glycine 0 CA--C 1.531 1.089 0 C-N-CA 124.365 0.983 . . . . 0.0 113.638 175.043 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -126.58 -42.58 1.79 Allowed 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.739 1.216 . . . . 0.0 112.336 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 91.53 -10.74 74.0 Favored Glycine 0 CA--C 1.534 1.232 0 C-N-CA 124.682 1.134 . . . . 0.0 115.607 -176.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 40.8 t -106.1 124.13 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 125.16 1.384 . . . . 0.0 110.227 176.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 160.41 143.74 3.76 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 126.044 1.783 . . . . 0.0 111.982 176.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -121.32 130.77 53.82 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.992 1.317 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.79 107.21 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 123.268 0.627 . . . . 0.0 109.498 -177.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.93 -18.49 29.02 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 124.702 1.201 . . . . 0.0 112.085 -177.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 170.96 -171.97 44.12 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.795 1.188 . . . . 0.0 112.902 175.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.4 mp -119.0 142.99 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 C-N-CA 125.614 1.566 . . . . 0.0 107.241 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.11 142.07 45.01 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.578 1.551 . . . . 0.0 110.511 177.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -137.93 113.78 9.82 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.898 1.279 . . . . 0.0 110.334 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.7 t -141.5 -177.89 5.37 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.52 1.128 . . . . 0.0 111.597 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -130.56 108.23 9.78 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 126.087 1.755 . . . . 0.0 109.397 179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.9 m -110.83 148.37 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 125.04 1.336 . . . . 0.0 110.602 177.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 49.3 27.0 1.73 Allowed 'General case' 0 CA--C 1.557 1.213 0 N-CA-C 114.865 1.432 . . . . 0.0 114.865 -176.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.48 14.82 82.04 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.799 1.19 . . . . 0.0 115.208 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.54 134.29 48.62 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 126.691 1.997 . . . . 0.0 111.785 -178.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 6.8 mtt180 -61.27 118.57 7.06 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.707 1.203 . . . . 0.0 110.16 174.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -131.17 118.16 20.08 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 125.305 1.442 . . . . 0.0 109.902 178.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 42.4 m -86.04 155.41 20.84 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 111.871 175.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -143.13 162.42 35.61 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.497 1.519 . . . . 0.0 110.94 179.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -104.09 130.98 51.81 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 125.363 1.465 . . . . 0.0 109.054 174.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.1 t -90.7 99.7 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.462 1.105 . . . . 0.0 108.321 175.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 26.2 tp -108.02 113.86 27.34 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 123.903 0.881 . . . . 0.0 110.212 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.03 121.76 33.11 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.097 0.959 . . . . 0.0 110.05 175.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.3 mm -77.42 102.7 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 126.478 1.911 . . . . 0.0 109.177 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 7.3 mp -56.36 -17.17 7.04 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 125.303 1.441 . . . . 0.0 114.729 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -53.86 -55.02 30.54 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 126.348 1.859 . . . . 0.0 112.153 178.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -134.31 6.63 3.58 Favored 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 125.908 1.683 . . . . 0.0 114.643 179.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.18 22.02 66.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.207 0.908 . . . . 0.0 113.934 -174.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.2 ttp -67.69 166.3 15.44 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 118.139 0.969 . . . . 0.0 112.237 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -126.46 116.07 20.56 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.412 1.485 . . . . 0.0 109.413 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.8 mt -119.49 113.95 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 C-N-CA 124.037 0.935 . . . . 0.0 109.559 176.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -67.5 148.25 51.74 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 123.043 0.537 . . . . 0.0 110.84 174.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 64.3 mt -131.11 106.28 14.95 Favored Pre-proline 0 CA--C 1.545 0.753 0 C-N-CA 124.71 1.204 . . . . 0.0 109.473 178.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -69.78 123.48 10.14 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.506 2.804 . . . . 0.0 111.669 177.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 20.1 pt -57.96 -19.48 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -50.59 -37.82 42.14 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 127.067 2.147 . . . . 0.0 113.496 175.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -93.5 -24.7 17.9 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 17.9 t -71.51 -57.22 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 125.469 1.508 . . . . 0.0 112.032 -179.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 70.28 -15.28 1.1 Allowed Glycine 0 CA--C 1.544 1.897 0 C-N-CA 126.627 2.06 . . . . 0.0 116.951 -176.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -158.62 -78.45 0.07 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 127.557 2.343 . . . . 0.0 110.458 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.31 -35.07 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.202 0 N-CA-C 114.747 1.388 . . . . 0.0 114.747 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 63.49 -3.86 1.16 Allowed Glycine 0 CA--C 1.542 1.758 0 C-N-CA 124.817 1.199 . . . . 0.0 115.988 -178.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.44 HD23 ' HB3' ' A' ' 14' ' ' ALA . 6.1 mp -88.37 146.03 25.48 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.963 2.105 . . . . 0.0 110.846 178.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -145.93 119.64 9.21 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.275 1.43 . . . . 0.0 110.28 177.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -79.49 73.39 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 O-C-N 120.292 -1.505 . . . . 0.0 111.165 -178.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 1.3 pt -94.3 -171.74 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 125.914 1.686 . . . . 0.0 111.693 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 10.8 tp -119.95 -29.59 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 126.098 1.759 . . . . 0.0 113.087 176.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -59.17 124.02 18.57 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 126.521 1.928 . . . . 0.0 112.25 175.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -137.55 143.26 41.49 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.888 1.675 . . . . 0.0 110.937 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -119.43 -64.7 1.24 Allowed 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 125.084 1.353 . . . . 0.0 111.498 179.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.068 1.747 . . . . 0.0 113.676 178.165 . . . . . . . . 1 1 . 1 stop_ save_